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ABSTRACT 
The use of many antibiotics to treat infections has become limited in the last 
decade. Enterobacteriaceae, especially Klebsiella spp., have acquired resistance to 
quinolones, aminoglycosides, cephalosporins and carbapenems. Resistance to β-lactams 
is mediated via extended-spectrum β-lactamases, AmpC type β-lactamases and 
carbapenemases combined with porin loss. Carbapenems are the antibiotics of last resort. 
The emergence of carbapenemase-producing organisms (CPOs) has led to Public Health 
England introducing a national toolkit to limit their spread. As part of this requirement, the 
Charing Cross microbiology laboratory of the Imperial College Healthcare NHS Trust 
revised its screening programme for the detection of CPOs. This improved the detection 
and isolation of CPOs, and highlighted Klebsiella spp. were more of a problem with 
respect to multidrug resistance than previously thought. 
Thirty-nine carbapenem-resistant Klebsiella strains were characterised. 
Phenotypic tests identified the strains as Klebsiella pneumoniae (n = 36) and Klebsiella 
oxytoca (n = 3). Detailed whole-genome sequence (WGS) analyses showed the K. 
oxytoca were Klebsiella michiganensis and one of the K. pneumoniae strains to be 
Klebsiella variicola subsp. variicola. 
The K. michiganensis strains were all of sequence type 138. They were predicted 
to encode the β-lactamases blaGES-5, blaSHV-66, blaTEM-1, blaOXA and blaCTX-M-15, and the 12-
gene operon of the kleboxymycin biosynthetic gene cluster. This gene cluster encodes for 
tilimycin and tilivalline, enterotoxins previously thought only to be carried by K. oxytoca 
strains. 
Incorporation of antimicrobial resistance and virulence gene data showed 
hypervirulent, multidrug-resistant K. pneumoniae strains encoding both aerobactin and 
rmpA (the regulator of mucoid phenotype) or colibactin are present in West London 
Hospitals. These are a cause for concern, as they have the potential to cause outbreaks 
that are untreatable. 
WGS analyses yield more accurate and comprehensive data compared with 
phenotypic testing, enabling exact identification of clinically important strains, detailed 
outbreak investigations and molecular characterisation of antibiotic resistance and 
virulence genes in clinical settings. 
Thirty-two bacteriophages were isolated from sewage water and found to infect 
one or more of the clinical Klebsiella isolates. Some phages with broad host ranges (i.e. 
they infected K. pneumoniae, K. michiganensis, K. variicola and K. grimontii strains) were 
identified, which may have use in clinical therapeutics against multidrug-resistant 
infections. These bacteriophages remain to be characterised in detail. 
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CHAPTER 1:  INTRODUCTION 
 
The global spread of carbapenemase-producing Enterobacteriaceae (CPE), 
Pseudomonas aeruginosa and Acinetobacter species has significantly increased 
in many parts of the world especially in South America, USA, Asia and Europe and 
has become a critical medical and public health issue (WHO, 2014). The concern 
is because these bacteria are generally resistant to all β-lactam antibiotics and 
also show co-resistance to multiple classes of other antimicrobial agents, leaving 
very few treatment options (Livermore, 2012a). Controlling the spread of 
carbapenemase-producing organisms (CPOs) is not easy due to the diversity of 
carbapenem-hydrolysing enzymes that have emerged and the ability of the 
resistance genes to spread among multiple bacterial species (Curran and Otter, 
2014; Grundmann et al., 2010). Whole-genome sequence (WGS) data are being 
used increasingly to study CPOs within academic and Public Health England 
(PHE) laboratories, but there is little opportunity for clinical laboratory workers to 
learn how sequence data can be used to better characterise the antibiotic-
resistance genes carried by CPOs. Bacteriophage (phage) therapy has been 
suggested as an alternative or adjunct treatment option in CPO-associated 
infections (Inal, 2003). The following will introduce the carbapenemases and 
provide background information on Klebsiella spp. (the focus of my studies). A 
review that I contributed to describing Klebsiella phages and their uses in 
treatment of clinical infections caused by Klebsiella spp. is also provided 
(Appendix 1). 
 
1.1 KLEBSIELLA PNEUMONIAE AND THE CLINICALLY RELEVANT 
RELATED SPECIES KLEBSIELLA OXYTOCA 
The genus Klebsiella belongs to the family Enterobacteriaceae, named after 
Edwin Klebs a 19th century German microbiologist. Klebsiella are non-motile, 
Gram-negative, lactose-fermenting facultatively to strictly aerobic bacteria. 
Members of the genus Klebsiella express two types of antigens on their cell 
surface that contribute to their pathogenicity; the lipoploysaccharide O antigen and 
a capsular polysaccharide K antigen whose structure varies. This in turn allows 
Klebsiella species to be classified into various serotypes. Until recently it was 
thought that there were 77 K antigens and 9 O antigens of Klebsiella pneumoniae. 
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However, using WGS analyses Wyres et al. (2016) were able to identify a total of 
134 distinct K-loci in Klebsiella spp.  
Klebsiella species are naturally found in the environment. Within the genus 
Klebsiella the two species that cause the majority of human infections are 
Klebsiella pneumoniae and Klebsiella oxytoca. These species are widely 
considered as opportunistic pathogens asymptomatically colonising the skin, 
mouth, respiratory and gastrointestinal (GI) tract of healthy humans (Holt et al., 
2015). WGS of 300 human-derived isolates of K. pneumoniae showed the 
existence of >150 lineages of K. pneumoniae with numerous multidrug-resistant 
(MDR) or hyper-virulent clones (Holt et al., 2015). The genome of some K. 
pneumoniae strains encodes virulence factors associated with invasive 
community-acquired diseases (Holt et al., 2015). Antimicrobial resistance genes 
are generally more common in human carriage isolates causing hospital-acquired 
infections (HAIs) than the community-carriage isolates. So far no studies have 
been carried out in the UK to determine GI carriage of K. pneumoniae and closely 
related species and their relationship to infection. 
Studies conducted by Conlan et al. (2012a), Farida et al. (2013) and Dao et 
al. (2014) from healthy volunteers have shown the carriage rate of Klebsiella spp. 
to be more prevalent from mouth, nose and skin samples (~10%) than from stool 
samples (3.8%). Feldman et al. (2013) showed that most HAIs with 
carbapenemase-resistant K. pneumoniae are caused by clonal group ST258 or 
the hyper-virulent type belonging to clonal group ST23 (which causes pyogenic 
liver abscesses) carried within the GI tract of the patient. Hypervirulent K. 
pneumoniae is more virulent than classical K. pneumoniae and mainly infects 
individuals in the community and is now occurring globally. The genetic factors 
(related to capsule and aerobactin production) that confer K. pneumoniae’s 
hypervirulent phenotype are present on a large virulence plasmid. Similar to 
classical K. pneumoniae, hypervirulent K. pneumoniae is becoming increasingly 
resistant to antimicrobials due to acquisition of mobile elements carrying 
resistance genes. New hypervirulent strains emerge when extensively drug-
resistant classical strains acquire hypervirulent-specific virulence determinants, 
resulting in nosocomial infections leading to invasive disease in individuals (Russo 
and Marr, 2019). 
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Martin et al. (2016) showed an increased risk of infection with K. 
pneumoniae was associated with GI colonisation, ~5.2% in colonised patients 
versus 1.3% in non-colonised patients. Gorrie et al. (2017) demonstrated K. 
pneumoniae to be a normal member of the human GI microbiota and the GI 
carriage of the organism with patients on their admission to intensive care was 
associated with subsequent infection rather than from upper-respiratory-tract 
carriage. Using genome data, these authors showed a match between GI carriage 
and infection isolates in most patients. 
In the community K. pneumoniae causes lung diseases, typically 
community-acquired pneumonia in older populations with debilitating diseases 
such as alcoholism, diabetes or chronic broncho-pulmonary diseases after the 
host aspirates colonising organisms into the lower respiratory tract (Holt et al., 
2015). In the hospital setting, K. pneumoniae accounts for approximately 8% of all 
HAIs. Carbapenem-resistant K. pneumoniae are ranked among the recently 
published World Health Organisation list of antibiotic-resistant “priority/critical” 
pathogens, for nosocomial infections for which research and development of new 
antibiotics are required (WHO, 2017a). 
K. pneumoniae causes nosocomial infections of the urinary tract, lower 
respiratory tract and surgical wound sites of patients, particularly those in intensive 
care units. Here the route of entry is endogenous, i.e. due to colonisation 
(especially from the GI tract), or exogenous from the healthcare environment and 
contamination of invasive devices, respiratory support equipment or urinary 
catheters. Excessive use of antibiotics also contributes to the increased likelihood 
of nosocomial infection (Holt et al., 2015). 
Similar to K. pneumoniae, K. oxytoca has a prominent polysaccharide 
capsule which provides resistance against host defence mechanisms (Trivedi et 
al., 2015). It is a Gram-negative bacterium found in the environment (Hoffman et 
al., 2010). K. oxytoca has been associated with neonatal septicaemia among 
premature infants in neonatal intensive care units: here the route of infection is 
due to colonisation of an infant’s GI tract during delivery and also from the hospital 
environment (Moles et al., 2015). Mode of delivery, invasive procedures such as 
enteral feeding using nasogastric tubes, and bacterial contamination of milk and 
the hands of healthcare workers can contribute to infant colonisation with K. 
oxytoca (Berthelot et al., 2001). K. oxytoca can also be detected in the GI tract of 
	 
	
18	
~2-10% of healthy humans (Schlenker and Surawicz, 2009), and is considered to 
be part of the normal gut microbiota, with the potential to become an opportunistic 
pathogen. The bacterium has been shown to be a causative agent of antibiotic-
associated haemorrhagic colitis (AAHC), a disease caused by the overgrowth of K. 
oxytoca with the release of cytotoxin when the indigenous GI microbiota is 
disturbed during antibiotic treatment (Zollner-Schwetz et al., 2008; Herzog et al., 
2014). AAHC is usually preceded by antibiotic treatment with penicillins, which are 
frequently prescribed for paediatric patients (Herzog et al., 2014). 
 
1.2 TREATMENT OF KLEBSIELLA INFECTIONS 
Klebsiella infections are mainly treated with cephalosporins, carbapenems 
and aminoglycosides but there is now emerging resistance to these antibiotics 
because Klebsiella spp. produce extended spectrum β-lactamases (ESBLs) or 
carbapenemases that confer resistance to cephalosporins and carbapenems 
(Sekyere et al., 2016). By acquiring a combination of resistance mechanisms to 
these antimicrobials Klebsiella spp. can become MDR: the carbapenem group of 
antibiotics is the last line of defence against Gram-negative infections that are 
resistant to other antibiotics. Consequently, MDR Klebsiella infections are treated 
with combination therapy comprising a β-lactam and aminoglycosides or using 
colistin and tigecycline as a monotheraphy (Sekyere et al., 2016). 
The emergence of MDR strains of K. pneumoniae has become an urgent 
threat to human health because of their association with outbreaks of HAIs and 
community-acquired infections globally (Holt et al., 2015). Since carbapenemases 
are transferred from species via plasmids, GI carriage of Enterobacteriaceae 
(members of the normal gut microbiota) serves as a reservoir and vector of CPEs 
and also promotes cross-transmission of resistance in healthcare settings (Viau et 
al., 2016). 
 
1.3 CARBAPENEMASES 
Carbapenemases are a diverse group of bacterial enzymes that vary in 
their ability to hydrolyse carbapenems and other β-lactam antibiotics (Queenan 
and Bush, 2007). Carbapenem antibiotics include ertapenem, meropenem, 
imipenem and doripenem, and are β-lactam antibiotics with broad-spectrum 
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antibacterial activity. Carbapenemases can be acquired via transferable plasmids, 
or be chromosomally encoded, and are widely distributed in Gram-negative 
bacteria (Ambler, 1980; Jeon et al., 2015). The Ambler classification system is 
used to characterise carbapenemases, and differentiates β-lactamases into four 
classes (A, B, C and D) based on their amino acid sequences (Ambler, 1980; Hall 
and Barlow, 2005). 
Class A enzymes inactivate the β-lactam ring by means of a catalytically 
active serine residue in the enzyme active site, e.g. serine-based penicillinases 
(Jeon et al., 2015). Class A enzymes include K. pneumoniae carbapenemase 
(KPC) determinants, and are associated with successful clonal lineages of 
bacteria (e.g. K. pneumoniae ST258). Four of these lineages have a selective 
advantage in hospital settings, where antimicrobial use is high and the 
environment provides numerous opportunities for transmission of organisms, with 
further dissemination of the resistance genes via transmissible plasmids and 
integrons (Curiao et al., 2010). K. pneumoniae ST258 has given rise to several 
epidemics globally, especially in the United States and Israel (Livermore, 2012a; 
Grundmann et al., 2010). Recently the isolation of another hypervirulent clone, the 
MDR K. pneumoniae ST23 reported in Korea, Vietnam, China and Brazil, has 
become a cause for concern as this sequence type is associated with severe 
invasive human diseases (Cejas et al., 2014). 
Plasmid-encoded GES-type β-lactamase also belongs to the class A 
enzymes and is an ESBL discovered in 2000 in K. pneumoniae clinical isolates 
from French Guiana, and subsequently named "Guiana extended spectrum" 
(Bonnin et al., 2017). GES-type β-lactamases are slow carbapenem hydrolysers 
with increased hydrolysis of cephamycin and ceftazidime. To date, 31 variants of 
GES have been identified, most commonly in Pseudomonas aeruginosa, 
Acinetobacter baumannii, Escherichia coli and K. pneumoniae. All GES-carrying 
Enterobacteriaceae have carbapenem-hydrolysing activity due to a replacement of 
glycerine at position 170 by an asparagine or a serine. The GES-5 variant has also 
been found in K. oxytoca due to plasmid or intergron transfer in UK hospitals 
(Diene and Rolain, 2014). The GES-5 variant has now disseminated quite widely, 
being reported both in nosocomial and environmental settings in South America, 
Korea and Africa due to the selective pressure resulting from the overuse of 
carbapenems (Nordmann and Poirel, 2014).  
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Class B enzymes are known as metallo-β-lactamases (MBLs) and can 
hydrolyse carbapenems effectively. They require zinc as a metal co-factor for their 
catalytic activity (Hall and Barlow, 2005; Palzkill, 2013). MBLs include the Verona 
integron-mediated metallo-β-lactamase (VIM), which has been a concern in 
Europe for several years, and the imipenemase (IMP) class, which is more 
prevalent in Japan and the Asian subcontinent and now spreading globally 
(Livermore and Woodford, 2006). MBLs are detected usually in P. aeruginosa, and 
members of the family Enterobacteriaceae (Livermore and Woodford, 2006). The 
reason there is a threat of carbapenem resistance within the UK in our healthcare 
settings is due to the above-mentioned organisms acquiring an additional 
resistance gene that encodes for the New Delhi metallo-β-lactamase (NDM) and 
now passed on to K. pneumoniae. NDM K. pneumoniae has been introduced into 
the UK by individuals who have visited India or Pakistan, and NDM strains are a 
major cause of outbreaks in the high-dependency units of west London hospitals 
(Johnson and Woodford, 2013; Nordmann et al., 2011). The discovery of a K. 
pneumoniae ST14 strain harbouring the NDM carbapenemase gene, from a 
Swedish patient who received healthcare in India, is becoming a major threat 
worldwide producing pockets of outbreak situations in healthcare settings (Giske 
et al., 2012).  
Class C enzymes also have a serine at their active site and are rare 
chromosomally encoded cephalosporinases (Ambler class C/AmpC) produced by 
Enterobacteriaceae and may possess slightly extended activity towards 
carbapenems, but their clinical significance remains unclear (Queenan and Bush, 
2007). 
Class D oxacillinases (OXA) have an active serine residue and hydrolyse 
carbapenems weakly; these enzymes belong to the OXA family and are most 
commonly produced by Acinetobacter species but have also been identified in 
some P. aeruginosa, E. coli and K. pneumoniae strains. OXA-48, which often 
mediates low-level carbapenem resistance but not resistance to the extended 
spectrum β-lactams, is now spreading rapidly in Europe and is also a cause for 
concern in UK hospitals (Potron et al., 2013a; Glasner et al., 2013). 
Current resistance status of CPOs since the detection of the first strain in 
1980 indicates that CPOs have spread rapidly worldwide with epidemiological 
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studies showing that different carbapenemases predominate in different areas of 
the world. NDM carbapenemase is more prevalent in the Indian subcontinent, 
while KPC is endemic in the United States. OXA-48 carbapenemase producers 
are more prevalent in Turkey and North Africa (Suay-García and Pérez-Gracia, 
2019). 
 
1.4 CLINICAL ASPECTS OF INFECTIONS CAUSED BY CARBAPENEM-
RESISTANT GRAM-NEGATIVE BACTERIA 
In the UK, CPOs - especially K. pneumoniae (KPC, NDM) and 
Acinetobacter (OXA-48) species - are a real challenge to infection control in both 
hospital and community settings (Figure 1.1 and Figure 1.2): firstly, due to their 
ability to spread and cause outbreaks with different species of Enterobacteriaceae 
with the same mobile resistance gene (Grundaman et al, 2010); secondly, CPOs 
inhabit the GI tract and decolonisation therapy only reduces the number of CPOs 
without elimination (Curran and Otter, 2014). The majority of people are colonised 
with these organisms with no further complications but, in immunocompromised 
patients, colonisation can lead to endogenous infection, which can be a cause of 
cross-infection (Curran and Otter, 2014; Patel et al., 2007). Falagas et al. (2014) 
have shown that patients with invasive CPO infections have a twofold higher 
number of deaths than those infected with antibiotic-sensitive strains. 
Infections caused by CPEs include urinary tract infections, peritonitis, 
septicaemia, pulmonary infections, soft-tissue infections and device-associated 
infections with no gender preference and most of the cases are in adults in high-
dependency units (Freeman et al., 2015). Carbapenem-resistant K. pneumoniae 
strains carrying a virulence gene (magA) responsible for the production of capsular 
type K1 and causing community-acquired pyogenic liver abscess are on the 
increase globally (Lin et al., 2013). A. baumannii carbapenemase OXA-23, OXA-
48 and OXA-51 strains account for most (30%) of the imipenem resistance in 
southern England (Livermore, 2012a; Azimi et al., 2015). CPOs are extremely 
MDR (resistant to carbapenems, penicillins and cephalosporins) and often carry 
genes that confer resistance to other antimicrobials (aminoglycosides and 
quinolones) leading to limited therapeutic options in infections caused by these 
organisms (Livermore and Woodford, 2006). 
  
	 
	
22	
 
Figure 1.1. The number of confirmed CPO isolates referred from UK laboratories. 
There has been a rapid increase in CPOs in the UK between 2000 and 2014, from 
five per year from 2003 to 2007 to as high as 1,000 in 2013 (Curran and Otter, 
2014). Most CPOs in the UK are Enterobacteriaceae.  Red bars, 
Enterobacteriaceae; orange bars, non-fermenters. Data are from the PHE 
Antibiotic Resistance Monitoring and Reference Laboratory (AMRHAI). Figure 
taken from Livermore (2012a). 
 
 
 
Figure 1.2. Carbapenemase-producing Enterobacteriaceae: laboratory-confirmed 
cases from UK laboratories 2003 to 2015 (last updated 10 October 2016). Data 
used to produce the graph taken from https://bit.ly/2miStRD (accessed 26 March 
2018).  
	 
	
23	
1.5 CURRENT THERAPEUTIC TREATMENT OPTIONS AND THE CAUSE OF 
THE RISE OF CPOS 
For many years, oxyimino-cephalosporins such as cefuroxime and 
cefotaxime were the "workhorse" antibiotics of UK hospitals and worldwide 
(Livermore and Woodford, 2006). The wide use of these antibiotics as a primary 
therapy for the treatment of urinary, respiratory and abdominal infections has led 
to bacteria acquiring resistance against this class of antibiotics through the 
production of ESBLs. This has led to the use of carbapenems, often used as the 
antibiotics of last resort against MDR organisms, which in turn has given rise to 
bacteria that have acquired the carbapenemase-resistance gene (Livermore, 
2012a). In addition, excessive usage and bad stewardship of antibiotics in 
healthcare settings has brought about selective pressure for antibiotic resistance 
in organisms that cause HAIs (Freeman et al., 2015). Development of new 
antibiotics is scarce, and pharmaceutical companies shying away from investment 
in the development of new antibiotics (because of financial, licensing and 
regulatory concerns) compacts today's crisis caused by MDR strains 
(Theuretzbacher, 2012). Costs and complexity associated with conducting clinical 
trials together with the fact that CPOs are diverse with respect to their production 
of resistance enzymes, the species involved and epidemiology further add to the 
problems associated with development of new antibiotics/antimicrobials/inhibitors. 
In the past two decades only three new classes of antibiotics have been 
developed with a narrow spectrum and they are only active towards Gram-positive 
bacteria (Theuretzbacher, 2012; Gupta and Nayak, 2014; Ling et al., 2015). Butler 
et al. (2017) recently listed 37 new antibiotics that would possibly be effective 
towards both Gram-negative and Gram-positive bacteria. Two β-lactamase/β-
lactam combinations mainly for Gram-negative bacteria are in the pipeline and 
being evaluated in clinical trials (running since 2015). The outcome of these trials 
is awaited to see if these combination therapies can be of clinical use. Another 
report showed that as of May 2017, only 8 out of 51 antibiotics in the clinical 
pipeline belong to new classes, again stressing the lack of novel antibiotic 
development (WHO, 2017b). Recent literature shows there are a few antibiotics 
which have been approved for therapeutic usage and have been used 
successfully: they are ceftazidime/avibactam, meropenem/vaborbactam, 
plazomicin and eravacycline, but therapeutic failure is already developing with 
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some of them (Suay-García and Pérez-Gracia, 2019). To date, treatment options 
for the newly emerging CPOs are limited, with isolates remaining susceptible to 
colistin (although resistance is on the rise) and intermediate to tigercycline with 
significant drawbacks in terms of their therapeutic viability which can lead to 
resistance and with colistin usage limited due to its neurotoxicity and 
nephrotoxicity (Carmeli et al., 2010; Livermore, 2012a). Therefore, a need for an 
alternative therapy is inevitable. In the current climate phage therapy (PT) could be 
an effective alternative for the treatment of resistant bacterial infections.  
 
1.6 CHARACTERISATION OF KLEBSIELLA SPP. IN THE GENOMIC ERA 
Whole genome sequencing is the generation of the complete nucleotide 
sequence of a genome from DNA extracted from an organism and allows clinical 
isolates of, for example, Klebsiella spp. to be compared with one another and with 
reference sequences which are deposited in public repositories such GenBank 
and EMBL. The high resolution (e.g. differentiating strains at the single nucleotide 
level) offered by WGS has revolutionised our understanding and management of 
Klebsiella-associated infections. WGS allows accurate characterisation of 
transmission events and outbreaks, and provides information concerning the 
genetic basis of phenotypic characteristics, including antibiotic susceptibility and 
virulence (Van Belkum, 2003; Relman, 2011; Ladner et al., 2019; Yu et al., 2019). 
With respect to nosocomial infections, it is the responsibility of the clinical 
microbiology laboratory to identify the population of bacteria causing an infection. 
At present, this depends heavily on phenotypic methods such as growth on 
differential media, API 20E and MALDI-TOF. The time lag and low positive culture 
rate of traditional pathogen diagnosis make it difficult to rapidly identify many 
pathogens. In recent years, the increasing number of suspected infections and 
rapid increase in the rate of transmission have brought severe challenges to the 
diagnosis and treatment of infectious diseases. Therefore, successful identification 
of the microbe(s) responsible for an infection requires the rapid diagnosis of 
clinical infectious agents, and there is now a move to using ‘culture‐independent’ 
methods such as WGS to increase the speed with which infectious bacteria can be 
identified, and the accuracy with which they can be characterised. For example, 
the Mycobacterial Reference Service of PHE now routinely uses WGS for 
identification of Mycobacterium sp. isolates (PHE, 2019). 
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Development of third‐generation sequencing methods such as nanopore 
technology may allow point-of-care WGS in the near future. Nanopore sequencing 
has already been used to study an Ebola outbreak in real time (Quick et al., 2016), 
and is beginning to be used to monitor virulence plasmids of nosocomial isolates 
of "high-risk" clones of K. pneumoniae ST15, ST48, ST101, ST147 and ST383 
(Turton et al., 2019). This has the advantage of being faster, more accurate and 
high‐throughput than short-read sequencing methods that are widely available, 
and will play an increasingly important role in the rapid and accurate diagnosis of 
infectious diseases. With the continuous development of sequencing technologies 
and improvement in databases of genomes of pathogenic microorganisms, 
detection of infectious diseases and epidemic investigations can occur in real time, 
greatly improving the treatment of critical patients with severe infections (Van 
Belkum, 2003; Relman, 2011; Ladner et al., 2019; Yu et al., 2019). 
The emergence of MDR Klebsiella spp. is not only a global health problem 
but it is also becoming a threat in individual health organisations, as has been 
experienced in the Imperial College Healthcare NHS Trust (ICHNT). It is relatively 
inexpensive to generate WGS data. For example, microbesNG 
https://microbesng.com/) provides WGS of bacteria for as little as £50 per 
genome. This relative cheapness has allowed large-scale studies of Klebsiella 
genomes to be undertaken. The first of which was by Holt et al. (2015), which 
showed K. pneumoniae represented three distinct species: KpI (K. pneumoniae), 
KpII (K. quasipneumoniae) and KpIII (K. variicola). As more K. pneumoniae 
genome sequences have become available, it has become apparent that K. 
pneumoniae is more diverse than first thought, comprising seven distinct 
phylogenetic lineages: K. pneumoniae, K. quasipneumoniae subsp. 
quasipneumoniae, K. quasipneumoniae subsp. similipneumoniae, K. variicola 
subsp. variicola, K. variicola subsp. tropica, K. quasivariicola and K. africana 
(Rodrigues et al., 2019). Holt et al. (2015) also showed K. pneumoniae comprised 
more than 150 distinct deeply branching lineages (clonal groups) that included 
numerous multidrug-resistant or hypervirulent clones, and that antimicrobial 
resistance genes were common among K. pneumoniae isolates associated with 
human carriage and HAIs. 
Individual K. pneumoniae genomes contain approximately 5500 genes, 
including <2000 common genes shared among most strains and 3500 drawn from 
	 
	
26	
an extensive pool of ≥30,000 protein-coding sequences with hundreds of 
antimicrobial resistance (AMR) genes (Holt et al., 2015). A small number of 
globally distributed K. pneumoniae clonal groups are acquiring AMR genes at a 
rapid rate (Wyres et al., 2016). The most widely recognised AMR clone is ST258, 
associated with the dissemination of the KPC gene. Genome analyses have 
shown ST258 has extensive capsular antigen and AMR gene diversity, so too do 
ST14/15, ST43 and ST147 – which have each disseminated from a particular area 
globally; ST14/15 from Asia, ST43 from United Arab Emirates and ST147 from 
Europe. It is now routine for WGS to be used in research laboratories to 
characterise key elements of the Klebsiella spp. genomic framework: namely 
identification of STs, AMR determinants including acquired genes and common 
mutations, known virulence genes and alleles, plasmids, and capsular and O 
antigen loci (Wyres et al., 2016). 
Using WGS, Gorrie et al. (2017) showed the GI microbiota is a source of K. 
pneumoniae infections in ICU patients. From a clinical perspective screening 
patients before admission using the various genomic databases to understand the 
nature of the gut colonisation and subsequent isolation of carriers could help end 
outbreaks and prevent future ones. Also, advanced knowledge of the antimicrobial 
susceptibility profiles of K. pneumoniae carried in a patient’s gut before admission 
to hospital could guide the choice of prophylactic and therapeutic antimicrobial 
treatment. Screening of patients when transferred from tertiary referral hospitals to 
specialised hospitals using available genomic databases could be valuable to 
prevent hospital-to-hospital spread of AMR genes for the management or 
prevention of MDR infections (Gorrie et al., 2018). 
K. pneumoniae ST307 (closely related to ST258) has been around for the 
last 20 years but its importance went unnoticed before the availability of WGS 
(Wyres et al., 2019). Its resistance and virulence traits have become clinically 
significant, as ST307 has the ability to acquire and disseminate carbapenemases. 
With this knowledge clinical laboratories can enhance their surveillance 
programmes to monitor ST307 alongside other known clones and detect emerging 
MDR threats and stop outbreaks. 
Lam et al. (2018) used WGS to identify ST23, a hypervirulent K. 
pneumoniae that carries the virulence factor colibactin, a genotoxin encoded by 
the synthesis locus clb (pks) and responsible for promoting gut colonisation and 
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the mucosal invasion responsible for pyogenic liver abscess, which has been 
shown to be a significant risk factor for colorectal cancer. Lam et al. (2018) noted 
only those ST23 strains that encoded the clb locus caused disease. This 
information is important from a clinical perspective, as once known the patient can 
be treated and monitored to prevent further complications. The additional 
knowledge provided can also aid the clinical reference laboratory to update their 
characterisation tools. For example, to date UK clinical reference laboratories only 
monitor for the presence of rmpA and wcaG, capsule-associated virulence genes 
linked to pyogenic liver abscess formation in hypervirulent strains of K. 
pneumoniae. The findings of Lam et al. (2018) suggest reference laboratories may 
also need to include the clb locus and other genes which may be linked to invasive 
diseases in their routine screening. 
Another notable development from the study of Lam et al. (2018) was the 
genotyping tool Kleborate. This has been combined with Kaptive (Wyres et al., 
2016) and made available as an online tool (http://kaptive.holtlab.net) allowing 
those with limited bioinformatics expertise to capsule and O antigen type Klebsiella 
WGS data. The results can be downloaded in a graphical interface, presenting 
data in an easily interpretable manner that can be understood by anybody without 
a bioinformatic background (Wick et al., 2018). Tools such as this are very 
important to clinical microbiologists such as myself, who recognise WGS is going 
to become a routine tool in clinical laboratories but do not have any training in 
bioinformatics analyses. Online tools such as the Institut Pasteur Klebsiella 
pneumoniae MLST website (https://bigsdb.pasteur.fr/klebsiella/klebsiella.html) 
allow sequence type and other information (e.g. antibiotic resistance genes, 
virulence genes) to be easily generated from WGS data. The Klebsiella oxytoca 
MLST website (https://pubmlst.org/koxytoca/) allows only sequence typing, but is 
still useful to those with limited bioinformatics training. 
If WGS is the future of clinical microbiology, then it is paramount that staff 
working in clinical laboratories are trained or at least have a basic understanding 
of the tools available to characterise WGS data. During my Professional Doctorate 
studies I intend to gain experience in using these and other bioinformatics tools to 
better understand how WGS can benefit the clinical microbiology laboratory. There 
is now widespread recognition of the great potential for genomics to enhance 
surveillance and tracking of specific pathogens, and of AMR more generally, and 
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to aid infection control and outbreak investigations. At present, biomedical scientist 
training is based on phenotypic culture methods, but maybe it is time for training 
programmes to include genomics and bioinformatics as core components if we are 
to fully utilise these developing technologies. 
 
1.7 PHAGES TO TREAT ANTIBIOTIC-RESISTANT INFECTIONS 
Lytic phages are viruses that infect and kill bacteria, and are among the 
most abundant entities on Earth, with viruses being present at an estimated 
number of ~1031 particles (Breitbart and Rohwer, 2005). Phages are ubiquitous 
and are found anywhere there are bacteria: e.g. in water sources, sewage, soil 
and the intestines of animals (Hoyles et al., 2014). More than 6000 different (lytic 
and lysogenic) phages have been discovered and described morphologically; this 
includes 6196 bacterial and 88 archaeal viruses (Ackermann and Prangishvilli, 
2012). Most of these viruses are tailed with a small proportion being filamentous 
and all are classified according to their morphology and genetic content (i.e. DNA 
vs RNA) and the host they infect (Whittebole et al., 2014). Phages are obligate 
intracellular parasites of bacteria with different life cycles. For PT, lytic phages are 
recommended due to their lethal activity. Appendix 1 represents a review I 
contributed to, outlining what is known about phages infecting Klebsiella spp. and 
how these are being tested for use in PT, as alternatives or adjuncts to antibiotic 
therapy. The review has been made available as a preprint (Herridge et al., 2019) 
and is currently under review by the Journal of Medical Microbiology. I believe it 
should be possible to isolate phages against MDR Klebsiella strains, and these 
phages could be used in the future to treat MDR infections or decolonise patients 
when they are admitted to hospital, to reduce the likelihood of outbreaks and/or 
the incidence of MDR infections. 
The information obtained from the studies referenced in the review was 
useful for the current study, highlighting that many phage studies rely on in vitro 
assays. While a few phages have been tested in animal models with successful 
results, future research needs to be concentrated on clinical trials in animal 
models and humans to show the efficacy and safety of these treatments before 
they can be accepted as safe for use in humans. The current study will not be able 
to address animal or human studies due to lack of time and funding. 
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1.8 AIMS 
To control the spread of CPOs, improved clinical laboratory methods are 
needed to increase the range of bacteria detected and the diverse range of 
carbapenem-hydrolysing enzymes that have emerged. These methods can 
include isolation, phenotypic and genomic methods. Clinical laboratories rely on 
simple isolation approaches, antimicrobial susceptibility testing, MALDI-TOF and 
PCR-based methods to characterise clinical isolates, but WGS is becoming 
routine in academic and PHE reference laboratories, and is likely to be used 
routinely in clinical laboratories in the next 5-10 years. In addition, alternatives or 
adjuncts to antibiotic therapies are needed to combat the increasing number of 
antibiotic-resistant infections. Therefore, the aims of my Professional Doctorate 
studies are to: 
1. Develop an improved screening method for detection of CPOs in the West 
London Hospitals covered by the Imperial College Healthcare NHS Trust. 
2. Characterise a collection of carbapenem-resistant Klebsiella isolates, to 
understand how simple bioinformatics approaches can be used to identify 
and better understand resistance genes in clinically relevant bacteria. 
3. Isolate lytic phages active against clinically relevant carbapenem-resistant 
K. pneumoniae and K. oxytoca from sewage samples, and begin to 
characterise them in terms of their phenotypic and genomic properties. 
The objectives of the project are to: 
1. Undertake an extensive literature review on available infection control and 
screening programmes, and to use the information gathered to select the 
best products for testing for the isolation of CPOs in the Microbiology 
Laboratory of Charing Cross Hospital. 
2. Plan and conduct a study with the products identified in objective 1, and 
identify which commercial medium is best for isolating a wide range of 
CPOs. 
3. Screen sewage samples, known to be abundant sources of lytic phages 
active against Gram-negative bacteria, to isolate phages active against a 
collection of antibiotic-resistant strains of Klebsiella spp. isolated in West 
London hospitals since 2010. 
4. Propagate the phages from objective 3 to purity and screen them against a 
panel of clinical isolates to determine their host ranges. 
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5. Isolate DNA from the purified phages (objective 4) to allow restriction 
profiles to be generated. Phages with unique restriction profiles will have 
their whole genomes sequenced and their genes annotated and functions 
assigned. They will also be characterised phenotypically, by assessing their 
tolerance to stresses (e.g. temperature, pH, chloroform), their adsorption 
rates, burst sizes and one-step growth curves. 
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CHAPTER 2: EVALUATION OF FOUR DIFFERENT CHROMOGENIC MEDIA 
FOR THE DETECTION OF CARBAPENEMASE-PRODUCING ORGANISMS IN 
WEST LONDON HOSPITALS 
 
2.1 PERSONAL CONTRIBUTION TO THIS STUDY 
This project was carried out while I worked as a Senior Biomedical Scientist 
in the Microbiology laboratory of Charing Cross Hospital. I was tasked with 
identifying an improved screening procedure for detection of carbapenemase-
producing organisms (CPOs) from patient samples. I conducted an extensive 
literature review on available infection control and screening programmes. I also 
had meetings with product manufacturers, studied the different products on the 
market and selected the best products for the isolation of CPOs. Based on my 
findings I produced a project plan to study which of four different commercially 
available media was best for isolating a wide range of CPOs. The study was 
carried out under my supervision, and I assisted with the laboratory work. I also 
educated the team on antibiotic resistance, how to use the selected products, 
helped with the interpretation of results and research outcomes, and wrote up the 
work for publication (Shibu et al., 2016; Appendix 2). 
 
2.2 INTRODUCTION 
Carbapenems are used as last-resort antibiotics for the treatment of 
infections caused by multidrug-resistant (MDR) Enterobacteriaceae (Escherichia, 
Klebsiella and Enterobacter spp.) and pseudomonads (Acinetobacter and 
Pseudomonas spp.). During the last decade carbapenem resistance has been 
increasingly reported and CPOs have become a growing challenge in healthcare 
settings (Grundmann et al., 2010; Freeman et al., 2015). In the UK, CPOs – 
especially Klebsiella pneumoniae CPOs – are a challenge to infection control in 
hospital settings: firstly, due to their ability to spread and cause outbreaks with 
different species of Enterobacteriaceae with the same mobile resistance gene 
(Grundaman et al., 2010); secondly, as CPOs inhabit the gastrointestinal (GI) 
tract, decolonisation therapy only reduces the number of CPOs without elimination 
(Curran and Otter, 2014). The majority of people are colonised with these 
organisms with no further complications but in immunocompromised patients 
colonisation can lead to endogenous infection, which can be a cause of cross-
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infection (Curran and Otter, 2014; Patel et al., 2007). Furthermore, studies have 
shown patients with invasive CPO infections have a two-fold higher number of 
deaths than those infected with antibiotic-sensitive strains (Falagas et al., 2014). 
CPOs are extremely MDR (resistant to carbapenems, penicillins and 
cephalosporins) and often carry genes that confer resistance to other 
antimicrobials (aminoglycosides and quinolones) leading to limited therapeutic 
options for infections caused by these organisms (Livermore and Woodford, 
2006). CPOs may express a number of different genes which encode different 
types of β-lactamases capable of hydrolysing carbapenems. These enzymes 
include the class A carbapenemases (Klebsiella pneumoniae carbapenemase 
(KPC) types), the class B or metallo-β-lactamases (MBLs) (imipenem resistant 
metallo-β-lactamase (IPM), New Delhi metallo-β-lactamase (NDM), and Verona 
integron-encoded metallo-β-lactamase (VIM) types), and the class D oxacillinases 
(OXA) (e.g. OXA-48-like enzymes) (Livermore, 2012a). CPOs are associated with 
high rates of morbidity and mortality, particularly among critically ill patients with 
prolonged hospitalisation (Curren and Otter, 2014; Osei Sekyere et al., 2016). 
They are usually resistant to broad-spectrum β-lactam antibiotics (encompassing 
cephalosporins, carbapenems, penicillins, monobactams, and cephamycins) and 
β-lactam–β-lactamase inhibitor combinations (ampicillin-sulbactam, amoxicillin-
clavulanate, ticarcillin-clavulanate, and piperacillin-tazobactam), oxyimino-
cephalosporins (e.g. ceftriaxone, ceftazidime, and cefotaxime), aztreonam and 
carbapenems (e.g. meropenem, ertapenem, imipenem, and doripenem). They are 
also frequently resistant to antibiotics used in combination with β-lactam antibiotics 
(e.g. aminoglycosides, quinolones, and tetracyclines) because of additional types 
of resistance genes carried by Enterobacteriaceae, making them even more of a 
concern for the health sector since the treatment options are very restricted (Viau 
et al., 2016). 
To date, CPOs generally remain susceptible to colistin (although resistance 
is on the rise) and intermediate to tigecycline. However, there are significant 
drawbacks in terms of the therapeutic viability of tigecycline which can lead to 
resistance, and colistin usage is limited due to its neurotoxicity and nephrotoxicity 
(Carmeli et al., 2010; Livermore, 2012a). As such, tigecycline and colistin are used 
as the antibiotics of last resort to treat CPOs. Increased use of these antibiotics 
clinically (Freeman et al., 2014) and in animal husbandry (Zdziarski et al., 2003) 
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has led to the emergence of bacteria with resistance to these antibiotics, and 
resistant strains have been reported during therapy (Rodríguez-Avial et al., 2012; 
Osei Sekyere et al., 2016). In addition, carbapenemase-encoding genes 
harboured by CPOs are mostly transposon- and/or integron-encoded determinants 
that can easily disseminate to other enterobacterial strains and species (Johnson 
and Woodford, 2013; Osei Sekyere et al., 2016), which means cross-infection 
among patients is of great concern within hospital settings. GI carriers of CPOs 
are thought to be the main reservoir of cross-transmission in healthcare settings 
(Curran and Otter, 2014; Patel et al., 2007). Consequently, there is a need to 
implement adequate preventive measures, including active surveillance, in clinical 
laboratories to contain the spread of pathogenic CPOs (Viau et al., 2016). Several 
studies have highlighted the need for such programmes, and how they may help 
reduce transmission of GI CPOs in combination with control programmes. 
During 2006, most hospitals in Israel faced a clonal outbreak of 
carbapenem-resistant Klebsiella pneumoniae that was not contained by local 
control measures. This led the Ministry of Health to issue guidelines in March 2007 
that required individual hospitals to isolate patients who were suspected of 
carriage of resistance organisms with a dedicated nursing staff together with 
improved early detection methods within the Microbiology laboratory. Prompt 
feedback alerting infection control of all new carbapenemase-producing 
Enterobacteriaceae (CPE) isolates eventually resulted in the containment of the 
outbreak (Schwaber et al., 2011). Enfield et al. (2014) showed strict 
implementation of the CDC 2012 CRE Toolkit resulted in controlling an outbreak of 
CPE in intensive care units (ICUs) of hospitals in the United States. The CDC 
2012 CRE Toolkit comprised enhanced infection control measures including staff 
education, improved hand hygiene, strict isolation, thorough environmental 
hygiene and assessment, and antibiotic stewardship. The drawback with this study 
was that screening for CPEs was only done once a week and not for each patient 
on their admission to hospital, so it did not provide the true number of CPE carriers 
admitted to hospital. Sypsa et al. (2012) isolated CPEs on patient admission, kept 
CPE-colonised patients together and away from non-colonised patients, and 
implemented improved hand hygiene and contact precautions in the surgical unit 
of a tertiary-care hospital in Greece. This provided a better surveillance system 
and led to a notable reduction of the spread of CPE within 8-12 weeks of 
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implementation. A study carried out in the ICU ward of New York Downstate 
Medical Center, Brooklyn, documented a significant reduction in CPO carriage (the 
mean number ( ± SD) of new patients per 1,000 patient-days per quarter with 
cultures yielding carbapenem-resistant K. pneumoniae decreased from 9.7 ± 2.2 
before the intervention to 3.7 ± 1.6 after the intervention (P<0.001)) within the first 
year of implementation of a screening and infection control programme (Kochar et 
al., 2009). Success of the programme relied on screening of GI carriage of 
carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii by 
culturing rectal swabs and isolating patients in curtain-partitioned cubicles while 
results were pending; if results were positive, the ward was closed for 2 days and 
cleaned with isopropanol and an ammonium-based compound. Availability of a 
quick screening test would likely have led to even greater reduction of carriage 
rates (Viau et al., 2016). 
Kwong et al. (2018) showed rapid identification of CPE using real-time PCR 
methods combined with epidemiological and genomic investigations (i.e. whole 
genome sequencing (WGS) of the resistant bacteria) was critical for identifying 
and controlling transmission of CPE in Australian hospitals. The results of the 
study suggest that routine WGS of isolates would allow centralised comparison of 
CPEs between different hospitals that would aid rapid identification and location of 
the source of infection, and the potential to control further transmission. The main 
drawback of this study was the high cost, although WGS technologies are getting 
cheaper; albeit still rather prohibitive for routine screening use in the clinical 
setting. 
Colonisation rates for CPEs have been on the increase in the UK over the 
past decade. In 2014, Public Health England (PHE) produced guidelines to 
prevent or reduce the spread of CPEs in health and residential care settings (PHE, 
2014). They recommended risk-factor-based screening of all patients on 
admission to acute healthcare settings (PHE, 2013). This included the following 
measures. 
1. Determining whether the patient had recently been admitted to any hospital in 
countries/regions with reported high prevalence of healthcare-associated CPE 
(e.g. North Africa and the Middle East, Bangladesh, China, Cyprus, Greece, 
India, Ireland, Israel, Italy, Japan, Malta, Pakistan, South East Asia, 
South/Central America, Turkey, Taiwan and the USA). 
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2. Determining whether the patient had recently been admitted to a hospital in 
areas of the UK where problems associated with CPE had been reported (the 
North West (especially Manchester) and London). 
3. Following the patient admission flow chart for infection prevention and control 
of CPE (Figure 2.1). 
 
 
 
Figure 2.1. Acute trust patient admission flow chart for infection prevention and 
control (IP&C) of CPE including pseudomonads. Image reproduced from PHE 
(2013) under the terms of the Open Government Licence v2.0. 
 
 
The threat of carbapenem resistance within the UK’s healthcare system is 
further increased because the above-mentioned organisms can rapidly acquire an 
additional resistance gene that encodes for the New Delhi metallo-β-lactamase 
(NDM). The resistance genes are carried on plasmids which also harbour other 
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antibiotic resistance genes with rapid dissemination to other species of 
Enterobacteriaceae. This resistance (i.e. NDM) is now highly prevalent in 
Klebsiella pneumoniae. NDM Klebsiella pneumoniae was introduced into the UK 
by individuals returning from visits to India or Pakistan, where the NDM variant is 
endemic (Johnson and Woodford, 2013; Nordmann et al., 2011). This led to NDM 
strains causing outbreaks in the high-dependency units of west London hospitals. 
 
2.2.1 Prevalence of carbapenemase resistance in UK 
The first confirmed UK detected carbapenemase was an Acinetobacter 
isolate with IMP-1 in 2000, isolated from a hospitalized patient with a history of 
travel from an endemic area. From 2008, the numbers of confirmed CPE 
increased dramatically in the UK: 23 in 2008, 73 in 2009, 333 in 2010, and 561 in 
2011 (Figure 2.2). These were seen more in Klebsiella spp. (80%, mainly 
Klebsiella pneumoniae), followed by Escherichia coli (10%) and Enterobacter spp. 
(8%), with the remaining 2% comprising occasional isolates of Citrobacter, 
Morganella, Providencia, Raoultella and Serratia spp. The enzymes produced 
included KPC (62%), NDM (14%), VIM (12%), OXA-48-like (9%) and IMP (2%) 
types, each from a different hospital around north western side of UK. In 2008, 
Hammersmith Hospital (HH), part of the Imperial College Healthcare NHS Trust 
(ICHNT) in the London area, experienced the first carbapenemase outbreak in the 
renal unit. This was caused by Klebsiella pneumoniae with OXA-48; which was a 
dominant outbreak strain, but with horizontal transfer of an OXA-48-encoding 
plasmid to other strains (Thomas et al., 2013). 
From 2008, the southern area of UK started experiencing a wider 
distribution of Enterobacteriaceae with NDM and by the end of 2011 genes 
encoding NDM enzymes had been detected in 138 isolates of Enterobacteriaceae 
and 11 Acinetobacter baumannii isolates. Multiple species with NDM enzymes 
were isolated from several patients, which is consistent with either in vivo transfer 
of a resistance plasmid or initial colonisation or infection by more than one 
species. The epidemiological follow-up for these cases showed all these patients 
with NDM-positive isolates had travelled to or had healthcare contact in India or 
Pakistan. 
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Figure 2.2. Numbers of UK laboratories referring at least one carbapenemase-
producing Enterobacteriaceae (CPE) isolate to the Antibiotic Resistance 
Monitoring and Reference Laboratory (Health Protection Agency). Additionally, in 
2010 and 2011, two and one laboratories referred IMI-producing CPE isolates, 
respectively. In 2011, one laboratory referred at least one CPE isolate producing 
both KPC and VIM enzymes (Cantón et al., 2012). 
 
 
2.2.2 CPE history at the Imperial College Healthcare NHS Trust 
The first isolation of CPE (OXA-48) in the West London Hospitals belonging 
to the ICHNT was in 2008 in the renal unit of HH from a routine wound culture. 
PHE was notified of its isolation. Subsequent years showed an increase in OXA-
48 CPE within the renal unit and other wards within HH. A general increase of 
these CPE in UK hospitals was also noticed by the PHE surveillance unit at 
Colindale, which responded to the need to control their spread by the introduction 
of the CPE tool kit in 2014 (PHE, 2013). 
Between 2014 and 2015 a CPE outbreak of NDM CPE in the renal unit at 
HH and the vascular unit at St Mary's Hospital (SMH) was identified, and 40 
patients were confirmed with NDM Klebsiella pneumoniae on screening. The CPE 
toolkit (PHE, 2013) was only being used as a guide to screen selected high-risk 
patients at that time. As such, NDM Klebsiella pneumoniae was not being 
monitored in the ICHNT, as it was not a recognised problem within the Trust at 
that time. The outbreak was traced to a renal patient who had travelled abroad for 
surgery, returning to the UK with their gut colonised with NDM Klebsiella 
pneumoniae. The patient was admitted to both HH and SMH during the timeframe 
consistent with being the source of cross-transmission of the resistant CPE among 
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patients in this outbreak. The ICHNT response to this was to recognize the need 
for a continuous widespread screening campaign that was cost-effective, rapid, 
accurate, reproducible and able to cope with the large volume of samples 
expected each month (~4000 patients/month), with good sensitivity and specificity 
for all CPE and not only OXA-48. The Microbiology laboratory at Charing Cross 
Hospital (CXH) worked closely with the infection control team to implement such a 
large-scale screening programme, dealing with samples from all five hospitals 
within the West London ICNHT. The objective of this study was, therefore, to 
identify carbapenem-resistant organisms (CROs) using routinely collected local 
microbiology data, to describe the epidemiology of carbapenem resistance among 
clinical Enterobacteriaceae and its spread within five West London Hospitals. In 
order to manage the high laboratory demand for a large screening programme 
contributing to preventing or reducing the spread of CPE within ICHNT, a trial of 
different media and in-house testing was performed for one week. 
Before implementation of a screening programme it is important to consider 
certain factors, i.e. patient type at admission, identifying the high-risk group, the 
baseline prevalence and type of resistance mechanism within the locality. First, 
the infection control team worked out a screening protocol to identify high-risk 
patients according to the CPE toolkit (PHE, 2013) and appropriate in-house 
considerations. All high-risk general medicine admissions to the five hospitals 
within the Trust were screened for CPE for one week. In addition, all patients 
within the renal unit, the vascular unit, and all private patients, paediatric ICU 
patients and cancer patients were screened for CPE for one week. This was done 
to identify those at risk of CPE infections, and to gather baseline information 
regarding what CPEs were in circulation within the Trust. 
The Microbiology laboratory concurrently conducted a study to assess and 
validate four different chromogenic media (Brilliance CRE; chromID Carba; 
CXmSCARBA-1; and CXmSCARBA-2) designed for the isolation of CPEs 
including those producing OXA-48-like enzymes. These media incorporate 
antimicrobials for the inhibition of other micro-organisms and biomarkers to 
differentiate species using chromogenic substrates with a pH indicator. The overall 
aim was to find the most rapid, cost-efficient screening method with high sensitivity 
and specificity for the detection of CPEs for use in the West London ICHNT. They 
were compared with the standard method in use at the time, which comprised 
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inoculating samples (mainly rectal/perineum swabs) onto a MacConkey plate with 
ertapenem and meropenem discs (10 µg) and further characterisation of any 
isolates that showed resistance to these antibiotics. Namely, phenotypic 
identification of isolates (using matrix-assisted laser desorption/ionization time of 
flight; MALDI-TOF), testing with additional antibiotics and presumptive CPOs being 
sent to PHE for typing to identify the resistance gene(s). 
As the work on CPE screening was started at ICHNT, van der Zwaluw et al. 
(2015) published a new method (CIM method) to detect carbapenemase activity in 
Gram-negative rods within 8 h. This method reported high concordance with 
results obtained by PCR to detect genes coding for the carbapenemases IMP, 
KPC, NDM, OXA-23, OXA-48, and VIM. It was said to allow reliable detection of 
carbapenemase activity encoded by various genes in species of 
Enterobacteriaceae (e.g. Klebsiella pneumoniae, Escherichia coli and 
Enterobacter cloacae), but also in the non-fermenters Pseudomonas aeruginosa 
and Acinetobacter baumannii. The CIM method was reported to be a cost-effective 
and highly robust phenotypic screening method that could reliably detect 
carbapenemase activity. The medical team thus requested that the efficacy of this 
method be tested in a limited number of samples initially (due to limited 
resources). Accordingly, 18 positive controls and four negative controls were 
accessed by this method. 
 
2.3 MATERIALS AND METHODS 
2.3.1 Samples 
Clinical samples 
Rectal, perineal and/or throat swabs were taken for CRO screening from 
236 patients hospitalised on ten different wards during an outbreak (mainly in the 
high-dependency units, including the renal dialysis unit) at HH and SMH between 
March and April 2015. 
 
Positive and negative controls 
The positive controls comprised a collection of 20 CROs obtained from 
clinical samples (previously isolated from patients during routine screening; with all 
positive isolates stored in viabank cryogenic storage beads (ProLab) at -70°C). 
The isolates had been defined at the molecular level by the reference laboratory, 
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as part of standard operating procedure. The resistance mechanisms were 
determined by multiplex PCR (Poirel et al., 2011a), which detects various genes 
that encode for acquired carbapenemases. The positive controls comprised three 
isolates with NDM-1 (Escherichia coli, n = 1; Klebsiella pneumoniae, n = 1; and 
Proteus mirabilis, n = 1), two with IMP (Escherichia coli, n = 1; and Pseudomonas 
aeruginosa, n = 1), five with KPC (Klebsiella pneumoniae, n = 5), five with OXA-48 
(Acinetobacter baumannii, n = 1; Escherichia coli, n = 1; Klebsiella pneumoniae, n 
= 2; and Serratia marcescens, n = 1), and five with VIM (Enterobacter cloacae, n = 
1; Klebsiella oxytoca, n = 1; Klebsiella pneumoniae, n = 1; and Pseudomonas 
aeruginosa, n = 2). 
The negative controls comprised 20 isolates of non-CROs (taken from a 
collection of PHE characterised patient isolates stored in viabank cryogenic 
storage beads at -70°C) showing a diverse range of resistance mechanisms 
consisting of extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases 
with porin loss (Table 2.1). These were characterised by the standard operating 
protocols for susceptibility testing conforming to British Society for Antimicrobial 
Chemotherapy (BSAC) guidelines (BSAC, Version 12, 2015). Isolate identification 
was performed by MALDI-TOF MS (Biotyper, Bruker). 
 
2.3.2 Culture of bacteria from clinical swabs 
Each clinical swab was suspended in 0.5 ml of sterile saline (0.85% in water) to 
generate a homogeneous suspension and processed using the in-house 
screening protocol (Figure 2.3). After vortexing, an aliquot of this suspension (50 
µl) was used to inoculate each chromogenic medium (Wilkinson et al., 2012). In 
the limited number of cases that multiple swabs (from different sites) were 
obtained from the same patient, a single suspension was prepared using all swabs 
(rectal, perineal and/or throat). Samples were plated on to each of four different 
chromogenic media: Brilliance CRE (PO1226A, Oxoid Ltd, UK), chromID Carba 
(bioMérieux, France), CXmSCARBA-1 (Chromagar, France) and CXmSCARBA-2 
(Chromagar, France) provided by E&O laboratories (Figure 2.4). 
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Table 2.1: Negative controls used in this study. 
Control Strain Characteristics* 
1 Enterobacter cloacae M22 AmpC positive 
2 Klebsiella pneumoniae W88 ESBL positive with porin loss 
3 Enterobacter aerogenes W31 AmpC positive 
4 Enterobacter spp. X34 AmpC + ESBL positive 
5 Klebsiella pneumoniae W68 ESBL positive 
6 Escherichia coli H97 ESBL positive 
7 Klebsiella pneumoniae F44 ESBL positive 
8 Klebsiella pneumoniae H32 ESBL positive with porin loss 
9 Klebsiella pneumoniae T10 ESBL positive with porin loss 
10 Klebsiella pneumoniae T73 ESBL positive with porin loss 
11 Enterobacter spp. H88 AmpC positive with porin loss 
12 Klebsiella pneumoniae F22 CTX M ESBL positive with porin loss 
13 Enterobacter cloacae W46 AmpC positive 
14 Klebsiella pneumoniae M68 AmpC + ESBL positive 
15 Klebsiella pneumoniae X15 ESBL positive 
16 Pseudomonas aeruginosa M30 Porin loss + efflux  
17 Enterobacter cloacae F09 AmpC positive 
18 Klebsiella pneumoniae H03 ESBL positive 
19 Pseudomonas aeruginosa S89 Porin loss 
20 Enterobacter cloacae W66 ESBL + AmpC positive 
*AmpC, AmpC-type β-lactamase, ESBL, extended-spectrum β-lactamase; CTX M 
ESBL, cefotaxime-resistant ESBL. 
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Figure 2.3. Protocol used in the initial CRO screening study in ICHNT. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Examples of culture growth on the four different chromogenic media. 
(a) Klebsiella pneumoniae; (b) Escherichia coli; (c) Acinetobacter baumanii. Note: 
Chrom ID Smart = ChromID Carba. 
(a) (b) (c) 
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The inoculum was streaked to obtain individual colonies and all media were 
incubated aerobically at 37 °C for 18-20 h. Both coloured and white colonies were 
regarded as presumptive CROs in accordance with the manufacturers’ instructions 
(Figure 2.4). Strains of Escherichia coli produced red colonies on all four 
chromogenic media, whereas Klebsiella pneumoniae produced blue colonies on 
Brilliance CRE, CXmSCARBA-1 and CXmSCARBA-2, and green colonies on 
chromID Carba. Pseudomonas aeruginosa and Acinetobacter baumannii both 
formed colourless/white colonies on all four chromogenic agars. Pseudomonas 
spp. and Acinetobacter spp. were distinguished by performing an oxidase test 
(Oxoid), the former being oxidase positive and the latter oxidase negative. 
The clinical suspensions were also plated on to MacConkey agar (Oxoid) 
with ertapenem and meropenem discs (10 µg; Oxoid), the standard method at the 
time − which followed the standard operating protocols of the national guidelines 
(UK Standards for Microbiology Investigations, 2013) with susceptibility testing 
conforming to BSAC guidelines (Version 12, 2013; http://bsac.org.uk/stewardship-
surveillance/susceptibility/methodologylatestversion/). Here any 
Enterobacteriaceae with zones of inhibition (<27 mm) for ertapenem and/or 
meropenem were regarded as presumptive CROs. All presumptive CRO colonies 
were stored in cryobank cryogenic storage beads at -70°C and subcultured on 
nutrient agar slopes for sending to the PHE reference for laboratory identification. 
The culture media with a pure culture displaying colonies with morphological 
characteristic of interest were identified to species level using MALDI-TOF MS. If 
the culture plate were mixed or did not show enough growth (i.e. only one or two 
colonies in total), the colonies were subcultured on to blood agar (Oxoid) and 
identified the following day. All identified Enterobacteriaceae isolates from each 
patient were subcultured on to blood agar and incubated overnight to perform 
phenotypic testing. 
 
2.3.3 Culture of positive and negative controls 
Each isolate stored in cryovial beads at -70 °C was thawed and subcultured 
onto non-selective blood agar and incubated aerobically for 24 h at 37 °C. 
Colonies of fresh pure cultures of each positive control were then suspended in 
sterile saline and adjusted to McFarland 0.5 (~108 CFU/ml) with the aid of a 
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densitometer (Densimat, bioMérieux).The adjusted suspension was then ten-fold 
serially diluted to 105 CFU/ml (Wilkinson et al., 2012). Aliquots (10 µl) of each 
dilution were inoculated onto each of the four chromogenic agar plates. For the 
negative controls, a 10 µl aliquot of an undiluted 0.5 McFarland suspension was 
inoculated onto each of the four chromogenic agar and checked for growth 
following incubation. All culture plates were incubated for 18-20 h at 37 °C. 
The sensitivity and specificity for all methods were calculated using the 
formulae: 
Sensitivity = TP/(TP + FN) 
Specificity = TN/(FP + TN) 
Positive predictive value = TP/(TP + FP) 
Negative predictive value = TN/(FN + TN) 
TP = true positive; FP = false positive; TN = true negative; FN = false negative. 
To ascertain the limit of detection (LOD) of the four chromogenic media, 
control organisms displaying the five different resistant mechanisms were selected 
and a fresh pure culture of each was suspended in saline and adjusted to the 
density of McFarland 0.5 (∼108 CFU/ml), serially diluted to 10-8 (i.e. to 1 CFU/ml), 
and the different dilutions spread plated onto the four chromogenic media. The 
LOD was determined based on the minimal colony count allowing detection on the 
respective screening plates. 
 
2.3.4 Carbapenem Inactivation Method (CIM) 
A suspension of 10 µl (loop full) of organism grown on blood agar was 
prepared in 400 µl of water for each control strain. Subsequently, a disc containing 
10 µg meropenem (Oxoid) was immersed in the suspension and incubated for a 
minimum of 2 h at 37 °C. Similarly, discs containing ertapenem and imipenum (10 
µg; Oxoid) were used separately. The disc was removed from the suspension 
using an inoculation loop, placed on a Mueller-Hinton agar plate inoculated with a 
sensitive indicator strain of Escherichia coli (ATCC 29522; using 0.5 McFarland 
suspension) and incubated at 37 °C for 18-24 h. If the control strain produced 
carbapenemase, the meropenem/ertapenem/imipenum in the disc was inactivated 
and thus allowed uninhibited growth of the susceptible indicator strain. Discs 
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incubated in suspensions that did not contain carbapenemases yielded a clear 
inhibition zone, due to the antibiotics remaining intact. 
 
2.3.5 Identification of bacteria and susceptibility testing 
All isolates that grew on CPE selective media were identified by MALDI-
TOF MS, whether presumptive CROs or not, to gain some insight into the 
selectivity of the media. All isolates identified as Enterobacteriaceae, 
Psuedomaonas spp. and Acinetobacter spp. were screened for possible 
carbapenemase production following the standard operating procedures in 
accordance with the UK national guidelines (PHE, 2013). This involved sensitivity 
testing against 18 antimicrobials following the BSAC disc diffusion method, with 
the inclusion of MAST CAT ID discs for the presumptive CPO isolates showing 
resistance to meropenem. CAT ID discs consist of an indicator carbapenem 
(faropenem; MAST group Ltd, UK) and were tested for their sensitivity and 
specificity for detecting carbapenemase-producers (Figure 2.5). 
 
 
 
Figure 2.5. Image illustrating interpretation criteria for CAT ID discs. (a) Organism 
sensitive to CAT ID = negative (non-CPO). (b) Organism showing micro colonies 
within the zones was interpreted as an OXA-48 type CPO. (c) Organism resistant 
to CAT ID = positive (CPO). 
 
The results were interpreted using BSAC break points 
(http://bsac.org.uk/stewardship-
surveillance/susceptibility/methodologylatestversion/). Any organisms showing 
resistance to one of the two selected carbapenem discs (ertapenem and 
metropenem) were further tested by E-strip (Launch) to ascertain the Minimum 
Inhibitory Concentration (MIC). Isolates showing phenotypic evidence of 
(a) (b) (c) 
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carbapenemase production (i.e. MIC to ertapenem ≤0.5 µg/ml or to meropenem ≤2 
µg/ml) were sent to the PHE reference laboratory at Colindale, UK, for typing 
through Variable Number Tandem repeats (VNTR) analysis and resistance 
mechanisms sort by multiplex PCR which detects various genes that encode for 
acquired carbapenemases including class A (GES, IMI, KPC, NMC, and SME), 
class B (AIM, GIM, IMP, KHM, NDM, SIM, SPM, TBM, and VIM) and class D 
(OXA-48-like) carbapenemases. 
 
2.3.6 Validation of Cepheid’s GeneXpert System (in-house molecular 
detection of carbapenemases)  
Cepheid’s GeneXpert System provides a molecular platform claimed to 
deliver faster, more accurate results that improve patient outcomes, operational 
efficiencies, and reduce the overall cost of care. The Xpert Carba-R PCR is able to 
detect the five prevalent carbapenemases (IMP-1, KPC, NDM, OXA-48, and VIM) 
and can be performed directly from rectal swabs or from culture. The PCR test is 
quick and simple to use with results available within <1 h. Due to limited resources 
(only 30 cartridges were provided free by Cephid) to validate the Xpert® Carba-R 
PCR test, and the priority to test any presumptive isolate that needed an urgent 
result due to infection control purposes and better patient management, only those 
isolates identified by the medical microbiology consultants on daily benchrounds 
were targeted for evaluation. Of the 49 presumptive CPO isolates from patients, 
23 isolates were tested together with four positive controls (Klebsiella pneumoniae 
ATCC 1705: KPC positive; Klebsiella pneumoniae NCTC 13442: OXA 48 positive; 
Klebsiella pneumoniae NCTC 13443: NDM positive; and Pseudomonas 
aeruginosa NCTC 13437, VIM positive; Oxoid) using Xpert® Carba-R PCR 
following the manufacturer’s instructions. The primers and probes in the Xpert® 
Carba-R assay detect proprietary sequences for the blaIMP-1 (IMP-1), blaKPC (KPC), 
blaNDM (NDM), blaOXA-48 (OXA-48), and blaVIM (VIM) gene sequences associated 
with carbapenem-resistance in Gram-negative bacteria. 
 
2.4 RESULTS 
During the screening period, a total of 236 clinical samples (perineum, 
rectum or throat swabs) were examined for CPOs using the standard method at 
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that time and to the four chromogenic agars. 236 samples from 236 patients 
yielded 267 colonies of interest that were subcultured to purity on blood agar and 
their identification confirmed using MALDI-TOF. These included Acinetobacter 
baumannii, Citrobacter koseri, Enterobacter cloacae, Escherichia coli, Klebsiella 
pneumoniae, Morganella morganii, Pseuodomonas aeruginosa, Pseuodomonas 
citronellolis and Pseuodomonas spp. In some cases (n = 26; patients) the target 
organisms were isolated on all five agars and in other cases (n = 264) they were 
only isolated on some of the media. Colonies which exhibited similar 
morphological characteristics to the target bacterial groups (for example, correct 
colour and shape but smaller size) were also checked by Gram staining and any 
Gram-negative organisms identified by MALDI-TOF. This was done to assess the 
performance of the chromogenic agars. In all such cases, the isolates were shown 
to either be Gram-positive cultures (n = 100) or identified as Enterococcus faecium 
(n = 22) or Stenotrophomonas maltophilia (n = 9). For the remaining clinical 
samples (187 patients), no colonies of interest were observed on any of the agars. 
A representative isolate of each organism of interest per clinical sample was 
selected for phenotypic characterisation (n = 85); either that originally isolated by 
the standard method (n = 31) or the healthiest looking subculture from the 
chromogenic agars if not found using the standard method for a particular clinical 
sample (n = 54 samples). Forty-nine of the representative isolates displayed 
phenotypic evidence of carbapenemase and were further characterized by PCR at 
the PHE reference laboratory. Thirty-three isolates were confirmed as CPOs (i.e. 
positive for genes that encode acquired carbapenemases; each isolated from a 
different patient) and 16 were identified as non-CPOs (showed phenotypic 
evidence of carbapenemase but PCR confirmed the resistance was due to 
ESBL/AmpC activities; isolated from 15 different patients, i.e. two of the 16 non-
CPOs were isolated from one patient). 
The standard screening method isolated 23 of the 33 CPOs, but failed to 
detect nine NDM and one OXA-48 producer (Table 2.2). Brilliance CRE isolated 
32/33 CPOs, failing to detect one NDM (Klebsiella pneumoniae 118; which was 
detected by chromID Carba and CXmSCARBA-2); chromID Carba isolated 31/33 
CPOs, failing to detect two NDM (Klebsiella pneumoniae 159 and Klebsiella 
pneumoniae 173; both of which were only isolated on Brilliance CRE); whilst both 
CXmSCARBA-1 and CXmSCARBA-2 isolated 29/33 CPOs and failed to detect 
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four NDM (three of which were not detected by either of the CXmSCARBA plates) 
(Table 2.2). Of the 30 presumptive CPOs isolated using the standard method, 
seven were found to be negative by the reference laboratory PCR (i.e. non-CPOs; 
false positives) (Table 2.2, Table 2.3). Brilliance CRE isolated the most 
presumptive CPOs (n = 45), with 13 of these being false positives. Of the 37 
presumptive CPOs isolated on Chrom ID CARBA, six were false positives (non-
CPOs), whilst seven out of 36 presumptive CPOs isolated on CXmSCARBA-1 
were false positive and five false positives were obtained using CXmSCARBA-2 
(from 34 presumptive CPOs). 
Among the 33 CPO isolates, 32 were confirmed as blaNDM carbapenemase 
producers by both phenotypic testing and PHE reference laboratory PCR. 
Klebsiella pneumoniae was the most prevalent NDM CPO and was isolated from 
30 patients. Escherichia coli blaNDM carbapenemase producer was isolated from 
two patients, and Acinetobacter baumannii blaOXA-48 carbapenemase producer was 
isolated from one patient. 
 
 
Table 2.2: Results showing comparison of four different chromogenic 
culture media for detection of CPOs in clinical samples compared to the 
standard screening method. 
Clinical samples 
(n = 236) 
Medium 
Standard 
method 
Brilliance 
CRE 
chromID 
Carba 
CXm 
SCARBA-1 
CXm 
SCARBA-2 
Negative* (n = 188) 206 191 199 200 202 
Positive** (n = 48) 30 45 37 36 34 
(CPO)*** (n = 33) 23 32 31 29 29 
Non-CPO**** (n = 15) 7 13 6 7 5 
*Organisms sensitive to carbapenemase but grew on the plate. 
**Presumptive CPOs. 
***Organisms with confirmed carbapenemase resistance gene.  
****Organisms showing resistance to carbapenemase due to ESBL/AmpC or porin 
loss. 
 
 
 
	 
	
49	
Table 2.3: Evaluation results for screening of four different chromogenic 
agar with 236 clinical samples. 
 Standard 
method 
Brilliance 
CRE 
chromID 
Carba 
CXm 
SCARBA-1 
CXm 
SCARBA-2 
TP 23 32 31 29 29 
TN 196 190 197 196 198 
FP 7 13 6 7 5 
FN 10 1 2 4 4 
Sensitivity 0.6970 0.9697 0.9394 0.8788 0.8788 
Specificity 0.9655 0.9360 0.9704 0.9655 0.9754 
Positive predictive value 0.7667 0.7111 0.8378 0.8056 0.8529 
Negative predictive value 0.9515 0.9948 0.9899 0.9800 0.9802 
TP = True positive, TN = True negative, FP=False positive, FN = False negative. 
 
 
2.4.1. Comparison of the performance of the chromogenic media and 
standard screening method to detect CPOs 
Clinical swab samples from 236 patients were assessed for CPOs using 
four different chromogenic agars in parallel with the standard method. Forty-nine 
presumptive CPOs were found from 48 clinical samples, of which 33 were 
confirmed to be CPOs by the Reference laboratory (32 NDM and one OXA48). In 
general, the more recently developed commercial chromogenic agars were better 
for determining which clinical samples in this screening study contained CPOs 
than the standard method (Table 2.3). All four chromogenic media displayed 
higher sensitivity and better negative predictive values than the standard method. 
Three of the chromogenic media also provided better positive predictive values 
(98.0–99.5%) and specificity as good as (96.6%; CXm SCARBA-1) or better 
(97.0% and 97.5%; chromID Carba and CXm SCARBA-2, respectively) than the 
standard method (76.7% positive predictive value and 96.6% specificity) (Table 
2.3). The specificity (93.6%) and positive predictive value (71.1%) of Brillance 
CRE were the lowest of all methods (as a result of the higher number of false 
positives), but its negative predictive value (99.5%) was the highest. 
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2.4.2. Investigation of the LOD for the four chromogenic media 
The LOD of the four chromogenic media was tested using 20 CPO controls, 
with different serial dilutions. In general, the positive controls grew well on the four 
chromogenic agars, with similar colony counts seen for the plated dilutions of 
positive control strains (~108, 105 and 103 CFU/ml) on the chromogenic plates as 
obtained using blood agar. However, three of the OXA-48 carbapenemase control 
strains (Escherichia coli S780063, Klebsiella pneumoniae NCTC 13442 and 
Klebsiella pneumoniae S315414) showed poor growth on chromID Carba; Proteus 
mirabilis F1266228 (NDM-1) did not grow on chromaID Carba and displayed poor 
growth on the other three chromogenic media, compared to blood agar counts; 
and Klebsiella oxytoca X1299295 (VIM) did not grow on Brilliance CRE (data not 
included). 
To determine the LOD of each chromogenic agar, a representative positive 
control strain for each carbapenemase group was re-examined with serial dilution 
of the McFarland 0.5 suspension to 10-8 and plating of undiluted suspension, 10-3, 
10-5–10-8 dilutions. Overall, CXmSCARBA-1 chromogenic medium was observed 
to provide the best LOD of carbapenemase-producing bacteria of the four 
chromogenic media (Table 2.4).  
 
2.4.3. Investigation of the specificity of the four chromogenic media 
The different chromogenic media displayed different levels of specificity, based on 
inhibition of growth of negative controls (n = 20) (Table 2.5). All 20 negative 
controls displayed heavy growth on blood agar (control plates) (data not included). 
None of the chromogenic media tested inhibited the growth of all negative 
controls, and all four media displayed heavy growth for controls 2, 5 and 9 
(Klebsiella pneumoniae W1945888, W1741068 and T1490010, respectively). In 
addition, all four chromogenic media afforded growth (weak in some cases) of all 
nine Klebsiella pneumoniae negative control strains. Only five of the 20 negative 
controls were unable to grow on any of the chromogenic media (3, 4, 6, 13 and 17; 
five of the seven Enterobacter strains tested). Overall, CXmSCARBA-2 inhibited 
the growth of the negative controls better than the other chromogenic media (Table 
2.5). 
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Table 2.4: Limit of detection of each chromogenic agar determined using 
carbapenemase-producing positive controls with known resistance 
mechanisms (n = 20). 
Data are presented as CFU/ml. 
Medium 
NDM* 
(n = 3) 
OXA-48 
(n = 5) 
KPC 
(n = 5) 
VIM 
(n = 5) 
IMP 
(n = 2) 
Brilliance CRE 102 102 102 102 103 
ChromID Carba 102 105-108 102-103 102 103 
CXmSCARBA-1 102 102 10-102 10-102 102 
CXmSCARBA-2 102 103 103 103 103 
Blood agar 1-102 102-103 10-102 10-102 102 
*NDM, New Delhi metallo-β-lactamase; OXA-48, OXA (oxacillinase) group of β-
lactamases (Class D); KPC, Klebsiella pneumoniae carbapenemase; VIM, Verona 
integron-mediated metallo-β-lactamase; IMP, IMP-type carbapenemases (metallo-
β-lactamases) (Class B). 
 
 
2.4.4. Examination of CAT ID disc test for detecting carbapenemase-
producers 
Due to the constraints in the number of discs that were provided by the 
manufacturers to validate the product, only the first 38 presumptive CPE isolates 
(chronologically) were tested with CAT ID to detect the presence of 
carbapenemases. In general, CAT ID showed good correlation with the PHE 
results (Table 2.6), apart from two isolates, Klebsiella pneumoniae 7 and 
Escherichia coli 22 (CAT ID resistant [indicating presence of carbapenemase] but 
the PHE results were negative for carbapenemase genes). A possible explanation 
for this discrepancy may be that these bacteria had porin loss, which can result in 
a positive CAT ID result. The inaccuracy of CAT ID for carbapenemase detection 
of Pseudomonas aeruginosa, which is intrinsically resistant to faropenem, was 
also highlighted (Table 2.6). Overall, however, CAT ID was able to detect all of the 
five common carbapenemases with 85.7% specificity, 96.88% positive predictive 
value and 100% negative predictive value. 
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Table 2.5: Examination of the growth of non CPOs (negative controls) on 
four test chromogenic agars. 
Control Brilliance CRE chromID Carba CXmSCARBA-1 CXmSCARBA-2 
1 NG* NG +/+++ NG 
2 +++ +++ +++ +++ 
3 NG NG NG NG 
4 NG NG NG NG 
5 +++ +++ +++ +++ 
6 NG NG NG NG 
7 +++ NG + NG 
8 +++ + +++ +++ 
9 +++ +++ +++ +++ 
10 +++ + +++ +++ 
11 NG +++ +++ +++ 
12 +++ + +++ +++ 
13 NG NG NG NG 
14 +++ + +++ +++ 
15 +++ + +++ + 
16 +++ +++ +++ +++ 
17 NG NG NG NG 
18 +++ +/+++ +++ + 
19 +++ +++ +++ +++ 
20 +++ + + NG 
NG 7 7 5 8 
+ 0 6 or 7 2 or 3 2 
+++ 13 7 or 6 11 or 12 10 
*NG, No growth; +, poor growth; +++, heavy growth.  
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Table 2.6: Validation of CAT ID using 38 presumptive carbapenemase-
producers. 
Strain CAT ID* Reference laboratory 
Acinetobacter baumannii 83 R OXA 58/51 
Escherichia coli 5 R NDM 
Escherichia coli 22 R Negative 
Escherichia coli 176 S Negative 
Escherichia coli 179 R NDM 
Klebsiella pneumoniae 7 R Negative 
Klebsiella pneumoniae 10 R NDM 
Klebsiella pneumoniae 39 R NDM 
Klebsiella pneumoniae 81 R NDM 
Klebsiella pneumoniae 82 R NDM 
Klebsiella pneumoniae 112 R NDM 
Klebsiella pneumoniae 113 R NDM 
Klebsiella pneumoniae 114 R NDM 
Klebsiella pneumoniae 115 R NDM 
Klebsiella pneumoniae 116 R NDM 
Klebsiella pneumoniae 117 R NDM 
Klebsiella pneumoniae 118 R NDM 
Klebsiella pneumoniae 119 R NDM 
Klebsiella pneumoniae 120 R NDM 
Klebsiella pneumoniae 121 R NDM 
Klebsiella pneumoniae 144 R NDM 
Klebsiella pneumoniae 159 R NDM 
Klebsiella pneumoniae 162 R NDM 
Klebsiella pneumoniae 173 R NDM 
Klebsiella pneumoniae 174 R NDM 
Klebsiella pneumoniae 177 R NDM 
Klebsiella pneumoniae 178 R NDM 
Klebsiella pneumoniae 180 S Negative 
Klebsiella pneumoniae 190 R NDM 
Klebsiella pneumoniae 191 R NDM 
Klebsiella pneumoniae 192 R NDM 
Klebsiella pneumoniae 216 R NDM 
Klebsiella pneumoniae 218 R NDM 
Klebsiella pneumoniae 223 R NDM 
Klebsiella pneumoniae 235 S Negative 
Pseudomonas aeruginosa 83 R Negative 
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Strain CAT ID* Reference laboratory 
Pseudomonas aeruginosa 175 R Negative 
Pseudomonas aeruginosa 221 R Negative 
Pseudomonas aeruginosa 236 R Negative 
*R, resistant – indicating presence of carbapenemase; S, sensitive – indicating no 
carbapenemase. 
 
 
2.4.5. Susceptibility testing of presumptive CPOs 
Of the three antibiotics included in CIM test, imipenem displayed the best 
detection of carbapenemase activity with a positive result obtained for all of the 
CPOs tested (irrespective of resistance gene) (Table 2.7). In addition, negative 
results were seen with imipenem for the four non CPOs included. Ertapenem and 
meropenem also gave negative results for the four non CPOs. However, 
meropenem also gave negative results for three CPOs, whilst ertapenem 
performed worst of the three antibiotics in the CIM test (with 5 CPOs identified as 
negative) (Table 2.7). 
 
2.4.6. Investigation of in-house PCR detection of carbapenemase-producers 
The in-house Xpert® Carba-R PCR performed in this screening study showed 
99.9% agreement with the PCR results from the reference laboratory (Table 2.8). 
But detected a false positive NDM carbapenemase gene for Klebsiella 
pneumoniae X96, which the reference laboratory identified was negative (Table 
2.8). The discrepancy may be due to poor laboratory technique. It was also noted 
that three of the samples physicians requested be tested were actually Gram-
positive organisms (not one of the target organisms). This was due to clinical 
considerations and the fact these PCRs were set up for these strains (which were 
also sent to PHE reference lab) before isolate identification was completed. Whilst 
this was a relatively limited investigation (24 presumptive CPOs, three Gram 
positive organisms and four control cultures), the findings suggest that Xpert® 
Carba-R PCR could be a useful in-house method for the rapid detection of 
carbapenemase activities. 
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Table 2.7: Investigation of CIM test to accurately detect carbapenemase 
activity of presumptive CPOs. 
 Resistance gene CIM test (10 µg)* 
Strain Imipenem Ertapenem Meropenem 
Acinetobacter baumannii 18 OXA-58/51 + - - 
Enterobacter cloacae 9 VIM + + + 
Escherichia coli 7 NDM & OXA-48 + + + 
Escherichia coli 16 OXA-48 + + + 
Escherichia coli 43 ESBL - - - 
Klebsiella oxytoca 14 VIM + + + 
Klebsiella pneumoniae 1 KPC + + + 
Klebsiella pneumoniae 3 OXA-48 + - - 
Klebsiella pneumoniae 4 NDM + - - 
Klebsiella pneumoniae 11 NDM + - + 
Klebsiella pneumoniae 12 NDM + + + 
Klebsiella pneumoniae 13 OXA-48 + + + 
Klebsiella pneumoniae 15 NDM + + + 
Klebsiella pneumoniae 44 ESBL & porin loss - - - 
Klebsiella pneumoniae 45 ESBL - - - 
Klebsiella pneumoniae 46 ESBL & porin loss - - - 
Proteus mirabilis 2 NDM + + + 
Pseudomonas aeruginosa 6 VIM + - + 
Pseudomonas aeruginosa 8 VIM + + + 
Pseudomonas aeruginosa 17 VIM + + + 
Serratia marcescens 5 OXA-48 + + + 
Serratia marcescens 10 NDM + + + 
*+, Positive; -, negative. 
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Table 2.8: Evaluation of Xpert®  Carba-R PCR to detect resistance genes 
harboured by presumptive CPOs and carbapenemase-positive controls. 
Strain Xpert® Carba-R PCR PHE results 
Klebsiella pneumoniae X30 NDM NDM 
Klebsiella pneumoniae F14 NDM NDM 
Klebsiella pneumoniae H84 NDM NDM 
Escherichia coli F81 Negative Negative 
Klebsiella pneumoniae M72 NDM NDM 
Escherichia coli S95 Negative Negative 
Klebsiella pneumoniae H26 NDM NDM 
Gram positive rod W15 Negative Negative 
Klebsiella pneumoniae X30 NDM NDM 
Klebsiella pneumoniae W77 OXA-48 OXA-48 
Escherichia coli H03 NDM NDM 
Klebsiella pneumoniae H97 Negative Negative 
Gram positive cocci W73 Negative Negative 
Klebsiella pneumoniae W26 NDM NDM 
Escherichia coli W08 Negative Negative 
Escherichia coli H79 Negative Negative 
Klebsiella pneumoniae W64 Negative Negative 
Gram positive cocci F04 Negative Negative 
Klebsiella pneumoniae W31 NDM NDM 
Escherichia coli F36 Negative Negative 
Klebsiella pneumoniae X96 NDM Negative 
Klebsiella pneumoniae X95 NDM NDM 
Klebsiella pneumoniae S84 NDM NDM 
Klebsiella pneumoniae M19 NDM NDM 
Klebsiella pneumoniae H17 NDM NDM 
Klebsiella pneumoniae H96 NDM NDM 
Klebsiella pneumoniae S62 NDM NDM 
Klebsiella pneumoniae NCTC 13422 OXA-48 OXA-48 
Klebsiella pneumoniae ATCC 1705 KPC KPC 
Escherichia coli NCTC 13476 IMP IMP 
Pseudomonas aeruginosa NCTC 13437 VIM VIM 
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2.5 DISCUSSION 
CPOs are of concern as they are associated with high rates of morbidity 
and mortality, particularly among critically ill patients with prolonged 
hospitalisation. CPOs are MDR pathogens, which makes them even more of a 
concern for the health sector as the treatment options are very restricted. It is also 
noted that the carbapenemase genes harboured by CPOs are mainly transposon- 
or integron-encoded determinants that can easily disseminate to other 
enterobacterial strains and species (Johnson and Woodford, 2013). This means 
cross-infection is of great concern within hospital settings. These facts suggest the 
need to implement adequate preventive measures, including active surveillance, to 
contain the spread of these pathogens. Since GI carriers of CPOs are thought to 
be the reservoir of cross-transmission in healthcare settings, surveillance is 
necessary. 
There is currently no accepted 'gold standard' method for the detection of 
CPOs from clinical samples (Nass et al., 2013). The purpose of this study was to 
evaluate screening and confirmation methods that, when paired, would provide a 
streamlined workflow for the detection of CPOs in the clinical microbiology 
laboratory. 
The first part of this study was evaluation of the suitability of four available 
chromogenic media that have been recommended for isolation of CPOs, 
compared to the standard method, to select the appropriate media for isolating 
CPOs in such surveillance programmes. Secondly, evaluation of different 
identification/characterization tests available at the time was performed to confirm 
carbapenemase production of the presumptive CPOs isolated. During outbreaks in 
clinical settings, it is necessary to determine the carbapenemase gene class of the 
isolated CPOs. Therefore, evaluation of a multiplex PCR method was also 
incorporated into the work, as an optimal endpoint of this workflow – designed to 
achieve the maximum sensitivity and specificity for detection of CPOs, with 
consideration for the cost and turnaround time for results. 
All four chromogenic media were shown to be better at isolating CPOs than 
the standard method. The standard method performed equally well as the 
chromogenic agar at inhibiting the growth of TN but performed poorly in relation to 
FN (i.e. did not pick up all TP). The overall sensitivity of the standard method was 
70% with 77% positive predictive value (PPV), much lower than the other media 
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examined. The standard method did, however, perform comparatively well for 
specificity (97%) and negative predictive value (95%). 
Brilliance CRE isolated the most TP CPOs (32/33) of all media tested, with 
the least FN. However, this medium also provided more FP and, therefore, was 
not specific enough to be selected as the screening medium. This was in 
agreement with previous findings, which showed that Brilliance CRE agar isolated 
non-CPOs, ESBLs and AmpCs, thus lacked specificity and required further 
confirmation tests of presumptive CPOs isolated using this medium (Cohen Stuart 
et al., 2013). The ChromeID Carba performed well in relation to TP and TN, and 
was also the best medium out of the four in relation to FN, with 94% specificity and 
97% sensitivity. However, it showed poor or no growth of OXA-48 control strains 
and poor growth of Proteus mirabilis F1266228 (NDM-1) strains. These results 
agreed with those of Girlich et al. (2013), who demonstrated ChromID Carba had 
limited efficacy in an OXA-48-dominant setting. 
CXm SCARBA-1 recovered less TP than Brilliance CRE and ChromeID 
Carba, with TN, FP and FN comparatively similar to ChromeID Carba; with 88% 
sensitivity and 97% specificity. On the LOD experiment CXm SCARBA-1 
recovered all the five carbapenemases at a low inoculum of 102 CFU/ml. CXm 
SCARBA-2 recovered less TP than Brilliance CRE and ChromeID Carba, but 
showed the best TN, FP and FN of the media tested, including the standard 
method, with 88% sensitivity and 98% specificity. On the LOD experiment CXm 
SCARBA-2 recovered all five carbapenemase types at a low inoculum of 103 
CFU/ml, thus did not perform as well as CXm SCARBA-1. 
CXm SCARBA-1 and CXm SCARBA-2 displayed the best LODs of the 
chromogenic media tested for the detection of the five most common CPEs (KPC, 
NDM, VIM, IMP and OXA-48). Both CXm SCARBA media showed the same 
sensitivity (87%), but CXmSCARBA-2 showed slightly higher specificity (98%, 
compared to 97% for CXm SCARBA-1). Whilst both CXm SCARBA media were 
capable of isolating bacteria with the five carbapenemases, they failed to detect 
four NDM CPOs from the clinical samples. Although our results showed CXm 
SCARBA-2 to be more specific in the detection of carbapenemases than the other 
media, CXm SCARBA-1 was selected for our screening medium because colonies 
on the agar were more defined and showed better colouration, and so were easier 
to interpret than those on CXm SCARBA-2. CXm SCARBA-1 was also better in 
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isolating the non-lactose-fermenting CPOs (i.e. Pseudomonas and Acinetobacter 
spp.) and had a lower LOD (10–102 CFU/ml) for KPC and VIM CPOs than the 
other media (Table 2.4). The lack of colouration and definition, with weak growth 
seen using CXm SCARBA-2 made it more difficult to interpret results from this 
medium than for CXm SCARBA-1. 
When selecting a screening chromogenic culture method, it is important to 
select a medium where the target organisms grow happily, with clear definition and 
precision of colour (according to manufacturer’s instructions) since the 
experience/expertise of users may vary. With this in mind, the colonies on CXm 
SCARBA-1 were easier for all biomedical staff with various levels of experience to 
interpret the results with more accuracy than for CXm SCARBA-2. Accordingly, 
CXm SCARBA-1 was chosen as the screening medium for clinical CPO 
surveillance procedures. 
A number of CPO characterization tests were investigated for efficacy and 
consideration of accurate and timely identification of carbapenemase type in the 
clinical setting. MAST CAT ID uses the carbapenem faropenem in a single paper 
screening disc compliant with EUCAST, and was shown to be a highly effective 
and easy-to-use tool in the confirmation of CPOs including OXA-48. However, all 4 
Pseudomonas aeruginosa presumptive CPOs, 22 Escherichia coli and 7 Klebsiella 
pneumoniae displayed resistant CAT ID results (indicating carbapenemase), 
despite being confirmed as non-CPOs by Reference laboratory (PCR). 
Pseudomonas and Acinetobacter spp. are known to be intrinsically resistant to 
faropenem (Schurek et al., 2007), which may account for these results. In addition, 
resistance to the CAT ID test may be due to porin loss rather than carbapenemase 
production. Accordingly, CAT ID would reduce the number of presumptive CPOs 
needing to be sent to reference laboratory for further gene-based testing, but still 
potentially include false positives (i.e. non-CPOs) being sent and thus 
unnecessary costs. 
The CIM test relies on the enzymatic hydrolysis of carbapenem antibiotics 
to detect the presence of carbapenemases. The efficacy of the CIM test was 
determined using 18 reference laboratory-confirmed CPOs and eight negative 
controls. Of the three antimicrobials tested, the carbapenem imipenem (10 µg 
disc) provided 100% agreement with PCR results from the reference laboratory 
followed by meropenem (10 µg disc) and ertapenem (10 µg disc). van der Zwaluw 
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et al. (2015) reported one limitation of the CIM was its inability to detect low-level 
carbapenemase activity among Acinetobacter baumannii isolates when using 
meropenem/ertapenem, which they were able to overcome by the usage of 
imipenem (10 µg disc). In this study, one Acinetobacter baumannii OXA-58/51 
strain was included and was consistent with van der Zwaluw and colleagues’ 
observations (i.e. negative for both meropenem and ertapenem, but positive for 
imipenem). Our results also showed that the CIM was capable of detecting 
carbapenemase production in Enterobacteriaceae (Table 2.7). Therefore, its 
performance superseded CAT ID. Indeed, the CIM test identified a new 
carbapenemase-producing isolate with unknown carbapenemase-encoded genes 
(not currently identified by standard reference laboratory PCRs) during a pilot 
screening study which ran for six months following the current research work, 
using the recommended workflow for screening CPEs (i.e. output of this work). 
Xpert® Carba-R PCR was able to detect the five most common 
carbapenemases (KPC, NDM, VIM, OXA-48, IMP-1), with the added benefit that 
this test can be performed directly using rectal swabs or from bacterial cultures. In 
addition, in-house use of Xpert® Carba-R PCR affords results for presumptive 
CPOs within hours, rather than the one to two weeks for PHE reference laboratory 
results to be returned. Clearly, there are potential clinical benefits from in-house 
application of Xpert® Carba-R PCR (whether on clinical samples or presumptive 
CPOs isolated from them). Our results showed good agreement between in-house 
Xpert® Carba-R PCR results and the reference laboratory resistance mechanism 
data (Table 2.8). 
In this study, the Xpert® Carba-R test was performed from cultures and 
proved to be a quick and simple confirmative tool for the detection of CPOs (<1 h) 
for known resistance genes. The only limitations of this assay were that new 
carbapenemase families or new variants of known families may not be detected 
and the relatively high cost (approx. £30 per isolate/sample). Initially, any 
presumptive CPOs identified using the standard method were confirmed by the 
modified Hodge test (mHT) (PHE, 2013). However, the mHT lacked specificity and 
produced FP results for organisms harbouring ESBL/AmpC or loss of permeability. 
This resulted in a large volume of FP isolates (non-CPOs) being sent to the 
reference laboratory, which increased costs. In addition, the mHT is very labour-
intensive, so not feasible for high numbers of samples/isolates. The findings of our 
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study demonstrate that mHT should be replaced with either Xpert® Carba-R PCR 
or the CIM method. However, whilst the Xpert® Carba-R PCR carbapenemase 
gene verification results showed high sensitivity and specificity, the costs and 
technical difficulties of this multiplex PCR assay are not ideal for routine use as a 
confirmatory test for CPOs. As such, our clinical recommendation was that Xpert® 
Carba-R be used when it is clinically relevant to confirm carbapenemase activity 
and gene class (i.e. including for infection, prevention and control investigation, 
and/or when the clinical situation requires rapid confirmation). It should also be 
noted that the CIM method requires extensive training of staff before use and is, 
thus, not as user-friendly across clinical laboratories as the CAT ID test. 
Taking everything into consideration (including performance (sensitivity, 
specificity, timeliness), ease of use by all technical staff and cost of the screening 
and confirmatory tests), the proposed workflow for CPO screening in clinical 
settings was to use CXmSCARBA-1 medium followed by the CAT ID (which was 
easier to perform than CIM) to reduce the number of non-CPOs sent for PCR 
testing. Xpert® Carba-R PCR should then be used to confirm positive carriers 
rapidly, limiting the unnecessary prolonged isolation of newly admitted patients 
and enabling the rapid isolation of those who are carriers, providing better 
management of patients and guiding the appropriate antibiotic therapy, thus 
reducing costs to the infection control programme and preventing outbreak 
situations. However, using Xpert® Carba-R PCR as a universal screening tool for 
rectal samples may not be desirable or affordable due to its high cost (£30 per 
sample). It can also be used as a tool for screening high-risk patients such as 
those returning from areas of endemicity, those who have been transferred from 
long-term care facilities or those who are known to have been in contact with a 
carrier. 
The MAST CAT ID proved to be a good indicator for the presence of 
carbapenemases in Enterobacteriaceae but was not suitable for Pseudomonas 
spp. As it is not specifically designed to detect OXA-48-like β-lactamases 
(interpretation of the disc is subjective to the observation of micro colonies within 
the zone; Figure 2.5) and their derivatives which are the main cause of 
carbapenemase resistance in Acinetobacter spp., this test is also not advisable for 
confirming Acinetobacter CPOs. However, high-level resistance to temocillin is a 
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presumptive indicator for the presence of OXA-48 in Acinetobacter spp. 
(Glupcznski et al., 2012), so could be used in such cases. 
 
2.5.1 Impact of the screening study on protocols/standard procedures for 
surveillance programmes and subsequent observations/findings 
Based on the initial screening study the infection control team at ICHNT 
implemented a risk-based admission screening programme taking into account the 
prevalence of carbapenemase resistance within the community, travel patterns 
and demographics of the population and the level of care provided by the hospital. 
The laboratory protocol below was implemented to deal with the screening 
specimens received (Figure 2.6), with additional weekly screens for one month on 
wards housing patients with carbapenemase-positive samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Flow chart for screening programme put together for the West London 
Hospitals belonging to the ICHNT. Average cost per screen £8. 
 
 
The “Guiana extended spectrum" (GES)-type plasmid-encoded β-
lactamase belongs to the class A enzyme and is an ESBL discovered in 2000 in 
Klebsiella pneumoniae clinical isolates from French Guiana (Naas et al., 2016; 
Bonnin et al., 2017). This carbapenemase slowly hydrolyses carbapenems due to 
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a replacement of glycine at position 170 by asparagine/serine. GES-5-positive 
Klebsiella oxytoca have been detected in UK hospitals, with their emergence 
thought to be due to plasmid or intergron transfer among related bacteria (Diene 
and Rolain, 2014). The optimised workflow was able to isolate such Klebsiella 
oxytoca GES-5 strains, previously not found in the ICHNT environment. (These 
strains will be discussed further in Chapter 3.) This also shows the importance of 
using a culture method as an initial platform to detect the presence of ‘new and 
emerging’ carbapenemases before they are characterised at the genomic level. 
Benefits noted since the introduction of the surveillance programme in 
March 2015 include improved infection control, although compliance with sample 
collection varied across wards/hospitals within the ICHNT (Figure 2.7). There was 
also improved record-keeping with respect to carbapenemase-positive samples, 
which enabled detection of ‘potential’ outbreaks (Figure 2.8). In addition, analysis 
of the data gathered (both from the routinely collected microbiology data and 
reference laboratory) enabled greater understanding of the epidemiology of 
carbapenem resistance in the ICHNT. This led to recognition of the increasing 
issue with carbapenem resistance within inpatient healthcare settings in the West 
London Hospitals (Figure 2.8). The prevalence of different CPOs and resistance 
mechanisms were found to change over time and more CPEs were isolated during 
the winter months. This could be due to increased respiratory infections in 
vulnerable cohorts in the community during the winter months (December–
February) with complications that require hospitalization. 
The question remains as to whether we are still missing any potential CPO carriers 
even with the screening programme. It is difficult to assess the sensitivity and 
specificity of the screening programme, but case studies have highlighted two 
instances of "silent carriers" within a bay in a ward of the renal unit of HH that were 
missed by the screening programme. All screened cases in the bay indicated no 
further spread of the CPE but typing of the two CPE isolates (from “silent carriers”) 
were consistent with that of an outbreak three months previously. One contact had 
been negative on previous routine screening and their positive CPO from 
subsequent screening was consistent type with that of an outbreak three months 
prior to their positive screen. The second case was a patient found to be CPO-
positive on ward weekly screening but who had been negative on six previous 
routine screenings. The typing of the isolate confirmed a match with a previous 
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contact of a CPO case nine months earlier (personal communication, Francis 
Davies). 
 
 
 
Figure 2.7. Compliance with screening policy in ICHNT. Arrows indicate peaks 
representing outbreaks of NDM in the vascular and renal units in 2015. Grey, all 
trust; light blue, private patients; orange, adult & paediatric ICU; yellow, renal unit; 
red, vascular unit, black, haematology (image produced by the statistics 
department of the ICHNT). 
 
 
Although ICHNT managed to introduce a successful screening method, the 
FP rate was relatively high. Based on observations, ~40% of the presumptive 
CPOs tested with the in-house Xpert® Carba-R PCR were negative but very few 
of these were confirmed as CPO by the reference laboratory (due to other 
resistance mechanisms, as stated above). It is plausible that inclusion of the CIM 
confirmatory test (of presumptive CPOs) may reduce the number of FPs being 
sent to reference laboratory thus reducing cost. In an effort to further improve 
specificity, evaluation of different methods of isolation and molecular 
characterisation were – at the time of writing – ongoing within the ICHNT.   
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Figure 2.8. Confirmed CPEs in the ICHNT between April 2014 and August 2016. 
Yellow, Klebsiella sp. GES-5 outbreak; dark blue, Enterobacteriaceae (other); 
orange, Escherichia coli OXA-48; green, Escherichia coli NDM; grey, Klebsiella 
pneumoniae OXA-48; light blue, Klebsiella pneumoniae NDM. Red arrow indicates 
introduction of new screening programme; the 6-month screening study ran 
between March and September 2015. 1, Klebsiella pneumoniae was the bacterium 
isolated most frequently and was responsible for an NDM-associated outbreak in 
April 2015. 2, An outbreak caused by GES-5-positive Klebsiella oxytoca was 
detected with the improved screening method. 3, An outbreak of Escherichia coli 
OXA-48 detected – slightly higher in number compared to preceding months, 
similar to that in December 2015 to February 2016. 
 
 
The limitation of this study was the scarcity of products to test due to 
financial constraints and lack of time to carry out experiments; most of the work 
was conducted during routine working hours. However, strengths of the study 
were that it was conducted in real time using multiple chromogenic media and was 
the first study to evaluate the CXm SCARBA-1 and CXm SCARBA-2 media. This 
study also resulted in the implementation of the first carbapenemase screening 
programme in the ICHNT. This allowed additional infection control measures to 
target CPE to be launched in April 2015: enhanced screening (including renal 
outpatients), contact precautions for known CPE carriers, enhanced chlorine 
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disinfection of the environment, labelling of electronic case notes for identification 
of readmission, regular teleconference calls internally and with PHE, and 
enhanced antibiotic stewardship. 
This study also gained a lot of publicity as it was presented orally to 
clinicians/infection control and technical staff at CXH. A scientific poster 
presentation of the study also took place at the European Congress of Clinical 
Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands 9-12 
April 2016 (Shibu et al., 2016; Appendix 2). The poster was also being used in 
promotional material by E & O Laboratories Ltd., for their growth media. The 
screening study led to implementation of a surveillance programme that satisfied 
PHE recommendations. Dissemination of my work led staff at other hospitals to 
contact me to provide guidance on organising screening studies within their 
hospitals. In addition, PHE acknowledged how well I ran the study (personal 
communication). Since the introduction of the new screening programme brought 
about a reduction of spread of CPOs in the ICHNT, the infection control team was 
very appreciative of my work and in return partly funded my fees for my 
Professional Doctorate. A summary of the work was published in the October 2016 
edition of The Biomedical Scientist. 
 
2.6 SUMMARY 
Screening for GI carriage of CPOs is significant for the development of 
infection control strategies for these organisms. When selecting a screening 
programme, adopting a universal surveillance has greater potential for detection 
and prevention of outbreaks but comes at a cost. This study showed chromogenic 
culture media are useful as screening tools for the isolation of antimicrobial-
resistant CPOs when compared with the standard method at that time (namely, 
MacConkey agar with 10 µg ertapenem/10 µg meropenem). The potential 
disadvantage of using chromogenic media in clinical laboratories is the increased 
cost and variable interpretation between different technicians (due to different 
levels of experience). However, the benefits regarding infection control are clear. 
The results of the current study showed no one chromogenic media topped all 
categories (specificity, sensitivity, PPV, NPV, LOD). Indeed, the medium selected 
for the surveillance programme had the best LOD of the four chromogenic media 
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tested, but may lack sensitivity for carbapenemase-producers that confer low-level 
resistance. The Xpert® Carba-R PCR performed well for in-house confirmation of 
CPOs, allowing earlier and more accurate information to be passed to infection 
control teams and clinicians, but is restricted to five genes. Laboratory detection 
and confirmation remains challenging, as there is phenotypic overlap with 
ESBL/AmpC hyper-production with permeability. This led to delay in the 
recognition of the GES-5-producing isolates in the follow-up surveillance period. 
The developed screening programme was a vast improvement on previous 
protocols and has been applied to support widespread surveillance of CPOs in 
clinical settings. This has directly led to better infection control and managing CPO 
carriage/transfer within the patient population. 
 
2.7 UPDATE BASED ON CURRENT RECOMMENDATIONS (AS OF JUNE 
2019) 
Since the study detailed in this Chapter was conducted and written up, PHE 
guidelines for the screening of MDR Enterobacteriaceae have remain unchanged 
and no changes have been made to the PHE tool kit (this is currently under 
review, and an updated version will be published in summer 2019). CPE remain a 
major concern as the number of positive isolates detected on a yearly basis is 
increasing throughout the UK. Since the introduction of the tool kit by PHE in 2015, 
many hospitals in the UK have adopted it and are using it to set up their own 
surveillance and screening systems. In complying with the recommendations, the 
ICNHT came up with the surveillance and screening protocol described above, 
which brought about an increase in and better method of CPE detection within the 
Trust. Since 2015, the CXH laboratory has continued to improve its screening 
methods; the changes are not mentioned here as I moved jobs and have changed 
Trust. 
There has been a marginal increase in the number of hospital-acquired 
infections caused by Klebsiella spp., highlighted by the introduction of laboratory 
surveillance of Klebsiella spp. bacteraemia in England, Wales and Northern 
Ireland (PHE, 2017). Between 2015 and 2016 the total number of cases of 
Klebsiella spp. bacteraemia in England, Wales and Northern Ireland increased by 
15% (from 7,746 to 8,944 episodes), an increase of 13.0 to 15.0 per 100,000 
population. 
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The surveillance report (PHE, 2017) also showed antibiotic susceptibility 
trends from 2012 to 2016 in England and Northern Ireland for blood culture 
isolates. Among Klebsiella spp. the most common mechanism of resistance to 
third-generation cephalosporins (cefotaxime or ceftazidime) was plasmid-mediated 
ESBL production. The analysis for Klebsiella spp. isolates (all species) showed 
that resistance to cefotaxime and ceftazidime remained stable between 2012 and 
2016, mostly at 10% over the five-year period for each antibiotic. For Klebsiella 
pneumoniae, resistance to cefotaxime and ceftazidime was stable throughout the 
five-year period remaining at 12% in 2016 for each antibiotic, whereas Klebsiella 
oxytoca showed a lower level of resistance to these agents compared to Klebsiella 
pneumoniae. The proportion of isolates reported resistant to piperacillin/ 
tazobactam increased gradually over the five-year period for Klebsiella 
pneumoniae and Klebsiella oxytoca (from 13% in 2012 to 17% in 2016), with a 
marginal increase in resistance to ciprofloxacin and gentamycin. Resistance to 
carbapenems (meropenem and ertapenem) remained low between 2012 and 
2016, with ≤2% of isolates reported as resistant. PHE (2017) also highlighted that 
Klebsiella spp. are the commonest hosts of carbapenemases belonging to the 
KPC, OXA-48-like, NDM, VIM or IMP families; other types of carbapenemase, 
such as GES-encoded enzymes, also occur and have caused outbreaks in some 
UK hospitals. The ESPAUR report in 2018 (PHE, 2018) also highlighted an 
increased number of IMP-positive CPE identified in 2017 compared with previous 
years due to an outbreak of IMP-positive Klebsiella pneumoniae in a London 
hospital, and also highlighted these bacteria are becoming more widespread. 
As resistance to carbapenems warrants close vigilance, in May 2015 PHE 
launched the electronic reporting system (ERS) for the enhanced surveillance of 
carbapenem resistance in Gram-negative bacteria to better understand the 
epidemiology of these organisms (PHE, 2016a). The web-based ERS enhanced 
surveillance website was designed to enable laboratories in NHS Trusts in 
England to capture specimen, demographic, healthcare setting and risk factor 
details as part of the core and enhanced dataset as CPE pose significant 
treatment and public health challenges (PHE, 2018). However, the website was 
withdrawn in April 2019. No reason has been given. 
From April 2017, due to the notable increase in Klebsiella spp. infections, 
the Government’s response was to extend the enhanced surveillance of 
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bacteraemias caused by Gram-negative organisms to include Klebsiella spp. 
(https://www.gov.uk/government/statistics/klebsiella-species-bacteraemia-monthly-
data-by-location-of-onset). This supports the ambition to reduce infections by 50% 
by 2021. To this end all NHS hospitals in UK are to report monthly patient-level 
data of any Klebsiella spp. bloodstream infections to Public Health England 
(https://www.gov.uk/government/statistics/klebsiella-species-bacteraemia-annual-
data). Data for 2017 to 2019 for 148 hospitals show an average of 850.84 isolates 
per month across the reporting hospitals (Figure 2.9). 
In April 2019, a survey was introduced by PHE for all tertiary hospitals to 
collect data on carbapenem resistance among Klebsiella spp. isolated from sterile 
sites. This survey will run for six months, with the results due to be issued later in 
2019. The survey was introduced in response to the ESPAUR report 2018 (PHE, 
2018), which showed the estimated burden of resistant bloodstream infections 
caused by Klebsiella pneumoniae in England in 2017. Isolates resistant to both 
carbapenems and colistin, 0.4%; resistant to colistin (but not carbapenems), 2.8%; 
resistant to carbapenems (but not to colistin), 0.8%; resistant to third-generation 
cephalosporins (but not to colistin or carbapenems), 12.6%. Data for Klebsiella 
oxytoca were also reported: resistant to both carbapenems and colistin, 0.0%; 
resistant to colistin (but not carbapenems), 1.8%; resistant to carbapenems (but 
not to colistin), 0.2%; resistant to third-generation cephalosporins (but not to 
colistin or carbapenems), 0.2%. 
When comparing results from PHE with the report of Public Health Wales 
(Public Health Wales, 2018), in Wales Klebsiella spp. remain the 3rd commonest 
cause of bloodstream infections with resistance patterns remaining almost the 
same as those reported by PHE (PHE, 2017). 
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Figure 2.9. Monthly count of total cases of Klebsiella spp. bacteraemia reported 
by 148 hospitals in the UK. Data retrieved from 
https://www.gov.uk/government/statistics/klebsiella-species-bacteraemia-monthly-
data-by-location-of-onset on 18 June 2019. 
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CHAPTER 3: GENOMIC CHARACTERISATION OF ANTIBIOTIC-RESISTANT 
ISOLATES ORIGINALLY IDENTIFIED AS KLEBSIELLA OXYTOCA, AND 
ISOLATION OF LYTIC BACTERIOPHAGES THAT INFECT THEM 
 
3.1 INTRODUCTION 
Around 3 to 7% of all HAIs are caused by Klebsiella spp. (Khan et al., 
2015). While much attention has been focused on the clinical relevance of 
Klebsiella pneumoniae, Klebsiella oxytoca has received very little attention but is 
being detected with increasing frequency in clinical laboratories (Chapter 2; Singh 
et al., 2016; Moradigaravand et al., 2017; Chen et al., 2019). This is due to a 
combination of improved screening methods (Chapter 2; Cheng et al., 2012) and 
use of molecular methods, including WGS, to characterise isolates 
(Moradigaravand et al., 2017; Chen et al., 2019). The English Surveillance 
Programme for Antimicrobial Utilisation and Resistance (Public Health England, 
2017) showed the two commonest species among blood culture isolates of the 
genus Klebsiella were K. pneumoniae (81%) and K. oxytoca (17%). Similar to K. 
pneumoniae, K. oxytoca strains are acquiring various antimicrobial resistance 
genes (Moradigaravand et al., 2017) and are detected in hospitals across the UK; 
consequently, K. oxytoca is now emerging as the second most important pathogen 
within Klebsiella species. 
 
3.1.1 Carriage of K. oxytoca and contribution to disease 
K. oxytoca is a member of the family Enterobacteriaceae, and is a Gram-
negative, non-motile, indole-positive encapsulated rod-shaped bacterium. It is 
found in the environment (Hoffman et al., 2010) at low levels and in the 
nasopharynx and the gastrointestinal tract of humans, where it is considered part 
of the normal gut microbiota of some individuals. Carriage rates vary from study to 
study, but are generally higher in stool samples from healthy subjects (5 to 38% 
(Thom, 1970), 1.6% (Högenauer et al., 2006), ~2 to 10% (Schlenker and 
Surawicz, 2009), 2.1 to 2.9% (Cheng et al., 2012)) than the nasopharynx (1 to 6%; 
Rosenthal and Tager, 1975). 
Like K. pneumoniae, K. oxytoca is an opportunistic pathogen in humans, 
and is becoming increasingly associated with nosocomial infections, particularly in 
immunocompromised patients and preterm infants with underlying conditions that 
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require prolonged stays in hospitals, and community-acquired infections, and is 
responsible for high morbidity among patients (Broberg et al., 2014; WHO, 2016; 
Chen et al., 2019). K. oxytoca is a causative agent of C. difficile-negative 
antibiotic-associated haemorrhagic colitis (AAHC) and diarrhoea, which can occur 
after treatment with penicillin, ampicillin, amoxicillin, first-generation 
cephalosporins or pristinamycin (Beaugerie et al., 2003; Högenauer et al., 2006; 
Herzog et al., 2014). Symptoms include sudden onset of bloody diarrhoea with 
severe abdominal cramps 4-10 days after taking antibiotics and are resolved on 
cessation of antibiotic therapy (Yamada et al., 2014). K. oxytoca overgrows other 
members of the gut microbiota in the presence of antibiotics, and strains release 
cytotoxins that cause disease (Zollner-Schwetz et al., 2008; Herzog et al., 2014; 
Unterhauser et al., 2019). Colitogenic strains encode the non-ribosomal peptides 
tilvalline and tilimycin (kleboxymycin; Tse et al., 2017), which are enterotoxic 
metabolites, but there is no information available on the prevalence of the relevant 
genes in strains (Unterhauser et al., 2019). These are encoded on a secondary 
metabolite biosynthetic gene cluster (Tse et al., 2017; Unterhauser et al., 2019), 
and both metabolites are present in the human intestine during active colitis. 
Tilimycin is a genotoxin that interacts with DNA to activate damage repair 
mechanisms that cause DNA strand damage that results in lesions in mouse 
caecal enterocytes, with the same thought to happen in human enterocytes 
(Unterhauser et al., 2019). Tilvalline binds tubulin and stabilises microtubules 
leading to mitotic arrest and loss of barrier integrity. Both enterotoxic metabolites 
induce apoptosis (cell death), and it is thought they work together in the 
pathogenicity of colitis (Unterhauser et al., 2019). K. oxytoca has also recently 
been linked to jejunal necrosis and antibiotic-associated fulminant 
pseudomembranous enterocolitis in a 79-year-old man with a history of antibiotic 
therapy, but it is not known whether enterotoxic metabolites were involved in the 
disease (Nagamura et al., 2019). In addition to causing colitis in some individuals, 
enteric carriage of K. oxytoca may play a role in the transmission of antibiotic 
resistance genes to other bacteria and act as a source of nosocomial infections 
(Molton et al., 2013). 
K. oxytoca has been detected in the faeces of a subset of preterm infants 
via cultivation or shotgun metagenomics, but its association with preterm-
associated infections such as late-onset sepsis or necrotising enterocolitis is 
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unknown (Chen et al., 2019). In this cohort, several factors contribute to 
colonisation of an infant’s gastrointestinal tract with one or more 
Enterobacteriaceae: these include the significant number of antibiotics 
(prophylactic and treatment) these infants receive in the first days and weeks post 
birth, an immature immune system, an unstable microbiome, mode of delivery, 
invasive procedures such as enteral feeding using nasogastric tubes, bacterial 
contamination of milk and the hands of healthcare workers, and the hospital 
environment (Berthelot et al., 2001; Moles et al., 2015; Chen et al., 2019). K. 
oxytoca was detected in the faeces of 24/146 US preterm infants based on a 
taxonomic analysis of shotgun metagenomic data (Chen et al., 2019). A 
nationwide multicentre observation study in France between 2006 and 2016 
showed that K. oxytoca caused meningitis in a small number of children (0.22%; 
4/1859), with K. pneumoniae responsible for 0.48% of cases (Carrie et al., 2019). 
Three cases of arthritis caused by K. oxytoca appear in the literature 
(Ménard et al., 2010; Silvagni-Gutiérrez et al., 2017; Hertting et al., 2018). The first 
case involved community-acquired spontaneous arthritis in a 30-month-old girl, 
and was caused by a bacterium identified as K. oxytoca using API 20E and 16S 
rRNA gene sequencing (Ménard et al., 2010). Silvagni-Gutiérrez et al. (2017) 
reported a case related to septic arthritis caused by K. oxytoca. Hertting et al. 
(2018) reported a case of septic arthritis in a 4-week-old infant, with K. oxytoca 
identified as the causative agent by MALDI-TOF. It is believed the infant acquired 
the infection through vein puncture when being treated in hospital during the first 3 
weeks of life. Hospital- or community-acquired endocarditis is sometimes caused 
by K. oxytoca (Table 3.1). Similar to arthritis, this is very rare as Klebsiella spp. 
account for only about 10% of endocarditis cases, which are predominantly 
healthcare-acquired (Hauser et al., 2017). Endocarditis due to K. oxytoca appears 
to be mainly community-acquired (Table 3.1). 
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Table 3.1: Hospital-acquired (HA) and community-acquired (CA) K. oxytoca 
endocarditis. 
HA or CA? Affected individual(s) Reference 
CA Elderly woman with high fever Chen et al. (2006) 
CA Drug addict Geisenberger et al. (2015) 
CA Intravenous drug user Hauser et al. (2017) 
CA Elderly patient with nephrolithiasis Memon et al. (2018) 
CA Intravenous drug user Mohamed et al. (2016) 
HA Haemodialysis patient Ruiz-Zorrilla López et al. (2009) 
HA Elderly man with stroke Ullah et al. (2016) 
HA Elderly man after transurethral 
resection 
Watanakunakom (1985) 
 
 
3.1.2 Nosocomial infections and antibiotic resistance associated with K. 
oxytoca 
Nosocomial infections are putting huge pressure on the healthcare system 
globally, both financially and with respect to morbidity and mortality rates. They 
also promote antimicrobial resistance. Because of these factors, nosocomial 
infections are considered a quality index of healthcare facilities (Bouza et al., 
2019). The EPINE study, which has documented nosocomial infections in Spain 
for the past 25 years (Bouza et al., 2019), reported the prevalence of these 
infections to be between 7.7 and 8.5%, remaining relatively stable over the 
reporting period. Across the European Union, nosocomial infections affect 
approximately 4.1 million patients each year (Bouza et al., 2019). 
K. oxytoca-associated nosocomial infections are reported infrequently. 
Singh et al. (2016) reported 23/654 Klebsiella isolates recovered from Indian 
clinical samples were K. oxytoca, with more than half these isolates resistant to 
imipenem, meropenem, gentamicin, amikacin, ceftazidime and ceftriaxone. Singh 
et al. (2016) also reported K. oxytoca is now being isolated more frequently from 
neonatal intensive care units and adult critical units than in the past. 
The English surveillance programme for antimicrobial utilisation and 
resistance (ESPAUR) report from a 5-year surveillance programme showed the 
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proportion of K. oxytoca bloodstream isolates resistant to different classes of 
antibiotics over time has increased (ESPAUR, 2017). Resistance to gentamicin, 
ciprofloxacin, third-generation cephalosporins and carbapenems was seen in ≤7% 
of isolates throughout the surveillance period. An increase in resistance to 
piperacillin/tazobactam and co-amoxiclav was seen (10-15% and 13-20%, 
respectively) in K. oxytoca isolates, with the proportion of resistant isolates higher 
in 2016 compared with 2012 (ESPAUR, 2017). 
K. oxytoca are acquiring a range of resistance mechanisms, including 
ESBLs and AmpC β-lactamases, leading to increased usage of broad-spectrum 
antibiotics including carbapenems to treat K. oxytoca infections, which has led to 
the increase observed in carbapenem resistance (D’Angelo et al., 2016). Eades et 
al. (2016) and Kabir et al. (2016) reported the first instances of GES-5-associated 
carbapenem resistance. Resistance to the carbapenems imipenem and 
meropenem is on the rise among K. oxytoca isolates worldwide, especially in the 
United States, and is also appearing in the UK (ESPAUR, 2017). 
In the UK, Public Health England (PHE) confirmed the presence of at least 
one carbapenemase in 2,595 Enterobacteriaceae that was classed within the ‘big 
5’ carbapenemase families (KPC, OXA-48-like, NDM, VIM, IMP). Within the UK, K. 
oxytoca harbouring the ‘big 5’ carbapenemases are seen infrequently compared 
with other countries (ESPAUR, 2017). In the United States, K. 
pneumoniae carbapenemase-1 (KPC-1) is the most common; this is a class A β-
lactamase capable of hydrolysing carbapenems (Yigit et al., 2003). In an Indian 
setting, Singh et al. (2016) showed 58% of K. oxytoca isolates were KPC 
producers, as compared to 30% of K. pneumoniae isolates. Similar results were 
observed in an Austrian study that reported meropenem resistance to be up to 
58% (Hoenigl et al., 2012) and described a nosocomial outbreak of KPC-
producing K. oxytoca, highlighting the clinical importance of infection with this 
bacterium. Although K. oxytoca carriage may remain asymptomatic, the bacterium 
is still considered to be an opportunistic pathogen of clinical significance with its 
association with infections in hospitalised patients, including children and 
neonates. Herruzo et al. (2017) described a VIM-linked K. oxytoca infection 
outbreak in a neonatal unit in Spain, where the source of the outbreak was other 
patients. K. oxytoca harbouring VIM-1 were isolated from community-onset 
infections among patients attending the outpatient department of a Greek hospital 
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(Tsakris et al., 2011). Separate case studies reported the first isolation of K. 
oxytoca strains producing IMP-1 metallo-β-lactamases and NDM-1 in China 
(Hagiya et al., 2015; Wang et al., 2017). 
 
3.1.3 Clinical characterisation of K. oxytoca isolates 
Studies by Holt et al. (2015) and Wyres et al. (2016) have shown the 
potential for genomics to enhance surveillance and tracking of specific pathogens, 
especially Klebsiella spp., and AMR strains to aid infection control and outbreak 
investigations. Holt et al. (2015) used genomics on over 300 strains to aid 
investigations of AMR Klebsiella in hospitals through the detection of polyclonal 
outbreaks resulting from transmission of plasmids encoding acquired AMR genes 
as well as identification of AMR clones. The key elements of 
the Klebsiella genomics consist of identification of core genes, AMR determinants 
including acquired genes and common mutations, known virulence genes and 
alleles, plasmids and capsular and O antigen loci. Current resources available for 
characterising Klebsiella genomes include: 
1. Klebsiella pneumoniae/oxytoca BIGSdb. An online database and 
integrated set of tools for analyses of genome assemblies (Bialek-Davenet 
et al., 2014). The K. pneumoniae MLST (multilocus sequence typing) 
database, core genome MLST, virulence and AMR gene databases are 
available through this single resource, which also hosts a searchable 
repository of K. pneumoniae, K. variicola and K. quasipneumoniae 
genomes. As of June 2016, the database included 2328 distinct STs 
(sequence types). Available at https://bigsdb.pasteur.fr/klebsiella. 
2. Kaptive. A database of complete sequences of Klebsiella capsule loci and 
accompanying tool for identification and typing of capsule loci from genome 
assemblies (Wyres et al., 2016; Wick et al., 2018). Available at 
https://kaptive-web.erc.monash.edu/. 
3. NCBI Pathogen Detection Resources. Curated databases of AMR genes 
and genomes of AMR bacterial pathogens. As at June 2016, the databases 
include 3275 AMR gene nucleotide sequences and 2391 annotated 
genomes drawn from GenBank. Genome-wide phylogenetic analyses, 
precomputed at the species level, can also be accessed. Available at 
https://www.ncbi.nlm.nih.gov/pathogens. 
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Our understanding of the phenotypic and genomic traits of K. oxytoca is 
limited when compared to K. pneumoniae. Molecular studies have revealed that K. 
oxytoca can be separated into three related but distinct phylogroups (Ko1, Ko2 
and Ko6) according to house-keeping genes and 16S rRNA gene analysis. Herzog 
et al. (2014) showed that Ko2 bacteria were prevalent in stool samples, while Ko1 
and Ko6 were more associated with the respiratory tract. These phylogroups have 
subsequently been found to represent distinct species: Klebsiella michiganensis 
(Ko1), K. oxytoca (Ko2) and Klebsiella grimontii (Ko6) (Brisse and Verhoef, 2001; 
Drancourt et al., 2001; Passet and Brisse, 2018). These species can only be split 
using genomic data, not phenotypic tests such as MALDI-TOF and API 20E strips 
routinely used in clinical laboratories (Moradigaravand et al., 2017; Chen et al., 
2019). K. michiganensis and K. oxytoca are distinguishable based on blaOXY-1 and 
blaOXY-2 genes, respectively (Brisse and Verhoef, 2001), while K. grimontii 
accommodates Ko6 strains based on rpoB, gyrA and rrs gene sequence analyses 
(Passet and Brisse, 2018). 
Despite the growing clinical importance of K. oxytoca, there is limited 
genomic information available for the population structure and epidemiology of 
antimicrobial-resistant K. oxytoca. A small pangenome study by Moradigaravand 
et al. (2017) showed that UK clinical isolates of K. oxytoca represent a highly 
diverse population, composed of several distinct clades corresponding to the three 
above-mentioned phylogroups (plus Ko5, a sublineage of Ko1 (Fevre et al., 
2005)). Although the K. oxytoca genomes were distinct from one another and K. 
pneumoniae genomes, they shared genes with K. pneumoniae, indicating 
recombination between the two species and further evidenced by sharing of 
antimicrobial resistance and virulence genes. However, Moradigaravand et al. 
(2017) also showed that the different K. oxytoca clades have acquired 
antimicrobial resistance and virulence genes independent of K. pneumoniae. K. 
oxytoca is acquiring resistance mechanisms involved in development of multidrug 
resistance. These include production of extended-spectrum β-lactamases 
(ESBLs), AmpC lactamases, Klebsiella pneumonia carbapenemase (KPC) and 
aminoglycoside-modifying enzymes (Moradigaravand et al., 2017). 
Initially identified as K. oxytoca using API 20E, the five Klebsiella isolates 
recovered by Chen et al. (2019) from faeces of preterm infants were found, on 
genomic analyses, to represent three strains of K. grimontii and two strains of K. 
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michiganensis. In addition, detailed analyses of shotgun metagenomic data from 
US infants with a curated dataset of K. oxytoca, K. michiganensis and K. grimontii 
genomes showed that samples initially found to harbour K. oxytoca based on a 
crude taxonomic analysis more often than not contained K. michiganensis rather 
than K. oxytoca. The discrepancy between initial results and the more-refined 
analyses was due to poor annotation of publicly available datasets and taxonomic 
tools (Chen et al., 2019). Therefore, there is the potential that K. michiganensis 
and K. grimontii may be more clinically relevant than K. oxytoca, and poor 
characterisation of isolates in the past has overlooked these opportunistic 
pathogens. 
 
3.1.4 Aims of this Chapter 
In Chapter 2, I showed that the improved screening method I helped 
implement in the clinical laboratory increased the detection of K. oxytoca from 
clinical samples and detected an outbreak caused by GES-5-positive K. oxytoca at 
the Haematopoietic Stem Cell Transplant (HSCT) unit of Charing Cross Hospital. 
Eades et al. (2016) subsequently presented findings on the outbreak at the 26th 
European Congress of Clinical Microbiology and Infectious Diseases. During 
routine laboratory screening a K. oxytoca strain isolated from a urine sample from 
a neutropenic HSCT recipient was identified as a presumptive carbapenemase 
producer, but in-house PCR was negative for carbapenemases. Consequently, the 
strain was sent to PHE for determination of the resistance mechanism. PCR 
confirmed the presence of the first blaGES-5-positive K. oxytoca isolate associated 
with a clinical infection. Within a subsequent 18-month period of screening, 430 
additional isolates of K. oxytoca were identified, 14 of which harboured the GES-5-
encoding gene (Eades et al., 2016). I had access to three of the strains 
(PS_Koxy1, PS_Koxy2 and PS_Koxy4) that I had determined the antimicrobial 
susceptibility profiles for. Molecular results from PHE showed PS_Koxy1 to have a 
unique pulsed-field gel electrophoresis (PFGE) profile, while PS_Koxy2 and 
PS_Koxy4 had PFGE profiles SMAR45KL-5 and VNTR profile 3,8,24,46,53,32,48 
(Figure 3.1). 
Whole-genome sequence data (unavailable to me) generated by Eades et 
al. (2016) were used only to show PS_Koxy1 (isolated from a throat swab from 
patient 3 on 18/12/2014), PS_Koxy2 (isolated from a urine sample from patient 5 
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on 13/8/2015) and PS_Koxy4 (isolated from a rectal swab from patient 4 on 
2/9/2015) were K. oxytoca of sequence type (ST) ST138. No details were provided 
regarding how species identification was confirmed using genomic data. Presence 
of blaGES-5 – a relatively rare Amber class A carbapenemase among 
Enterobacteriaceae – and the ESBL CTX-M-15 was confirmed by PCR. The 
genome sequence data were not interrogated for presence of other antibiotic-
resistance determinants. Therefore, the first aims of this Chapter were to fully 
characterise the isolates at the genomic level and compare their antimicrobial 
susceptibility profiles with their genomic profiles. 
 
 
 
Figure 3.1. PFGE profiles of XbaI-digested DNA from GES-5-positive K. oxytoca 
strains. The image is taken from Eades et al. (2016). All the strains were described 
as being highly similar based on their PFGE profiles. Strains studied in further 
detail in this Chapter are shown. 
 
 
Brown et al. (2017) proposed that phages active against K. oxytoca could 
be used to modulate the gut microbiome and growth of K. oxytoca in clinical 
settings. I believe bacteriophages – viruses that infect bacteria – may be used to 
decontaminate patients colonised with antibiotic-resistant K. oxytoca, and could 
contribute to infection control programmes. Therefore, the final aim of this Chapter 
was to isolate and begin to characterise lytic phages that infected GES-5-positive 
clinical strains of K. oxytoca. This represents the first study to isolate lytic phages 
against these bacteria. 
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3.2 MATERIALS AND METHODS 
Note: the materials and methods detailed here apply to Chapters 3 and 4. 
 
3.2.1 Collection and characterisation of isolates recovered from patients 
Rectal and perineal swabs were taken for 236 patients hospitalised during 
an outbreak (mainly the high dependency unit including the renal dialysis unit) at 
the Hammersmith and Saint Mary’s Hospital between March and April 2015 to 
screen for carbapenem-resistant organisms (CROs). 
Each swab was suspended in 0.5 ml of 0.85% saline to generate a 
homogeneous suspension of material. After vortexing an aliquot of this suspension 
(50 µl) was used to inoculate ColorexTM mSuper CARBATM (E&O Labs 
Chromagar, France) agar provided by E&O laboratories. Plates were incubated 
aerobically at 37 °C for 18-20 h. Coloured colonies (metallic blue, K. pneumoniae 
and K. oxytoca) were regarded as presumptive isolates of carbapenem-resistant 
Klebsiella spp. in accordance with manufacturer’s instructions. All Klebsiella 
isolates were preserved on Cryobank cryogenic beads and stored at -70 °C. 
 
3.2.2 Phenotypic identification and antibiotic susceptibility testing 
Matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) mass 
spectrometry: Recovered isolates were identified by MALDI-TOF mass 
spectrometry (Bruker, Coventry, UK). MALDI-TOF is a form of mass spectrometry 
that produces a protein spectrum (fingerprint) for an organism. A laser is fired at 
the test organism, which is co-crystallised with a matrix onto a metal target. The 
matrix absorbs the laser energy and protects the test organism such that whole 
proteins are desorbed from the target. The matrix also acts as a proton donor to 
ionise the proteins. When high voltage is applied, the ionised proteins are 
accelerated and then travel up the flight tube to a detector. The mass-to-charge 
ratio of the proteins is proportional to the square of the time taken to reach the 
detector. By measuring the time of flight, the mass/charge ratio can be calculated. 
Proteins from 2 kDa to 20 kDa can be detected with the Bruker Microflex LT 
instrument. The associated MALDI Biotyper software compares the protein 
spectrum obtained from the test organism with that of a library of spectra from well 
characterised organisms to provide ‘best match’ information. A score is assigned 
to each match to assist in interpretation. 
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From an overnight culture of each strain grown on ColorexTM mSuper 
CARBATM (E&O Labs), a single colony was selected using a sterile wooden stick. 
The biological material was smeared as a thin film directly onto the available spots 
on the MALDI target plate (consisting of 96 target spots in total). Once dry, the 
biological materials on the target plate were overlaid with 1 µl of α-cyano-4-
hydroxycinnamic acid (HCCA) matrix solution (BRUKER) within 1 h and allowed to 
dry at room temperature. The matrix solution was prepared as follows. To a 1.5 ml 
Eppendorf tube were added 500 µl of Chromasolv acetonitrile (ACN) (Fluka), 475 
µl of Chromasolv water (Fluka) and 25 µl trifluoroacetic acid (Sigma Aldrich). The 
liquid was mixed well by inversion, ensuring the cap of the Eppendorf was always 
tightly closed as ACN evaporates quickly. 250 µl of the solution was added to a 
vial of HCCA (stored in the fridge at 2 to 8 °C). The HCCA was dissolved by 
scratch-mixing and vortexing at room temperature until the solution was clear, 
ensuring there was no yellow pellet left at the bottom of the vial. The resulting 
HCCA solution was stored in the dark and used within 1 week of making. 
Each target plate was quality controlled by spotting it with control strains 
Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213. The dried 
plates were loaded onto the MALDI-TOF Biotyper for identification of isolates. 
Organisms placed on the MALDI-TOF Biotyper were identified and given a score 
relating to the confidence of the identification. The scoring range is: 0.000-1.699 = 
no reliable ID (red); 1.7-1.999 = probable genus ID (yellow); 2.0-2.299 = secure 
genus ID, probable species ID (green); 2.3-3.000 = highly probable species ID 
(green). Scores of 2.0 and above are acceptable. Any organism giving a score of 
less than 2.0 should be investigated and possibly identified using other phenotypic 
or genotypic methods. Repeating the smearing of the organism onto new spots 
may give a clearer result. Alternatively, the extended direct smearing method or 
the formic acid extraction method could be used to gain a more reliable score, 
which was not needed in this case as all identifications fell within 2.0-2.299 range. 
 
API 20E: All isolates identified as K. pneumoniae and K. oxytoca by MALDI-TOF 
were further identified using the API (Analytical Profile Index) 20E (bioMérieux) kit, 
a biochemical panel of phenotypic tests for identification and differentiation of 
members of the family Enterobacteriaceae (Figure 3.2). For each isolate, a strip 
was set up according to the manufacturer’s instructions and incubated at 37 °C for 
	 
	
82	
18 to 24 h. Most results can be read after 24 h but for TDA, IND and VP, a drop of 
ferric chloride, a drop of Kovacs reagent, and a drop of 40% KOH plus a drop of α-
naphthol, respectively, have to be added and left at room temperature for 10 min 
before results are recorded. Appearance of each chamber is compared to the API 
Reading Scale and marked positive or negative based on appearance. A seven-
digit code is then obtained based on the total of positive scores (Figure 3.3). This 
code is used to identify the isolate under study. 
 
Antimicrobial susceptibility testing: Isolates confirmed as K. pneumoniae or K. 
oxytoca using phenotypic tests were screened for possible carbapenemase 
production following UK national guidelines (PHE, 2013). This involved testing 
isolates against 18 antimicrobials (amikacin, amoxicillin, augmentin, aztreonam, 
cefotaxime, cefoxitin, ceftazidime, cefuroxime, ciprofloxacin, colistin, ertapenem, 
gentamicin, meropenem, tazocin, temocillin, tigecycline, tobramycin and 
trimethoprim) following the EUCAST disc diffusion method with the inclusion of 
MAST CAT-ID discs consisting of faropenem (MAST group LTD, UK). Control 
organisms used to monitor test performance of the antimicrobials were 
Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213. 
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Figure 3.2. API 20E strip for identification of Enterobacteriaceae. The API 20E 
strip consists of 20 mini-test chambers containing dehydrated media with 
chemically defined compositions for each test. ONPG, tests for β-galactosidase 
activity by hydrolysis of the substrate o-nitrophenyl-β-D-galactopyranoside; ADH, 
decarboxylation of the amino acid arginine by arginine dihydrolase; LDC, 
decarboxylation of the amino acid lysine by lysine decarboxylase; ODC, 
decarboxylation of the amino acid ornithine by ornithine decarboxylase; CIT, use 
of citrate as sole carbon source; H2S, production of hydrogen sulphide; URE, test 
for urease activity; TDA, detection of tryptophan deaminase activity (has to have 
reagent ferric chloride added); IND, indole test - production of indole from 
tryptophan by the tryptophanase (indole is detected by addition of Kovac’s 
reagent); VP, the Voges-Proskauer test for the detection of acetoin (acetyl 
methylcarbinol) produced by fermentation of glucose by bacteria using the 
butylene glycol pathway; GEL, test for gelatinase (gelatin liquification); GLU, 
fermentation of glucose (hexose sugar); MAN, fermentation of mannose (hexose 
sugar); INO, fermentation of inositol (cyclic polyalcohol); SOR, fermentation of 
sorbitol (alcohol sugar); RHA, fermentation of rhamnose (methyl pentose sugar); 
SAC, fermentation of sucrose (disaccharide); MEL, fermentation of melibiose 
(disaccharide); AMY, fermentation of amygdalin (glycoside); ARA, fermentation of 
arabinose (pentose sugar). 
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Figure 3.3. Recording of API 20E results to identify an isolate. Positive scores are 
given points. The total value of the points is used to generate the seven-digit code 
to identify an isolate. The code can be entered into the API web 
(https://apiweb.biomerieux.com/servlet/Authenticate?action=prepareLogin) to 
identify the isolate.  5245773 = K. oxytoca, ID 97.8%; possibility of Raoultella 
planticola, ID 1.6%. 
 
 
Antimicrobial sensitivities were determined by preparing inoculum 
suspensions with several morphologically similar colonies (when possible) from 
overnight growth (16–24 h of incubation) preferably from a non-selective medium 
(blood agar). Using a sterile loop the colonies were suspended in sterile saline 
(0.85% NaCl, w/v, in water) to the density of a McFarland 0.5 standard, 
corresponding to approximately 1–2x108 CFU/mL for Escherichia coli. The density 
of the suspension was measured with a densitometer that had been calibrated 
with a 0.5 McFarland standard according to the manufacturer’s instructions. It was 
important to carefully prepare the inoculum so that it produced semi-confluent 
growth after overnight incubation. A denser inoculum results in reduced zones of 
inhibition and a lighter inoculum can have the opposite effect. All inoculum 
suspensions were used within 15-60 min of preparation. 
A sterile cotton swab was dipped into the inoculum suspension and the 
excess fluid removed by turning the swab against the inside of the tube to avoid 
over-inoculation of plates. The inoculum was spread evenly over the entire surface 
of the agar plate by swabbing in three directions or by using an automatic plate 
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rotator on to a Muller-Hinton agar plate (4 mm depth with +/- 0.5 mm maximum 
variation). Antimicrobial discs were handled and stored according to the 
manufacturer’s instructions, and were applied firmly on the agar surface within 15 
min of inoculation of the plates. It is important that zone diameters can be reliably 
measured and the maximum number of discs on a plate depends on the size of 
the plate, so that unacceptable overlapping of zones can be avoided. In this 
instance a maximum of six discs was used per plate. Discs were applied to plates 
using a disc dispenser and plates were incubated within 15 min of application of 
antimicrobial discs. The plates were inverted and incubated at 35 °C for 16–20 h. 
In any disc diffusion test, the reading of zones is the most difficult variable 
to standardise. Reading of zones includes measuring the zone diameter, 
inspecting the zone edge and the detection of colonies within the inhibition zone. 
The zone sizes were read using calibrated callipers and interpreted as sensitive or 
resistant by referring to the EUCAST breakpoint guidelines (EUCAST, 2015). 
Carbapenemase confirmatory tests were performed on isolates found to be 
resistant or to have reduced susceptibility to the indicator carbapenems (i.e. 
ertapenem and meropenem). Meropenem offers the best compromise between 
sensitivity and specificity in terms of detecting carbapenemase producers. 
Ertapenem shows high sensitivity but low specificity in terms of detecting 
carbapenemase producers, and so is not recommended for routine use. However, 
ertapenem can be used for detection in specific instances such as in investigating 
an outbreak known to have been caused by an organism that is ertapenem-
resistant but appears to be susceptible to meropenem, or where increased 
sensitivity is required. Another drawback with the use of ertapenem is the cost 
implications. 
All organisms showing borderline or complete resistance to the indicator 
carbapenemases were further tested with the ertapenem and meropenem E-strips 
to ascertain the Minimum Inhibitory Concentration (MIC). Any organisms with MIC 
>0.12 µg/mL to both carbapenemases were sloped and sent to the PHE reference 
laboratory at Colindale for PCR and further testing to understand resistance 
mechanisms. 
 
Gradient MIC testing (E-test®): E-test® is a well-established method for 
antimicrobial resistance testing in microbiology laboratories around the world. E-
	 
	
86	
test® consists of a predefined gradient of antibiotic concentrations on a plastic 
strip and is used to determine the MIC of antibiotics. Fresh colonies of an isolate 
grown on blood agar were transferred to saline to produce a suspension of 0.5 
McFarland standard. A swab dipped in the suspension was used to inoculate a 
Mueller Hinton agar plate. E-strips (Launch) were applied and plates incubated for 
24 h at 30-35 °C. Antimicrobials tested included: 3GC, third-generation 
cephalosporin; AMN, amikacin; AZT, aztreonam; CAZ, ceftazidime; COL, colistin; 
CPD, cefpodoxime; CRO, ceftriaxone; CTX, cefotaxime; ETP, ertapenem; FOX, 
cefoxatin; GEN, gentamicin; MER, meropenem; TEM, Temocillin; and TOB, 
tobramycin. After incubation the MIC gradients were read against the EUCAST 
breakpoint guidelines. Those isolates showing MICs >0.12 µg/mL for meropenem 
and ertapenem were considered resistant (EUCAST, 2015). 
Also, organisms showing resistance to ETP, MER and TEM were 
considered presumptive carbapenemase-producers. Organisms could also show 
resistance to AZT, CAZ, COL, CPD, CRO, CTX and FOX. 
 
3.2.3 Genotypic characterisation of bacteria 
PHE characterisation: The isolates were characterised by PHE using a rapid and 
reliable multiplex PCR-based technique that was able to detect genes encoding 
carbapenemases belonging to different classes. Primers used in the PCR target 
11 genes: blaAIM, blaBIC, blaDIM, blaGIM, blaIMP, blaKPC, blaNDM, blaOXA-48, blaSIM, 
blaSPM and blaVIM (Poirel et al., 2011a). A real-time TaqMan multiplex PCR assay 
was also used to detect genes encoding the rare types of serine carbapenemases: 
GES, IMI/NMC and SME (Swayne et al., 2011). Variable number tandem repeat 
(VNTR) analysis, in which isolates are characterised by their repeat numbers at 
multiple loci, was also used to characterise the bacteria. The 34 K. pneumoniae 
isolates were further tested by a multiplex PCR which allowed identification of 
some common capsular types (K1, K2, K5, K54 and K57), which are those most 
associated with invasive disease or pathogenicity, a further capsular type (K20), 
the presence or absence of two putative virulence factors (rmpA and wcaG) and 
the 16S–23S internal transcribed spacer unit of K. pneumoniae, facilitating 
identification of this organism (Turton et al., 2010). Use of the multiplex PCR 
coupled with the VNTR analysis provides a rapid means of characterisation and 
typing of isolates. 
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Whole-genome sequencing of Klebsiella isolates: Due to phage specificity, 
Klebsiella phages often have a limited host range and can only infect strains of 
Klebsiella spp. with particular capsule types (Hoyles et al., 2015). Therefore, it was 
important to accurately determine the capsule types of Klebsiella spp. isolated in 
the west London hospitals, beyond the limited scope of the multiplex PCR used by 
PHE to type only five capsule types. 
Isolates were plated onto MacConkey agar, and passaged three times 
before DNA was extracted using the Gentra PureGene Qiagen DNA extraction kit 
(Qiagen). DNA quality was assessed by using agarose gel electrophoresis. 
Extracted DNA was frozen at -20 °C and sent to the Quadram Institute Bioscience, 
Norwich for library preparation and sequencing. Samples were run on an Illumina 
Nextseq500 instrument using a Mid Output Flowcell (NSQ® 500 Mid Output KT v2 
(300 CYS); Illumina Catalogue FC-404-2003) following Illumina’s recommended 
denaturation and loading procedures, which included a 1% PhiX spike-in (PhiX 
Control v3; Illumina Catalogue FC-110-3001). Data were uploaded to Basespace, 
where the raw data were converted to eight fastq files for each sample (four for 
R1, four for R2). Tentative identities had been attributed to genomes using Kraken 
1.0 with the raw sequence data by Dr Lesley Hoyles (Wood and Salzberg, 2014), 
and this information was used to inform further analyses. Sequence data were 
quality checked, trimmed, assembled and annotated by Dr Lesley Hoyles, who 
provided me with Prokka-annotated files, with which I performed all additional 
bioinformatics analyses (except PhyloPhlAn and CheckM, which were done by Dr 
Hoyles using servers belonging to the UK MEDical BIOinformatics partnership (UK 
Med-Bio; Medical Research Council grant number MR/L01632X/1)). FastANI and 
BLASTP analyses were performed on the CLIMB (CLoud Infrastructure for 
Microbial Bioinformatics) server (Connor et al., 2016). 
Briefly, paired read data returned by the sequencing provider for each 
genome were concatenated (per genome: four files each for R1, four files each for 
R2) and checked using fastqc v0.11.8 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Data were trimmed 
using trimmomatic 0.39 (SLIDINGWINDOW:5:20 MINLEN:50) (Bolger et al., 
2014), and paired reads retained. Genomes were assembled using the trimmed 
paired reads with SPAdes v3.13.0 (default settings) (Bankevich et al., 2012). Gene 
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predictions and annotations were completed using Prokka v.1.12 (default settings) 
(Seemann, 2014). Completeness and contamination of genomes was assessed 
using CheckM v1.0.18 (Parks et al., 2015). Average nucleotide identity of 
genomes with their closest relatives and type strains of species was assessed 
using FastANI (Jain et al., 2018). PhyloPhlAn 0.99 (Segata et al., 2013) was used 
to determine phylogenetic placements of strains within species. K. oxytoca-related 
genomes were uploaded to the Klebsiella oxytoca MLST website 
(https://pubmlst.org/koxytoca/) sited at the University of Oxford (Jolley et al., 2018) 
on 6 September 2019 to determine allele number against previously defined 
house-keeping genes (rpoB, gapA, mdh, pgi, phoE, infB and tonB). K. 
pneumoniae genomes were analysed using the Institut Pasteur MLST database 
(https://bigsdb.pasteur.fr/klebsiella/klebsiella.html) on 10 September 2019. 
Kleborate (Lam et al., 2018; Wick et al., 2018) and Kaptive (Wyres et al., 2016) 
(http://kaptive.holtlab.net) were used to identify capsular type and O antigen type. 
Presence of antibiotic-resistance genes within strains was determined by BLASTP 
analysis of amino acid sequences of predicted genes within genomes against the 
Comprehensive Antibiotic Resistance Database (CARD) (downloaded 27 July 
2019; protein homolog dataset) (Jia et al., 2017). 
Virulence factors encoded in the K. pneumoniae genomes were determined 
by BLASTP searches against proteins included in the Virulence Factor Database 
(VFDB) (http://www.mgc.ac.cn/cgi-bin/VFs/v5/main.cgi; core dataset downloaded 
on 27 July 2019; Liu et al., 2019). Results are reported for >70% identity and 
>90% query coverage (Chen et al., 2019). 
 
Checking for presence of the kleboxymycin gene cluster in the genomes of the K. 
oxytoca isolates. To determine whether the K. oxytoca isolates harboured the 
kleboxymycin biosynthetic gene cluster (Tse et al., 2017), the proteins encoded in 
the genomes of the K. oxytoca strains were searched against those of the 
reference sequence (GenBank accession number MF401554; Tse et al., 2017). 
This operon encoded all 12 genes of the biosynthetic gene cluster. I used the 
protein sequences of the 12 genes to create a BLASTP database, against which I 
compared the clinical strains. 
I used the following commands to carry out the blast search: 
makeblastdb -in MF401554.faa -dbtype 'prot' -out tilimycin 
	 
	
89	
blastp -query PSKoxy1.faa -db tilimycin -outfmt '6 qseqid sseqid pident qlen qstart qend' -
max_target_seqs 1 -out PS_Koxy1_kleboxymycin.txt 
blastp -query PSKoxy2.faa -db tilimycin -outfmt '6 qseqid sseqid pident qlen qstart qend' -
max_target_seqs 1 -out PS_Koxy2_kleboxymycin.txt 
blastp -query PSKoxy4.faa -db tilimycin -outfmt '6 qseqid sseqid pident qlen qstart qend' -
max_target_seqs 1 -out PS_Koxy4_kleboxymycin.txt 
The data were imported into Excel and I calculated the coverage of the 
query sequence for each BLASTP result, examining only hits with >90% coverage 
and 95% identity with database sequences, to avoid detection of false positives. I 
determined coverage using the following equation with each of the BLASTP 
outputs. 
((Query end-Query start)/Query length) x 100 = Percent coverage 
The Prokka-generated GenBank files for PS_Koxy1, PS_Koxy4 genomes 
and the GenBank file for MF401554 were imported into Geneious Prime 
v2019.2.1. Mauve was used to align each genome against MF401554 to identify 
contigs encoding genes of MF401554. Those contigs that had matches to 
MF401554 were extracted and a second Mauve alignment was produced; the 
alignment view was exported as an image to visualise the arrangement of genes in 
the genomes compared with MF401554. 
 
3.2.4 Sewage samples 
Mixed-liquor sewage wastewater samples were collected from five tanks at 
the Mogden Water Treatment Works and four at Ascot Sewage Treatment Works 
(both Thames Water) and stored at 4 °C. Aliquots were centrifuged at 5000 g for 
20 min to pellet debris. The supernatant was filter-sterilised by passing it through a 
0.45 µm cellulose acetate filter (Millipore) and stored at 4 °C until needed. 
 
3.2.5 Isolation of lytic phages active against the Klebsiella isolates 
For each isolate a colony grown on nutrient agar (Oxoid Ltd) was used to 
inoculate overnight cultures (aerobic, 37 °C) in 5 mL nutrient broth (Oxoid Ltd). 
Aliquots (9 mL) of filter-sterilised sewage samples were mixed with 1 ml of sterile 
10x concentrated nutrient broth containing 50 mM CaCl2 and 50mM of MgCl2, and 
200 µl of the overnight culture were added. The culture was incubated aerobically 
for 6 h at 37 °C. Samples were then centrifuged at 10,000 rpm for 5 min. Aliquots 
(200 µl) of the overnight cultures of the isolates were used to inoculate 0.2% agar 
overlays (kept molten at 45 °C) which were then poured over nutrient agar plates. 
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Once the overlays had set, aliquots (100 µl) of the centrifuged supernatants were 
spotted onto the set overlay. Plates then were incubated aerobically overnight at 
37 °C. Presence of phages in supernatants was indicated by zones of clearing 
(lysis) or individual plaques on overlays. 
 
3.2.6 Purification of phages 
The isolated phages were then purified against their host strain (Hoyles et 
al., 2015). Supernatants were diluted (10-1 to 10-9) in nutrient broth. An aliquot (100 
µl) of each dilution was added to 3 ml of 0.2% agar overlay (kept molten at 45 °C) 
with 200 µl of an overnight culture of the host strain and poured over nutrient agar 
plates, which were incubated aerobically at 37 °C overnight. The following day 
individual plaques were picked and suspended in 1 ml nutrient broth for a 
minimum of 1 h. A second dilution series was prepared, and the above process 
repeated. Again, individual plaques were picked and suspended in nutrient broth. 
In total, the process was repeated at least three times to generate pure phage 
stocks, which were stored at 4 °C. 
 
3.2.7 Preparation of bulk stocks of isolated phages 
Once each phage was purified, it needed to be bulked up to allow isolation 
of sufficient DNA for analyses. To 100-200 ml of sterile nutrient broth containing 5 
mM CaCl2 and 5 mM of MgCl2 was added 1 ml of an overnight broth culture of the 
phage’s host strain. The culture was grown to mid-exponential phase, then it was 
inoculated with 100 µL of pure phage stock and incubated at 37 °C until the 
medium became clear (i.e. the bacteria were lysed by the phage). The lysate was 
poured into 50 mL Falcon tubes and centrifuged at 5000 rpm for 30 min. The 
supernatant was filter-sterilised using a 0.45 µm cellulose acetate filter (Millipore) 
into a sterile Falcon tube. To precipitate the phages, 10% (w/v) polyethylene glycol 
8000 (PEG)/6% (w/v) NaCl was added to the filter-sterilised supernatant, with 
gentle mixing to dissolve all the PEG and NaCl. The sample was then incubated at 
4 °C for 16 h (Hoyles et al., 2015). Then, the samples were centrifuged at 5000 
rpm for 30 min at 4 °C. Pellets were resuspended in 250 µl of SM buffer (50 mM 
Tris/HCl, pH 7.5; 100 mM NaCl, 8 mM MgCl2.7H2O; 
http://cshprotocols.cshlp.org/content/2006/1/pdb.rec8111.full?text_only=true). PEG 
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was removed from samples by adding an equal volume of chloroform. Samples 
were mixed then centrifuged at 13,000 rpm for 5 min inside a safety cabinet. Once 
centrifuged the aqueous layer was removed without disrupting the PEG interface. 
The aqueous layer containing the purified phage particles was stored at 4 °C until 
DNA extraction. 
 
3.2.8 Extraction of DNA from the isolated phages, and restriction enzyme 
profiling 
DNA was extracted from phages using the method of Murphy et al. (2013). 
To the purified phages 250 µL of DNAse (20 mg/ml) and 5 µL RNAse (2 mg/ml) in 
200 µL of SM buffer were added to remove bacterial (host) DNA. The mixture was 
left on a heating block at 37 °C for 30 min, then incubated at 80 °C for another 10 
min to break up the phages to release proteins and DNA. After 10 min the mixture 
was placed into ice and transferred to a fume cupboard. Phage Disruption Buffer 
was made up by adding 7.2 µL of 2-mercaptoethanol (Sigma) to 1 mL of GTC 
stock solution consisting of 22.5 mL of 6 M guanidium thiocyanate solution 
(Sigma), 6.8 mL of H2O, 1.76 mL of sodium citrate (pH 7) and 2.64 mL of 10% 
sarkosyl. This was mixed with 1 mL of DNase- and RNase-treated bacteriophage 
lysate and left to incubate for 10 min at room temperature. An equal volume of 
phenol:chloroform:isoamyl alcohol (Sigma) and 500 µL of Tris EDTA were then 
added, with the sample vortexed and centrifuged at 13,000 rpm for 5 min inside 
the fume cupboard. After centrifugation, the top (aqueous) layer was transferred to 
a sterile microcentrifuge tube and a second phenol extraction was carried out to 
remove all proteins. The DNA present in the aqueous phase was precipitated by 
adding 2.5 volume of 96% ice-cold ethanol and 1 volume of sodium acetate to 
~500 µL of the sample. The sample was mixed gently and placed in ice for 2 min 
to help precipitate the DNA, then centrifuged for 15 min at 13,000 rpm at 10 °C. 
The supernatant was tipped off, and the DNA was left to air dry. The air-dried DNA 
was incubated for a few minutes at 65 °C to drive off excess ethanol, then the 
pelleted DNA was resuspended and dissolved in 50 µL of sterile water. 
Agarose gel electrophoresis was used to assess the quality of DNA isolated 
from each phage. Agarose gels were prepared by adding 0.24 g of agarose to 30 
mL of TAE buffer, which was heated for 1 min to dissolve all the agarose. After 
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cooling to ~50 °C, 5 µL of ethidium bromide was added to the molten agarose. The 
molten agarose was poured into a gel cast and a well comb was added. The gel 
was left for 20 min to set. The agarose gel was placed in a gel tank and covered in 
TAE buffer. A 1 kb DNA ladder was run with all DNA samples for 60 min at 50 mA. 
DNA in gels was visualised under UV light. The purity/quantity of DNA in samples 
was measured using a Nanodrop. Aliquots of DNA were digested with different 
restriction enzymes as recommended by the manufacturer (Thermo Scientific Fast 
digest): EcoR1 (digest time 5 min at 37 °C), Eco321 (digest time 5 min at 37 °C), 
HindIll (digest time 10 min at 37 °C) and Nco1 (digest time 5 min at 37 °C). An 
aliquot (30 µL) of each reaction mixture was loaded on to the gel with 3 µL of 
loading dye and run for 2.5 h at 50 V, 100 mA. The gel was then stained with 
ethidium bromide (300 µL TAE + 0.5 µL of ethidium bromide) for 20 min and 
viewed under UV light. Restriction enzyme profiling produces fingerprints of 
phages allowing the identification of novel phages (i.e. those with unique 
fingerprints) (Kęsik-Szeloch et al., 2013). 
 
3.2.9 Determination of host ranges for isolated phages 
The host ranges of the purified phages were tested against a panel of 
strains available in the laboratory at the University of Reading, using agar overlays 
inoculated with 200 µL overnight culture of the test bacterium. For each phage, 10 
µL of the purified phage was spotted onto the overlay, then left to dry for 10 min. 
Once dried, the plates were incubated at 37 °C overnight and checked the next 
day for the presence of bacterial lysis (i.e. clearing) and potential depolymerase 
activity (i.e. haloes). This ‘spot testing’ is a rapid and efficient method for 
determining the host ranges of phages in a large collection of bacteria (Clokie and 
Kropinski, 2009). The host ranges of the purified phages were tested against all 
strains described in Chapters 3 and 4, and a selection of Klebsiella strains 
described by Chen et al. (2019). 
 
3.3 RESULTS 
3.3.1 Phenotypic and genomic characterisation of the K. oxytoca isolates 
PS_Koxy1 was isolated from the throat of a 75-year-old male, PS_Koxy2 
was isolated from the urine of a 47-year-old female, and PS_Koxy4 was isolated 
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from a rectal swab of a 65-year-old male in a high-dependency unit (Renal Dialysis 
Unit of a group of west London hospitals). All three isolates were identified by 
MALDI-TOF and API 20E (profile 5245773, 97.8%) as K. oxytoca. 
Antimicrobial sensitivities were determined. The strains were resistant to 
amoxicillin (zone diameter <14 mm), augmentin (<19 mm), aztreonam (<21 mm), 
cefotaxime (<17 mm), cefoxitin (<19 mm), ceftazidime (<19 mm), cefuroxime (<18 
mm), ciprofloxacin (<19 mm), ertapenem (<22 mm), gentamicin (<14 mm), tazocin 
(<17 mm), temocillin (<19 mm), tobramycin (<14 mm) and trimethoprim (<14 mm), 
and sensitive to amikacin (>18 mm), colistin (MIC <2 µg/mL), meropenem (>22 
mm) and tigecycline (>18 mm). Ertapenem resistance was confirmed by E-test 
(had an MIC > 0.12 µg/mL), as ertapenem is used as an indicator antibiotic for the 
detection of carbapenemase enzyme. The isolates were sloped and sent to the 
PHE reference laboratory at Colindale for PCR and further testing to understand 
resistance mechanisms. 
It is not possible to differentiate K. oxytoca from closely related species K. 
michiganensis and K. grimontii using phenotypic tests (Saha et al., 2013; Passet 
and Brisse, 2017; Chen et al., 2019), though it can be distinguished from 
Klebsiella huaxiensis on the basis of its Voges-Proskauer reaction (Hu et al., 
2019). From recent studies (Moradigaravand et al., 2017; Chen et al., 2019), it is 
clear that K. michiganensis and K. grimontii are clinically relevant but under-
reported because of inadequate genomic characterisation of isolates. 
For the assignment of strains to species using whole-genome sequence 
data, ANI values should be calculated with all phylogenetically closely related 
species and ideally using the genome sequences of the type strains of species 
(Chun et al., 2018; Table 3.2). ANI values generated represent a measurement of 
how similar two genome sequences are to one another. If the genomes of two 
strains share >95% ANI, they are considered to belong to the same species (Chun 
et al., 2018). 
Determination of ANI with genomes of authentic K. oxytoca, K. grimontii, K. 
michiganensis (Chen et al., 2019), ‘Klebsiella pasteurii’, ‘Klebsiella spallanzanii’ 
and K. huaxiensis strains showed PS_Koxy1, PS_Koxy2 and PS_Koxy4 all 
represented isolates of K. michiganensis, not K. oxytoca, following the 
recommendations of Chun et al. (2018). They shared 98.74, 98.70 and 98.71% 
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ANI, respectively, with the type strain of K. michiganensis, and 99.12 to 100.00% 
ANI with each other (Table 3.2). 
Classification should also be confirmed with at least one method of 
phylogenetic analysis in which at least 30 genes are included (Chun et al., 2018). 
Phylogenetic analysis of sequences of the 400 most conserved proteins in a 
dataset of authentic K. oxytoca, K. michiganensis, K. grimontii and related 
genomes (Chen et al., 2019; Hu et al., 2019; Merla et al., 2019) with the three 
strains confirmed PS_Koxy1, PS_Koxy2 and PS_Koxy4 were K. michiganensis, 
with the three clustering together in the phylogenetic tree confirming they were 
highly similar to one another (Figure 3.4). 
 
3.3.2 Genomic characterisation of the K. michiganensis isolates 
Whole-genome sequences of each of the isolates were uploaded to the 
Klebsiella oxytoca MLST website (https://pubmlst.org/koxytoca/), to confirm the 
results of Eades et al. (2016). All three strains were ST138. None of the genomes 
included in Figure 3.4 were of this sequence type (Chen et al., 2019). No further 
data are available on this ST. Sequence data were uploaded to Kaptive 
(http://kaptive.holtlab.net) to see whether capsule and O antigen types of the 
isolates could be determined. All three isolates were of unknown capsule (K) 
(Figure 3.5) and O antigen (Figure. 3.6) types. The K types of the three strains 
were most closely related to KL68: PS_Koxy1 – low confidence match, 93.06% 
coverage, 87.65% identity, 17/18 genes matched; PS_Koxy2 and PS_Koxy4 – low 
confidence match, 93.06% coverage, 87.41% identity, 16/18 genes matched). All 
three strains were of an O antigen type related to O1v1: low confidence match, 
93.33% coverage, 73.12% identity, 4/7 genes matched). 
The protein sequences of the genes encoded by the isolates were 
compared against the latest release of CARD (Jia et al., 2017), a “curated 
collection of characterized, peer-reviewed resistance determinants and associated 
antibiotics, organized by the Antibiotic Resistance Ontology (ARO) and AMR gene 
detection models”. Presence of the β-lactamase with carbapenemase activity 
GES-5 (100% identity, bit-score 591 – perfect CARD match) was confirmed, so too 
was that of the ESBL CTX-M-15 (100% identity, bit-score 593 – perfect CARD 
match) (Figure 3.7; Eades et al., 2016). GES-5 was not detected in any of the 
	 
	
95	
other strains included in Figure 3.4, nor has it been reported by CARD as being 
encoded by K. oxytoca. PS_Koxy1, PS_Koxy2 and PS_Koxy4 also encoded SHV-
66 (99.65% identity, bit-score 580 – strict CARD match; Figure 3.7), an ESBL not 
reported by CARD (Table 3.3) as being present in K. oxytoca and related species. 
In this study, SHV-66 (99.65% identity, bit-score 580 – strict CARD match) was 
also found in K. michiganensis strains E718 (Liao et al., 2012), GY84G39 
(unpublished), K1439 (unpublished) and 2880STDY5682598 (Moradigaravand et 
al., 2017) (accession numbers GCA_000276705, GCA_001038305, 
GCA_002265195 and GCA_900083915, respectively), which had been included in 
the phylogenetic analysis (Figure 3.4). 
 
 
Table 3.2: ANI values determined using FastANI for PS_Koxy1, PS_Koxy2 
and PS_Koxy4 against each other and type strain whole-genome sequences. 
Query sequence Reference sequence (GenBank accession number) ANI (%) 
PS_Koxy1 PS_Koxy2 99.12 
PS_Koxy1 PS_Koxy4 99.99 
PS_Koxy2 PS_Koxy4 100.00 
PS_Koxy1 K. oxytoca ATCC 13182T (GCA_900977765) 92.59 
PS_Koxy1 ‘K. pasteurii’ SB3355 (GCA_901563825) 94.27 
PS_Koxy1 K. grimontii 06D021T (GCA_900200035) 93.91 
PS_Koxy1 ‘K. spallanzanii’ SB3356 (GCA_901563875) 89.26 
PS_Koxy1 K. huaxiensis WCHKl090001T (GCA_003261575) 88.25 
PS_Koxy1 K. michiganensis W14T (GCA_901556995) 98.74 
PS_Koxy2 K. michiganensis W14T (GCA_901556995) 98.70 
PS_Koxy4 K. michiganensis W14T (GCA_901556995) 98.71 
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Figure 3.4. Phylogenetic analyses of whole-genome sequences confirming 
PS_Koxy1, PS_Koxy2 and PS_Koxy4 represent isolates of K. michiganensis. The 
phylogenetic tree was produced using PhyloPhlAn 0.99 (Segata et al., 2013) 
implementing FastTree, which generates approximately maximum-likelihood trees 
for large alignments. The tree visualised using iTOL (https://itol.embl.de) and 
coloured using Adobe Illustrator. Scale bar, normalised fraction of total branch 
length. Analyses carried out and image produced by L. Hoyles. 
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PS_Koxy1 
 
PS_Koxy2 
 
PS_Koxy4 
 
Figure 3.5. Capsule (K) typing of K. michiganensis PS_Koxy1, PS_Koxy2 and 
PS_Koxy4 as determined using the online version of Kaptive. Gene images were 
downloaded from Kaptive. 
 
 
 
Figure 3.6. O antigen typing of K. michiganensis PS_Koxy1, PS_Koxy2 and 
PS_Koxy4 as determined using the online version of Kaptive. The gene image 
was downloaded from Kaptive. 
 
 
In addition to the β-lactamases GES-5, CTX-M-15 and SHV-66, PS_Koxy1, 
PS_Koxy2 and PS_Koxy4 encoded several other antibiotic-resistance genes 
(Figure 3.7), some reported as rare (e.g. acrB, acrD, mdtB, mdtC) in K. oxytoca 
genomes by CARD while others were common (e.g. baeR, emrA, emrB, fosA5, 
marA) (Table 3.3). Antimicrobial profiling had shown the strains to be resistant to 
14 of the antibiotics they were tested against (section 3.3.1). The strains’ 
resistance to amoxicillin and augmentin (amoxicillin/clavulanic potassium) can be 
explained by them carrying OXA-1, a β-lactamase found in K. oxytoca. All the 
strains encoded CTX-M-15, which is an ESBL responsible for cephalosporin 
resistance (i.e. cefotaxime, cefoxitin, cefuroxime). E. coli ampH a class C AmpC β-
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lactamase also confers cefoxitin resistance. AAC(6’)-Ib7, aadA, APH(3’’)-Ib, 
APH(6)-Id and AAC(3)-IIe genes encoded by the strains are responsible for 
aminoglycoside resistance (gentamicin, tobramycin). The isolates were sensitive 
to the aminoglycoside amikacin, which could be used therapeutically because of 
its reliable activity against Gram-negative aerobes; even with increased usage 
there is low incidence of resistance (Luis and Spencer, 1998). The presence of 
GES-5, SHV-66 and TEM-1 is responsible for the strains’ resistance to the 
carbapenems amoxicillin, temocillin, ertapenem and tazocin; however, the strains 
were sensitive to meropenem. OXA-1 also confers resistance to tazocin, which 
would otherwise inhibit SHV and TEM β-lactamases. Ciprofloxacin resistance was 
due to the presence of the QnrB1gene together with oqxA and oqxB RND efflux 
pump. Trimethoprim resistance was conferred by dfrA14 (Sköld, 2010). 
 
3.3.3 Detection of the kleboxymycin biosynthetic gene cluster in the 
genomes of PS_Koxy1, PS_Koxy2 and PS_Koxy4 
Tse et al. (2017) described the 12-gene operon encoding the kleboxymycin 
biosynthetic gene cluster. They deposited the annotated sequence of the cluster in 
GenBank (accession number MF401554). I used the protein sequences of the 12 
genes encoded by the reference sequence to create a BLASTP database against 
which the proteins encoded in the genomes of PS_Koxy1, PS_Koxy2 and 
PS_Koxy4 were compared. Results were ordered by descending order of query 
coverage and sequence identity, to identify proteins in the three isolates showing 
high (>95%) identity with genes encoded within the kleboxymycin gene cluster. All 
three isolates encoded all 12 genes of the biosynthetic gene cluster, in 
consecutive genes (Table 3.4). PS_Koxy4 encoded the genes in the same 
orientation as MF401554, while PS_Koxy1 and PS_Koxy2 encoded the genes in 
the reverse orientation. 
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Figure 3.7. Comparison of genome data for the three K. michiganensis isolates 
with sequences in The Comprehensive Antibiotic Resistance Database (Jia et al., 
2017). Strict CARD match, not identical but the bit-score of the matched sequence 
is greater than the curated BLASTP bit-score cut-off; perfect CARD match, 100% 
identical to the reference sequence along its entire length. Loose matches are not 
shown to avoid presenting false positives based on sequences with low homology 
and bit-scores below CARD BLASTP cut-off recommendations. BLASTP analyses 
carried out by me and image produced by L. Hoyles. 
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Table 3.3: Summary of information for CARD genes found in K. 
michiganensis PS_Koxy1, PS_Koxy2 and PS_Koxy4. 
CARD data from analyses of 107 K. oxytoca genomes 
(https://card.mcmaster.ca/prevalence). CARD Prevalence 3.0.5 is based on 
sequence data acquired from NCBI on 31 July 2019, analysed using RGI 5.0.0 
(DIAMOND homolog detection) and CARD 3.0.3. 
ARO: accession Name Definition Prevalence (%) in 
K. oxytoca* 
3000074 emrB Translocase in the emrB-TolC efflux protein in E. coli. It 
recognises substrates including carbonyl cyanide m-
chlorophenylhydrazone, nalidixic acid and thioloactomycin. 
99.19 
3000165 tet(A) Tetracycline efflux pump found in many species of Gram-
negative bacteria. 
3.25 
3000216 acrB Protein subunit of AcrA-AcrB-TolC multidrug efflux complex. 
AcrB functions as a heterotrimer which forms the inner 
membrane component and is primarily responsible for 
substrate recognition and energy transduction by acting as a 
drug/proton antiporter. 
1.63 
3000263 marA In the presence of antibiotic stress, E. coli overexpresses the 
global activator protein MarA, which besides inducing MDR 
efflux pump AcrAB, also down-regulates synthesis of the porin 
OmpF. 
95.33 
3000410 sul1 Sulfonamide resistant dihydropteroate synthase of Gram-
negative bacteria. It is linked to other resistance genes of 
class 1 integrons. 
28.79 
3000412 sul2 Sulfonamide resistant dihydropteroate synthase of Gram-
negative bacteria, usually found on small plasmids. 
6.54 
3000491 acrD Aminoglycoside efflux pump expressed in E. coli. Its expression 
can be induced by indole, and is regulated by baeRS and 
cpxAR. 
1.87 
3000516 emrR EmrR is a negative regulator for the EmrAB-TolC multidrug 
efflux pump in E. coli. Mutations lead to EmrAB-TolC 
overexpression. 
99.07 
3000518 CRP CRP is a global regulator that represses MdtEF multidrug efflux 
pump expression. 
100 
3000793 mdtB MdtB is a transporter that forms a heteromultimer complex with 
MdtC to form a multidrug transporter. MdtBC is part of the 
MdtABC-TolC efflux complex. 
0.93 
3000794 mdtC MdtC is a transporter that forms a heteromultimer complex with 
MdtB to form a multidrug transporter. MdtBC is part of the 
MdtABC-TolC efflux complex. In the absence of MdtB, MdtC 
can form a homomultimer complex that results in a functioning 
efflux complex with a narrower drug specificity. 
0.93 
3000828 baeR BaeR is a response regulator that promotes the expression of 
MdtABC and AcrD efflux complexes. 
98.13 
3000873 TEM-1 TEM-1 is a broad-spectrum β-lactamase found in many Gram-
negative bacteria. Confers resistance to penicillins and first 
13.08 
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ARO: accession Name Definition Prevalence (%) in 
K. oxytoca* 
generation cephalosphorins. 
3001121 SHV-66 SHV-66 is an extended-spectrum β-lactamase found in K. 
pneumoniae. 
ND 
3001396 OXA-1 OXA-1 is a β-lactamase found in E. coli. 2.80 
3001878 CTX-M-15 CTX-M-15 is a β-lactamase found in the family 
Enterobacteriaceae. 
1.87 
3002334 GES-5 GES-5 is a β-lactamase found in the family Enterobacteriaceae. ND 
3002392 OXY-1-4 OXY-1-4 is a β-lactamase found in K. oxytoca. 2.80 
3002578 AAC(6’)-Ib7 AAC(6')-Ib7 is a plasmid-encoded aminoglycoside 
acetyltransferase in Enterobacter cloacae and Citrobacter 
freundii. 
4.67 
3002601 aadA ANT(3'')-Ia is an aminoglycoside nucleotidyltransferase gene 
encoded by plasmids, transposons, integrons in 
Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Vibrio cholerae. 
21.50 
3002639 APH(3’’)-Ib APH(3'')-Ib is an aminoglycoside phosphotransferase encoded 
by plasmids, transposons, integrative conjugative elements 
and chromosomes in Enterobacteriaceae and Pseudomonas 
spp. 
9.35 
3002660 APH(6)-Id APH(6)-Id is an aminoglycoside phosphotransferase encoded 
by plasmids, integrative conjugative elements and 
chromosomal genomic islands in K. pneumoniae, Salmonella 
spp., E. coli, Shigella flexneri, Providencia alcalifaciens, 
Pseudomonas spp., V. cholerae, Edwardsiella tarda, 
Pasteurella multocida and Aeromonas bestiarum. 
11.21 
3002714 QnrB1 Plasmid-mediated quinolone resistance protein found in K. 
pneumoniae. 
0.93 
3002859 dfrA14 Integron-encoded dihydrofolate reductase found in E. coli. 13.08 
3002986 bacA BacA recycles undecaprenyl pyrophosphate during cell wall 
biosynthesis, which confers resistance to bacitracin. 
1.87 
3003209 fosA5 Fosfomycin resistance gene isolated from clinical strain of E. 
coli E265. It is susceptible to amikacin, tetracycline and 
imipenem, and resistant to sulphonamide, cephalosporins, 
gentamicin, ciprofloxacin, chloramphenicol and streptomycin. 
87.85 
3003578 pmrF Required for the synthesis and transfer of 4-amino-4-deoxy-L-
arabinose to Lipid A, which allows Gram-negative bacteria to 
resist the antimicrobial activity of cationic antimicrobial 
peptides and antibiotics such as polymyxin. 
0.93 
3003922 oqxA RND efflux pump conferring resistance to fluoroquinolone. 91.59 
3003923 oqxB RND efflux pump conferring resistance to fluoroquinolone. 2.80 
3003950 msbA Multidrug resistance transporter homolog from E. coli and 
belongs to a superfamily of transporters that contain an 
adenosine triphosphate (ATP) binding cassette (ABC) which is 
also called a nucleotide-binding domain (NBD). MsbA is a 
member of the MDR-ABC transporter group by sequence 
homology. MsbA transports lipid A, a major component of the 
bacterial outer cell membrane, and is the only bacterial ABC 
transporter that is essential for cell viability. 
97.20 
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ARO: accession Name Definition Prevalence (%) in 
K. oxytoca* 
3004580 K. pneumoniae 
KpnE 
KpnE subunit of KpnEF resembles EbrAB from E. coli. Mutation 
in KpnEF resulted in increased susceptibility to cefepime, 
ceftriaxon, colistin, erythromycin, rifampin, tetracycline, and 
streptomycin as well as enhanced sensitivity toward sodium 
dodecyl sulfate, deoxycholate, dyes, benzalkonium chloride, 
chlorhexidine and triclosan. 
97.20 
3004583 K. pneumoniae 
KpnF 
KpnF subunit of KpnEF resembles EbrAB from E. coli. Mutation 
in KpnEF resulted in increased susceptibility to cefepime, 
ceftriaxon, colistin, erythromycin, rifampin, tetracycline, and 
streptomycin as well as enhanced sensitivity toward sodium 
dodecyl sulfate, deoxycholate, dyes, benzalkonium chloride, 
chlorhexidine and triclosan. 
98.13 
3004588 K. pneumoniae 
KpnG 
KpnG consists of ~390 residues and resembles EmrA of E. coli. 
Disruption of the pump components KpnG-KpnH significantly 
decrease resistance to azithromycin, ceftazidime, 
ciprofloxacin, ertapenem, erythromycin, gentamicin, imipenem, 
ticarcillin, norfloxacin, polymyxin-B, piperacillin, spectinomycin, 
tobramycin and streptomycin. 
97.20 
3004612 E. coli ampH AmpH is a class C ampC-like β-lactamase and penicillin-binding 
protein identified in E. coli. 
98.13 
3004621 AAC(3)-IIe Plasmid-encoded aminoglycoside acetyltransferase in E. coli. 2.80 
*ND, no data. 
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Table 3.4: Results of BLASTP analyses comparing the protein sequences 
encoded within the kleboxymycin operon with those of K. michiganensis 
PS_Koxy1, PS_Koxy2 and PS_Koxy4. 
Gene annotations for the PS_Koxy strains are from Prokka. 
Encoding 
gene 
PS_Koxy1 PS_Koxy2 PS_Koxy4 Identity 
(%) 
Coverage 
(%) 
mfsX PSKoxy1_03008 PSKoxy2_03101 PSKoxy4_04877 96.10 99.76 
uvrX PSKoxy1_03007 PSKoxy2_03100 PSKoxy4_04878 97.21 99.87 
hmoX PSKoxy1_03006 PSKoxy2_03099 PSKoxy4_04879 99.21 99.80 
adsX PSKoxy1_03005 PSKoxy2_03098 PSKoxy4_04880 96.00 99.85 
icmX PSKoxy1_03004 PSKoxy2_03097 PSKoxy4_04881 97.62 99.52 
dhbX PSKoxy1_03003 PSKoxy2_03096 PSKoxy4_04882 97.70 99.62 
aroX PSKoxy1_03002 PSKoxy2_03095 PSKoxy4_04883 96.92 99.74 
npsA PSKoxy1_03001 PSKoxy2_03094 PSKoxy4_04884 95.06 99.80 
thdA PSKoxy1_03000 PSKoxy2_03093 PSKoxy4_04885 92.11 98.68 
npsB PSKoxy1_02999 PSKoxy2_03092 PSKoxy4_04886 96.43 99.93 
npsC PSKoxy1_02998 PSKoxy2_03091 PSKoxy4_04887 94.62 98.47 
marR PSKoxy1_02997 PSKoxy2_03090 PSKoxy4_04888 99.39 99.39 
 
 
To determine the alignment of the genes encoded by the K. michiganensis 
strains with MF401554, all sequence data were imported into Geneious Prime 
v2019.2.1 in annotated GenBank format. For each genome, progressiveMauve 
alignments were done to determine which contig encoded the kleboxymycin 
biosynthetic gene cluster. Once the contigs had been identified, they were 
extracted from the GenBank files. The sequences of PS_Koxy1 and PS_Koxy2 
sequences were reversed and complemented, and all three sequences were 
aligned against MF401554 using progressiveMauve. The gene alignment showed 
the K. michiganensis strains encoded the entire biosynthetic gene cluster (Figure 
3.8). 
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Figure 3.8. Demonstration that PS_Koxy1, PS_Koxy2 and PS_Koxy4 encode the kleboxymycin biosynthetic gene cluster. All 
strains encode the same genes as the reference sequence, MF401554 (Tse et al., 2017). The image was produced by me using 
Geneious Prime 2019.2.1, from a progressiveMauve alignment of the reference sequence and the regions of the PS_Koxy1, 
PS_Koxy2 and PS_Koxy4 genomes encoding the gene cluster. 
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3.3.4 Isolation of lytic phages against the K. michiganensis isolates 
The three isolates encoding GES-5 were screened against filter-sterilised 
sewage samples collected from four different mixed-liquor tanks (A–D) at the 
Mogden Sewage Treatment Works. After addition of 9 ml filter-sterilised sewage 
water to 10x concentrated sterile nutrient broth, samples were inoculated with 200 
µl of overnight culture of each strain and incubated for 6 h at 37 °C. Aliquots (200 
µl) of the centrifuged spent medium were used in spot assays to determine 
whether cultures were positive for lytic phages (i.e. whether they produced zones 
of clearing or individual plaques in overlays). One of each different plaque type 
was propagated to purity. In total, seven phages were enriched for in the sewage 
samples (Table 3.5). 
 
 
Table 3.5: Phages propagated to purity from sewage water against GES-5-
positive strains. 
Strain Phage isolated from tank 
 A B C D 
PSKoxy 1 1Ai    
PSKoxy 2  2B 2C 2Di 
PSKoxy 4  4B 
 
 4Di 
4Dii 
 
 
Host ranges of the phages were determined against all three strains, to see 
if the isolated phages were able to recognise a receptor common among these 
different strains and thus displayed broad-spectrum activity (Table 3.6). 
Host ranges of the phages against a range of antibiotic-resistant K. 
pneumoniae and Acinetobacter spp. (6 Acinetobacter baumannii, 1 Acinetobacter 
pittii), and isolates recovered from preterm infants (Chen et al., 2019) were also 
determined. None of the phages had any effect on the Acinetobacter spp. tested. 
However, some of the phages were able to infect one or more K. pneumoniae 
strains (Table 3.7). 
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Table 3.6: Host ranges of the lytic phages against the GES-5-positive 
isolates. 
Strain 1Ai 2B 2C 2Di 4B 4Di 4Dii 
PS_Koxy1 + d – – – – – – 
PS_Koxy2 + d + + – + – – 
PS_Koxy4 – – – + + + + 
+, Lytic; d, depolymerase activity (haloes formed round plaques); –, no activity. 
 
 
Table 3.7: Host ranges of the lytic phages against clinically relevant 
Klebsiella isolates. 
Results are only shown for those phages that showed activity against one or more 
of the test strains. 
Species Strain MLST K, O types 2B 2Di 4Dii Reference 
K. pneumoniae PS_Kpn32 ST35 K22, O1v1 + d – – Chapter 4 
K. pneumoniae PS_Kpn39 ST14 K64, O1v1 – – + d Chapter 4 
K. pneumoniae PS_Kpn41 ST15 K112, O1v1 – – + d Chapter 4 
K. variicola PS_misc5 * K81, * – – + Chapter 4 
K. pneumoniae P010F ST253 *, O1v2 – + d – Chen et al. (2019) 
K. pneumoniae P057K W * K11, O3/O3a – + ?d – Chen et al. (2019) 
K. grimontii P079F P ST76 *, O1v1 – + d + d Chen et al. (2019) 
K. pneumoniae P080S T ST2211 K10, O1v2 – – + Chen et al. (2019) 
K. pneumoniae P008E ST461 K10, O1v2 – – + Chen et al. (2019) 
K. grimontii P038I * *, * – + d + Chen et al. (2019) 
+, Lytic; d, depolymerase activity (haloes formed round plaques); ?d, may be 
depolymerase activity (requires further study); –, no activity. 
*, Unknown type. 
 
 
3.4 DISCUSSION 
3.4.1 Genomic characterisation of the GES-5-positive strains reveals them to 
be K. michiganensis 
Strains PS_Koxy1, PS_Koxy2 and PS_Koxy4 had been isolated from a 
throat swab, urine sample and rectal swab, respectively, from patients hospitalised 
during an infection outbreak mainly associated with the high-dependency units 
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including the renal dialysis unit at the Hammersmith and Saint Mary’s Hospitals 
between March and April 2015. They were collected for screening for 
carbapenem-resistant organisms using the screening protocol described in 
Chapter 2. The blue colonies on the culture medium (ColorexTM mSuper 
CARBATM; E&O Labs Chromagar, France) were identified by MALDI-TOF and API 
20E (profile 5245773, 97.8%) as K. oxytoca. 
When received in the laboratory for my work, I confirmed the identity of the 
strains as K. oxytoca by API 20E testing. Eades et al. (2016) had previously 
reported the strains to be K. oxytoca based on whole-genome sequence data. 
They had also found the strains to be of ST138. As the whole-genome sequence 
data generated by Eades et al. (2016) were not publicly available, new sequence 
data were generated for the strains. Analysis of the genomes via the Klebsiella 
oxytoca MLST website confirmed the strains to be ST138. Following the 
recommendations of Chun et al. (2018) regarding using ANI between genomes to 
determine species affiliations, the three strains were found to be K. michiganensis 
(Table 3.2), with phylogenetic analyses confirming this affiliation (Figure 3.4). In 
addition, the strains were found to represent unknown capsule and O antigen 
types (Figure 3.5, Figure 3.6). 
Antimicrobial susceptibility testing showed the isolates to be resistant to 
amoxicillin, augmentin, aztreonam, cefotaxime, cefoxitin, ceftazidime, cefuroxime, 
ciprofloxacin, ertapenem, gentamicin, tazocin, temocillin, tobramycin and 
trimethoprim, and sensitive to amikacin, colistin, meropenem and tigecycline. The 
genotypic testing of the strains using the in-house Xpert® Carba-R PCR failed to 
detect any resistance genes, thus agreeing with Dortet et al. (2016). This is why I 
(while working in the Charing Cross microbiology laboratory) had originally 
submitted the strains to the PHE reference laboratory at Colindale for PCR and 
further testing to understand resistance mechanisms. 
As discussed below, bioinformatics analysis of the whole-genome 
sequences of the strains showed them to encode a number of antibiotic-resistance 
genes not reported by Eades et al. (2016), and a biosynthetic gene cluster known 
to produce enterotoxins found in intestinal contents of patients suffering from 
AAHC. 
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3.4.2 Clinical significance of K. michiganensis 
K. michiganensis was originally proposed to describe an isolate closely 
related to K. oxytoca recovered from a toothbrush holder (Saha et al., 2013). The 
bacterium is now recognised as an emerging pathogen, with this recognition due 
to improved genomic characterisation of clinical isolates that would have 
previously been described as K. oxytoca based on simple phenotypic tests (Zheng 
et al., 2018; Pedersen et al., 2018; Chen et al., 2019; Seiffert et al., 2019). Reports 
specific to K. michiganensis have only recently begun to appear in the literature. 
A carbapenemase-producing K. oxytoca isolate was recovered from the 
stool sample of an immunocompromised patient hospitalized with acute diarrhoea 
in Fahzu, China (Zheng et al., 2018). On analysis of genomic data, the isolate was 
found to harbour the carbapenemase-encoding genes blaKPC-2, blaNDM-2 and 
blaNDM-5. ANI analysis of the isolate’s genome showed it shared 100% ANI with the 
type strain of K. michiganensis. This study was the first to isolate K. michiganensis 
carrying these genes in China. A blaKPC-2-encoding isolate of K. michiganensis 
recovered from a blood sample has also been reported in the US (Hazen et al., 
2018). 
During a study of multidrug-resistant Enterobacteriaceae recovered from in-
patients in 10 private hospitals in Durban, South Africa, Pedersen et al. (2018) 
isolated a strain of K. michiganensis belonging to ST170 and encoding blaNDM-1. In 
addition, a blaOXA-181- and blaNDM-1-encoding strain of K. michiganensis isolated 
from a cancer patient in KwaZulu-Natal Province, South Africa has been reported 
(Founou et al., 2018). 
Seiffert et al. (2019) reported on a bloodstream infection caused by K. 
michiganensis in an immunocompromised patient in St Gall, Switzerland. Initially, 
the isolate was identified by MALDI-TOF as K. oxytoca but whole-genome 
sequence analysis identified it as K. michiganensis. Susceptibility testing revealed 
the isolate was resistant to first- to fourth-generation cephalosporins and the 
carbapenem ertapenem, and sensitive only to amikacin and colistin. Genomic 
analyses showed the strain to encode genes conferring resistance to β-
lactamases (blaTEM-1B, blaOXY-1-1), aminoglycosides (aac(3)-IId, aph(3′)-Ia, aadA5, 
strA, strB), macrolides (mph(A)), sulphonamides (su11, su12), tetracycline (tet(B)) 
and trimethoprim (dfrA17). K. pneumoniae carbapenemase (KPC)3 gene was 
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encoded on plasmid IncFIIK2-FIB. This was the first study to identify blaKPC in K. 
michiganensis in Europe. A blaKPC-3-encoding isolate of K. michiganensis has also 
been reported in the US (Hazen et al., 2018). 
During a study to characterise Klebsiella spp. recovered from preterm 
infants, Chen et al. (2019) showed ~10% of faecal samples harboured Klebsiella 
isolates, of which 1.8% were K. michiganensis. Once again, API 20E data had 
initially identified the isolates as K. oxytoca. ANI and phylogenetic analyses of 
whole-genome sequence data revealed the strains to be K. michiganensis. 
Phenotypic testing showed the K. michiganensis isolates had intermediate 
resistance to both benzylpenicillin (encoded FosA5) and meropenem (encoded 
OXY-1-2), β-lactamases which may prove problematic when selecting treatment 
regimens for necrotising enterocolitis or sepsis. Results from this study also 
highlighted refined analyses with curated sequence databases are needed to 
differentiate K. oxytoca and closely related species. 
Similar to the above-mentioned studies, the three K. michiganensis strains 
characterised in this Chapter were isolated from immunocompromised patients 
with underlying conditions and carried a range of antibiotic-resistance genes 
(Table 3.3). 
BLASTP of the proteins encoded in the strains’ genomes against CARD 
confirmed the presence of the carbapenemase-encoding gene blaGES-5 (discussed 
below) and the ESBL CTX-M-15, along with the β-lactamases blaTEM-1 and blaSHV-
66. SHV-66 was also encoded in the genomes of K. michiganensis strains E718, 
GY84G39, K1439 and 2880STDY5682598 (included in the phylogenetic analysis, 
Figure 3.4). SHV-66 has previously only been reported in a minority of β-
lactamase-producing K. pneumoniae in Guangzhou, China (Zuo et al., 2006). 
Moradigaravand et al. (2017) noted that 2880STDY5682598 encoded a blaSHV 
gene but did not document its type nor indicate its novelty. 
 
3.4.3 The “Guiana extended spectrum" (GES)-type β-lactamase 
GES-type β-lactamase is an Ambler Class A plasmid-encoded ESBL. It was 
discovered in 2000 in K. pneumoniae clinical isolates from French Guiana (Naas 
et al., 2016; Bonnin et al., 2017). This carbapenemase slowly hydrolyses 
carbapenems due to a replacement of glycine at position 170 by 
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asparagine/serine. Over time, GES β-lactamases have been identified in other 
Gram-negative bacteria such as Pseudomonas aeruginosa and Enterobacter 
cloacae, and are increasingly being identified in Acinetobacter baumannii (Chihi et 
al., 2016). One of the worrying features that GES enzymes share, as compared to 
other β-lactamases, is their ability to evolve into carbapenem-hydrolysing enzymes 
via single point mutations. Since GES-1 was first detected in 2000, numerous 
GES-types have been found in several countries, with 31 variants recognised 
(Bonnin et al., 2017). GES-associated outbreaks have also been reported (Smith 
et al., 2012). GES-1 variants that have emerged have the ability to hydrolyse 
carbapenems with increased affinity. More concerning, they are difficult to detect 
in clinical laboratories and available clinical data on outbreaks are scarce 
(Weldhagen, 2006). 
The first GES-5 carbapenemase (glycine to serine substitution) was found 
in 2004, in K. pneumoniae recovered from patients at Bundang CHA Medical 
Center, Republic of Korea (Jeong et al., 2005). Since then, GES-5 has been 
reported in various Gammaproteobacteria (predominantly P. aeruginosa and K. 
pneumoniae) around the world (Table 3.8). 
Eades et al. (2016) reported the GES-5-positive K. oxytoca-associated 
outbreak in UK hospitals, with the emergence of this genotype thought to be due 
to plasmid or intergron transfer among related bacteria (Diene and Rolain, 2014). 
It was not the first report of GES-5 in K. oxytoca: that appeared in Kabir et al. 
(2016), but is likely to reference one of the strains reported by Eades et al. (2016) 
as both were PHE publications. 
Many laboratories in the UK and other countries find it difficult to isolate 
GES-5-positive carbapenemase-producing organisms as they remain sensitive to 
meropenem (i.e. it shows a different sensitivity pattern to other carbapenemase-
producing organisms (CPOs)), which is one of the indicator carbapenems used for 
detection of CPOs. In the microbiology laboratory, if we had not used the indicator 
carbapenem ertapenem, which is more sensitive than meropenem in picking up 
carbapenemase activity, coupled with the optimised workflow outlined in Chapter 
2, we would not have isolated the three GES-5-positive K. michiganensis strains 
discussed in this Chapter. Therefore, this study has also shown the importance of 
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using a culture method as an initial platform to detect the presence of ‘new and 
emerging’ carbapenemases before they are characterised at the genomic level. 
 
 
Table 3.8: Worldwide detection of GES-5-positive strains in clinical settings. 
Species Isolated from Country Reference(s) 
P. aeruginosa Burn wound, clinical isolates China Wang et al. (2006); Wang et al. 
(2010) 
K. pneumoniae Sputum, clinical isolates South Korea Jeong et al. (2005); Bae et al. 
(2015) 
P. aeruginosa Bloodstream infections Brazil Picão et al. (2009) 
K. pneumoniae Rectal swab Brazil Picão et al. (2010) 
P. aeruginosa Clinical isolates Spain Viedma et al. (2009); Juan et al. 
(2013); Recio et al. (2018) 
E. coli Bed sore specimen, clinical 
isolate 
South Korea Kim et al. (2011); Bae et al. 
(2015) 
P. aeruginosa Nosocomial infections Canada Mataseje et al. (2012) 
P. aeruginosa Clinical isolates Mexico Castillo-Vera et al. (2012) 
P. aeruginosa Clinical isolate Turkey Iraz et al. (2014) 
P. aeruginosa Urine India Maurya et al. (2014) 
K. pneumoniae Clinical isolates Portugal Papagiannitsis et al. (2015); 
Aires-de-Souza et al. (2019) 
P. aeruginosa Clinical isolate Lithuania Mikucionyte et al. (2016) 
K. oxytoca Urine, wound, blood, rectal 
swab, bronchoalveolar lavage 
UK Eades et al. (2016) 
A. baumannii Clinical isolate Saudi Arabia Al-Agamy et al. (2017) 
S. marcescens Ascitic fluid Brazil Nodari et al. (2017) 
K. pneumoniae Rectal swab France Bonnin et al. (2017) 
E. coli Hospital wastewater Thailand Runcharoen et al. (2017) 
P. aeruginosa Clinical isolates Czech 
Republic 
Papagiannitsis et al. (2017) 
E. cloacae Wound Czech 
Republic 
Chudejova et al. (2018) 
P. aeruginosa Clinical isolate Australia Sherry et al. (2018) 
K. pneumoniae Clinical isolates South Africa Pedersen et al. (2018) 
P. aeruginosa Clinical isolates Estonia Telling et al. (2018) 
P. aeruginosa Clinical isolates Japan Hishinuma et al. (2018) 
P. aeruginosa Clinical isolates Dubai Ayoub Moubareck et al. (2019) 
P. aeruginosa Clinical isolates Indonesia Saharman et al. (2019) 
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This study also highlighted the difficulty in identifying novel 
carbapenemases by relying on routine clinical laboratory tests: the three K. 
michiganensis strains gave negative phenotypic carbapenemase test results – 
they were sensitive to meropenem in routine testing and produced a negative 
result with the in-house carbapenemase PCR (Ribeiro et al., 2014; Spyrakis et al., 
2019). This misrepresentation is due to the fact that, at present, several 
subclasses of β-lactamases breach the barrier between classical ESBLs and 
carbapenemases. For example, the GES enzymes that possess carbapenemase 
activity (e.g. GES-5) are still reported in the literature as ESBLs, and many 
laboratories are recording them under the ESBL subgroup and this 
misclassification can also lead to lack of direct appropriate treatment. Although 
GES-5 belongs to the ESBL Ambler Class A plasmid-encoded β-lactamases 
exhibiting ESBL properties, changes in its active site enhance its activity 
conferring the ability to slowly hydrolyse carbapenems (Naas et al., 2008; Jeong et 
al., 2005); therefore, GES-5 should be classified as belonging to the 
carbapenemase group (Lee et al., 2012; Bae et al., 2007) and thereby the correct 
identification tools can be used to help to isolate GES-5-carrying strains in the 
clinical laboratory. 
 
3.4.4 The three strains of K. michiganensis all encode the kleboxymycin 
gene cluster 
It has been shown the K. oxytoca gut colonisation is linked with AAHC 
(Beaugerie et al., 2003). The disease is caused by the overgrowth of cytotoxin-
producing K. oxytoca secondary to use of antibiotics such as penicillin or 
amoxicillin resulting in the presence of diffuse mucosal oedema and haemorrhagic 
erosions (Beaugerie et al., 2003). This type of colitis is distinct from the more 
common form of antibiotic-associated diarrhoea caused by toxin-producing 
Clostridium difficile, which usually give rise to watery diarrhoea resulting in mild to 
moderate disease. 
Schneditz et al. (2014) showed TV, a pyrrolobenzodiazepine (PBD) 
derivative produced by K. oxytoca, is one of the enterotoxins responsible for 
causing AAHC. This toxic product is encoded by the heterologous expression of 
the kleboxymycin (also known as tilimycin (TM); Unterhauser et al., 2019) 
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biosynthetic gene cluster consisting of 12 genes (Tse et al., 2017). In vitro assays 
showed that both kleboxymycin and TV are linked with cytotoxicity, with 
kleboxymycin showing a higher cytotoxicity than TV. Tse et al. (2017) also 
suggested that TV is not the main cytotoxin produced by AAHC-associated K. 
oxytoca strains. During biosynthesis of TV, the enterotoxin gene cluster produces 
three distinct secondary metabolites, two of which (TM, TV) are cytotoxic to human 
cells. TV is not produced directly by the non-ribosomal peptide synthetase 
encoded by the biosynthetic gene cluster. Instead an N-acylprolinal, which reacts 
spontaneously with indole, produces TV from the secondary metabolites TM and 
culdesacin. TM and TV belong to the PBD family of natural products, which exhibit 
antibacterial and anticancer activity by alkylating DNA. TM damages DNA while 
TV stabilises microtubules. Both enterotoxins trigger apoptosis (i.e. cell death) 
characteristic for the colonic epithelium in AAHC. 
In this study, I used the protein sequences of the kleboxymycin gene cluster 
(Tse et al., 2107) to determine whether the three K. michiganensis strains 
encoded the gene cluster. PS_Koxy1, PS_Koxy2 and PS_Koxy4 all encoded the 
complete kleboxymycin biosynthetic gene cluster (Table 3.4, Figure 3.8), 
suggesting they may be virulent in addition to displaying multidrug resistance. 
Further study needs to be done to confirm the isolates are actively producing the 
cytotoxin. This could be achieved by following the method used by Tse et al. 
(2017), who examined culture supernatants of K. oxytoca MH43-1 and compared 
them to supernatants from non-toxigenic strains. They confirmed the production of 
TV and kleboxymycin (TM) by MH43-1, and the presence of the gene cluster in the 
strain’s genome. The virulence of strains that produce the enterotoxins could also 
be tested in mice (Schneditz et al., 2014). 
Schneditz et al. (2014) reported npsA/npsB were functionally conserved in 
six sequenced strains of K. oxytoca, based on a BLASTP analysis. All the 
genomes included in the study of Schneditz et al. (2014) were compared with 
those of the type strain of K. oxytoca and related species to confirm their species 
affiliations (Table 3.9). While some of the npsA/npsB-positive strains were K. 
oxytoca, others belonged to K. grimontii and ‘K. pasteurii’. Examining the genomes 
of the strains to determine if they carried the full kleboxymycin biosynthetic gene 
cluster, it was found that K. michiganensis 10–5242, E718 and KCTC 1686 did not 
encode homologues associated with the kleboxymycin biosynthetic gene cluster. 
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K. oxytoca 10–5245 encoded almost-complete homologues of four genes 
(EHS96696.1 (marA) 98.79% identity, 99.39% coverage; EHS96697.1 (npsC) 
95.38% identity, 99.23% coverage; EHS96698.1 (mfsX) 96.68% identity, 99.87% 
coverage; EHS96699.1 (uvrX) 94.88% identity, 99.76% coverage) in contig 
JH603137.1. K. oxytoca 10–5243, ‘K. pasteurii’ 10–5250, K. oxytoca 11492-1, K. 
grimontii SA2, K. oxytoca 10–5248 and K. grimontii M5a1 encoded the whole 
kleboxymycin biosynthetic gene cluster. All genes in all matches shared greater 
than 90% identity across greater than 99% query coverage. 
 
 
Table 3.9: Genomes included in analyses conducted by Schneditz et al. 
(2014) with corrected species affiliations. 
Assembly 
accession 
Strain Species ANI with shown genome* npsA/npsB 
GCA_000240325.1 KCTC 1686 K. michiganensis 98.69%, GCA_901556995.1 – 
GCA_000247835.1 10–5242 K. michiganensis 97.58%, GCA_901556995.1 – 
GCA_000247855.1 10–5243 K. oxytoca 99.31%, GCA_900977765.1 + 
GCA_000247875.1 10–5245 K. oxytoca† 99.13%, GCA_900977765.1 – 
GCA_000247895.1 10–5246 R. ornithinolytica 99.21%, GCA_001598295.1 – 
GCA_000247915.1 10–5250 ‘K. pasteurii’ 99.29%, GCA _901563825.1 + 
GCA_000252915.3 11492-1 K. oxytoca 99.15%, GCA_900977765.1 + 
GCA_000276705.2 E718 K. michiganensis 98.37%, GCA_901556995.1 – 
GCA_000427015.1 SA2 K. grimontii 99.33%, GCA_900200035.1 + 
GCA_001078235.1 10–5248 K. oxytoca 99.25%, GCA_900977765.1 + 
GCA_001633115.1 M5a1 K. grimontii 99.40%, GCA_900200035.1 + 
*GCA_901556995.1 = K. michiganensis W14T; GCA_900200035.1, K. grimontii 
06D021T; GCA_900977765.1 = K. oxytoca ATCC 13182T; GCA_001598295.1 = R. 
ornithinolytica NBRC 105727T; ‘K. pasteurii’ SB3355 GCA _901563825.1. 
 
 
Taking the results from my analysis of the three K. michiganensis strains 
and those from the reanalysis of the data of Schneditz et al. (2014), I have been 
able to show that the kleboxymycin biosynthetic gene cluster is not unique to K. 
oxytoca. Chen et al. (2019) showed that faecal carriage of K. michiganensis may 
be more clinically important than K. oxytoca. Therefore, it is possible that K. 
michiganensis is also a causative agent of AAHC. If K. michiganensis gut 
colonisation is linked with AAHC, laboratories may need to screen for presence of 
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toxigenic K. michiganensis (and K. oxytoca) isolates. Otherwise there is the 
potential for AAHC to be a silent killer if undetected from a clinical perspective. 
Further study is needed to investigate possible linkage between cytotoxin 
production and adverse clinical outcomes in K. michiganensis and K. oxytoca 
infections. Current knowledge on cytotoxin-producing K. oxytoca and its link to 
disease is severely limited by the lack of an accessible diagnostic test and little 
knowledge of the virulence of toxigenic strains. In the clinical laboratory, 
Clostridium difficile toxin is detected by screening stool samples from at-risk 
patients (i.e. in-patient, 3 days of hospitalisation, >64 years of age and displaying 
signs of diarrhoea) using an enzyme-linked immunoassay, a membrane-
bound assay and in-house Gene Xpert PCR (Cepheid). Similar tests are not 
available commercially for detection of Klebsiella-associated toxins in samples 
from at-risk patients. From my experience, between 3 and 5 from 70 samples 
received per day in the clinical laboratory test positive for C. difficile toxins. Some 
diarrhoea cases may be caused by Klebsiella-associated toxins. Therefore, it 
would be worth clinical laboratories sending K. oxytoca isolated from stool 
samples of patients suffering from AACH to reference laboratories to check for the 
presence of toxin genes or production of metabolites. 
 
3.3.5 Isolated phages infect GES-5-positive K. michiganensis, and clinically 
relevant strains of K. grimontii and K. pneumoniae 
Kęsik-Szeloch et al. (2013) screened 48 clinical isolates of K. oxytoca from 
their own collection against a range of phages they had isolated from 
environmental and sewage samples collected in Poland. All eight of their 
Myoviridae phages (KP9, KP15, KP23, KP24, KP25, KP27, KP28, KP29), 4/8 of 
their Siphoviridae phages (KP1, KP17, KP18, KP19) and 9/16 of their Podoviridae 
phages (KP1, KP2, KP4, KP12, KP13, KP20, KP21, KP31, KP32) infected one or 
more of the 48 clinical K. oxytoca isolates tested. No genomic information was 
provided for the K. oxytoca isolates, but it is unlikely that K. michiganensis and K. 
grimontii isolates were not included in the collection given what we now know 
about the diversity of clinically relevant K. oxytoca strains (Moradigaravand et al., 
2017; Chen et al., 2019). 
Complete genome sequences of 109 Klebsiella phages have been 
deposited in GenBank/RefSeq as of 17 July 2019 (Herridge et al., 2019). They all 
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belong to the double-stranded DNA (dsDNA) Caudovirales, comprising the 
families Myoviridae, Siphoviridae and Podoviridae. Of these, only PKO111 
(Myoviridae, Tevenvirinae, Jd18virus, Klebsiella virus PKO111) and KOX1 
(Siphoviridae, Tunavirinae, Webervirus; Herridge et al., 2019) are known to infect 
K. oxytoca (Park et al., 2017; Brown et al., 2017). PKO111 with a genome of 
168,758 bp was isolated from a sewage sample. It had a high efficiency of plating 
against K. oxytoca ATCC 43863 and KCTC 1686 (1.00 and 0.89, respectively) and 
very low efficiency of plating with K. pneumoniae KCTC 2242 (3x10-7) and 
Citrobacter sakazakii ATCC 29544 (1x10-7). KCTC 1686 was shown to be K. 
michiganensis not K. oxytoca by Chen et al. (2019), so PKO111 is the first phage 
known to infect K. michiganensis. Bioinformatics analyses showed the genome 
carried no human virulence-related genes (Park et al., 2017), so it could potentially 
be used therapeutically against K. oxytoca and K. michiganensis. 
Phage KOX1 (genome size 50,526 bp) was isolated from wastewater 
collected in Bendigo, Australia and was active against five of six K. oxytoca strains 
tested, including the type strain ATCC 13182T, but was inactive against K. 
pneumoniae. No detailed genomic analyses of the K. oxytoca strains was 
undertaken, so it is possible one or more of the additional four strains could be K. 
michiganensis or K. grimontii. Brown et al. (2017) intended to collect lytic 
bacteriophages against K. oxytoca that could eventually be formulated into dosage 
forms that could be used to modulate the gut microbiome and growth of K. 
oxytoca. This would have the potential to avert or treat AAHC and diarrhoea 
caused by K. oxytoca during antibiotic therapy. Phage viability was minimally 
affected by bile salts but was reduced by two orders of magnitude when exposed 
to gastric acid (pH 2.5). Therefore, Brown et al. (2017) proposed that the phage 
should be co-administered with a proton pump inhibitor, such as omeprazole, to 
enhance phage viability and therapeutic efficacy. 
Few other K. oxytoca-infecting phages have been reported. Karumidze et 
al. (2013) isolated a lytic bacteriophage, vB_Klox_2 (Podoviridae), active against 
K. oxytoca from sewage-contaminated river water in Georgia. No genome 
sequence data are publicly available for the phage, though it was reported that, 
based on restriction fragment profiling, the genome of vB_Klox_2 was 45 kb in 
size and a 1.2 kb fragment of DNA shared 99% identity with Klebsiella phage 
KP32. In addition, the phage was reported to infect 5–10% of the 123 Klebsiella 
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spp. it was tested against, but no details were given with respect to species so it 
has to be assumed that it infects both K. oxytoca and K. pneumoniae in the 
absence of additional information. More recently, Amiri Fahliyani et al. (2018) 
isolated and identified four novel lytic bacteriophages (phage-1, Myoviridae; 
phage-2, Myoviridae; phage-3, Podoviridae; phage-4, Podoviridae) from Isfahan 
public wastewater with activity against K. oxytoca ABG-IAUF-1, isolated from 
contaminated milk samples of Isfahan dairy herds suffering from mastitis. phage-2 
infected Enterobacter aerogenes ATCC 13048 in addition to K. oxytoca ABG-
IAUF-1. The bacteriophages were proposed as therapeutic agents to eradicate the 
pathogenic bacteria responsible for bovine mastitis in Iran. 
I isolated seven phages with lytic activity against GES-5-positive K. 
michiganensis isolates (Table 3.5). These greatly increase the number of phages 
known to infect K. michiganensis and closely related species. I was able to purify 
the phages and test their host ranges against a collection of clinically relevant 
Klebsiella isolates. Although not reported in the Results section, I attempted to 
isolate DNA and use restriction enzyme profiling to characterise the phages, but 
did not produce any usable data. Consequently, the phages are currently being 
further characterised by L. Hoyles at Nottingham Trent University and will be 
reported on in the future. 
Phage 1Ai infected PS_Koxy1, phages 2B, 2C and 2Di infected PS_Koxy2, 
and phages 4B, 4Di and 4Dii infected PS_Koxy4. The seven isolated phages were 
screened against 36 carbapenemase-resistant strains of K. pneumoniae (which 
will be described in more detail in Chapter 4) and some of the strains from Chen et 
al. (2019), which had been isolated from the faeces of preterm infants. The seven 
phages had different host profiles from one another (Table 3.6, Table 3.7). Several 
of the phages showed depolymerase activity against one or more of the K. 
michiganensis, K. pneumoniae and K. grimontii strains (Table 3.6, Table 3.7). 
Detection of depolymerase activity against test isolates means the phages are 
expressing polysaccharide depolymerases, enzymes which play a role in 
degrading the capsule surrounding Klebsiella spp. Depolymerases can destroy 
biofilms and increase the susceptibility of bacteria to antibiotics, phage infection 
and the immune system (Kęsik-Szeloch et al., 2013). Phage depolymerase action 
can be observed in the laboratory with the production of ‘haloes’ around clear 
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zones of lysis on bacterial culture plates after infection of bacteria with phage 
particles. 
Taking phage 4Dii as an example, this phage showed lytic activity against 
its original K. michiganensis host strain, PS_Koxy4, and towards several test 
strains (Table 3.7). When considering use of phages as alternatives to 
antimicrobial therapies, those that reliably employ the lytic life cycle to reproduce 
are most suitable given lytic phages completely destroy the host cell (Herridge et 
al., 2019). 
Phage 4Dii also showed depolymerase activity towards some of the clinical 
strains it infected (Table 3.7). These depolymerases may have therapeutic uses, 
and should be investigated further when the genome sequences of the phages are 
available. Majkowska-Skrobek et al. (2016) identified, cloned and expressed a 
phage-derived capsule depolymerase, depoKP36, which produced haloes on 
lawns of K. pneumoniae in agar spot-tests. They also tested the ability of 
depoKP36 to treat infection caused by K. pneumoniae in an insect model of 
infection (Galleria mellonella) and found that 100% died without treatment, up to 
40% survived when treated with depoKP36, and depoKP36 treatment of bacteria 
prior to infection resulted in only a 23% death rate. These results suggest that the 
decapsulating action of depoKP36 on K. pneumoniae produced a decreased 
ability of the bacterium to resist the host immune response. Pan et al. (2015) 
discovered nine polysaccharide depolymerases expressed by phage ΦK64-1, 
each of which demonstrated activity against a different capsular type of K. 
pneumoniae and could be used to generate cocktails of recombinant enzymes that 
could target a wide range of K. pneumoniae strains. 
The use of phages to control bacterial pathogens is complicated because of 
the high degree of phenotypic diversity within populations of both phages and 
bacteria. Therefore, individual strains of target bacteria may be more or less 
susceptible or even resistant to different co-occurring phages. When considering 
therapeutic applications, it is necessary to understand in detail the phage and host 
interaction, which is affected by both biological and physical factors. The biological 
aspect is related to bacterial resistance, whereas temperature and pH are the 
main physical factors affecting phage adsorption and bacterial growth (Shende et 
al., 2017). To understand phage-host interactions, it is important to identify which 
family phages belong to (e.g. Myoviridae, Podoviridae, Siphoviridae; as done for 
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Klebsiella-infecting phages by Herridge et al., 2019). Phage characterisation can 
be achieved phenotypically and genomically. Phenotypic characterisation can be 
used to assign phages to families based on morphology as determined via 
transmission electron microscopy. It can also determine desirable traits such as 
resistance to chloroform (useful for determining appropriate DNA extraction 
methods), and to extremes of pH and temperature (Kęsik-Szeloch et al., 2013), 
with pH tolerance being particularly relevant to use of phages to treat intestinal 
infections. Whole-genome sequencing will define the size and genetic content of 
phages, and allow identification of any virulence or antibiotic resistance genes 
encoded in genomes. Phages carrying such genes would not be used 
therapeutically as the genes may be introduced into the host bacterium during 
phage infection, especially if the phage has the potential to integrate into the 
bacterium’s genome (i.e. is a lysogenic phage). Lysogenic phages may transfer 
genes into the host that can confer toxin production and antibiotic resistance traits 
to the bacterium, thus making the infection more virulent and difficult to treat 
(Harper et al., 2018; Herridge et al., 2019). Characterisation of both the host 
bacterium and the phages is also necessary to understand the specific receptors 
on the surface of the host bacterium that the phage’s tail structure can attach to 
and identify susceptible bacteria and position itself for injecting its genetic material 
into the host cell. This can help in identifying novel therapeutic targets in bacteria. 
There are several considerations to be made when selecting phages 
suitable for use as therapeutic agents. The phages must be effective in killing the 
target micro-organism(s), e.g. Klebsiella spp. During phage characterisation, in 
vitro assessments of phage lysis and burst size need to be carried out on cultures 
of host strains. Phages that produce rapid lysis of a bacterium and release large 
numbers of phage particles will produce large clear plaques. Moreover, phages 
with a broad host range are generally considered more useful than those with 
narrow host range so that multiple strains may be targeted at once. Lytic phages, 
due to the nature of their life cycle, clear bacteria quickly and efficiently compared 
to lysogenic phages, which integrate their genetic information into the host 
genome and remain dormant for an unspecified amount of time. 
Phenotypic characterisation of the phages I isolated is required, including 
determination of burst size, and sensitivity to pH, temperature and chloroform. 
Once this is achieved the isolated phages must be tested in vivo using Galleria or 
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mouse models, to identify the therapeutic potential of the phages and whether they 
affect the immune response of the host. Hsu et al. (2019) showed that infection 
with lytic phages caused an increase in phage resistance (28% to 68%) in a 
known bacterial population common to the human gut microbiota. Quantitative 
shifts in sensitive and non-sensitive strains were seen, highlighting the system-
level effect of phage infection. Phage infection did not necessarily clear the target 
species but instead modulated the ecosystem towards a more stable gut 
environment. As I would like to use my phages to treat intestinal infections or 
decolonise patients carrying multidrug-resistant bacteria on their admittance to 
hospital, it is important to know phage effects on the gut environment. By following 
the method of Gu et al. (2012) it should be possible to generate a phage cocktail 
(i.e. a combination of phages that have different but overlapping host specificities) 
to produce fewer phage-resistance variants which are effective in treatment of, for 
example, AAHC. 
 
3.5 SUMMARY 
In this Chapter, I characterised three of the K. oxytoca isolates collected 
from the outbreak 2015 collection reported on by Eades et al. (2016). Whole-
genome sequence analyses showed these isolates to be K. michiganensis 
carrying a GES-5 carbapenemase gene previously not seen in K. michiganensis 
and a range of other antibiotic-resistance determinants not described by Eades et 
al. (2016). Further analyses showed the isolates encoded the 12-gene 
kleboxymycin biosynthetic gene cluster (Tse et al., 2017) associated with the 
production of the cytotoxins TM and TV, causative agents of the cell damage 
experienced in AAHC-affected patients. In addition, the gene cluster was found in 
‘K. pasteurii’ and K. grimontii strains. The gene cluster had previously been 
associated only with K. oxytoca. Therefore, there is the potential that species other 
than K. oxytoca may contribute to AAHC, and this requires further investigation. I 
isolated seven lytic phages active against K. michiganensis PS_Koxy1, PS_Koxy2 
and PS_Koxy4. These phages also infected clinically relevant K. pneumoniae and 
K. grimontii strains, showing they have a broad host range. The phenotypic and 
genomic characteristics of these phages will be determined in future work, as 
these phages could be used for other therapeutic effects (i.e. treating other 
Klebsiella infections or decolonisation) and not just in AAHC treatment. 
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CHAPTER 4: GENOMIC CHARACTERISATION OF CLINICAL STRAINS OF 
CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE FROM WEST 
LONDON HOSPITALS, AND ISOLATION OF LYTIC BACTERIOPHAGES THAT 
INFECT THEM 
 
4.1 INTRODUCTION 
Klebsiella pneumoniae belongs to the family Enterobacteriaceae. It is a 
Gram-negative, lactose-fermenting, gas-producing, facultatively anaerobic non-
motile bacterium about 1 to 2 µm long and 0.5 to 0.8 µm wide. It possesses a thick 
polysaccharide capsule that is produced in great amounts in carbohydrate-rich 
media. The organism grows well at 37 °C and is killed by moist heat at 55 °C for 
30 min (Gupta, 2002). K. pneumoniae is ubiquitous, commonly found in the natural 
environment (e.g. water and soil) and is a commensal of the human microbiota. 
The bacterium colonises the skin, mouth, and respiratory and GI tracts of healthy 
humans, but is also an opportunistic pathogen of immunocompromised individuals 
(Holt et al., 2015). The carriage rate of K. pneumoniae varies from study to study, 
but in healthy humans is ~10% in the mouth and nose and on the skin, 1-6% in the 
nasopharynx and 3.8-38% in stool samples; skin carriage is considered transient 
(Rose and Schreier, 1968; Podschun and Ullmann, 1998; Conlan et al., 2012b; 
Farida et al., 2013; Dao et al., 2014). Carriage rates for hospitalised patients 
increase with the length of stay to 77% in the stool, 19% in the nasopharynx and 
42% on the hands of patients. The high level of colonisation in these patients is 
associated with their increased exposure to antibiotics as part of treatment 
regimens (Rose and Schreier, 1968; Podschun and Ullmann, 1998). 
 
4.1.1 GI carriage of K. pneumoniae and exogenous sources contribute to 
disease 
Martin et al. (2016) suggested GI colonisation with K. pneumoniae was 
directly linked with extraintestinal infection. They screened 1765 patients for rectal 
carriage of K. pneumoniae then collected extraintestinal (respiratory, urinary or 
bloodstream) isolates from the same patients for a 3-month period. Almost a 
quarter of patients were colonised with K. pneumoniae, and 5.2% (21/406) of 
colonised patients developed an extraintestinal infection compared with 1.3% 
(18/1359) of non-colonised patients. Extraintestinal isolates matched rectal 
	 
	
122	
isolates from the same patient based on capsular typing, MLST and WGS 
analyses. Based on their findings, Martin et al. (2016) suggested a possible means 
of infection control: isolate the colonising strain from a patient upon their admission 
to hospital as part of a risk assessment, determine the strain’s antibiotic 
susceptibility profile and use this information to guide the treatment regimen if the 
patient became acutely ill. Gorrie et al. (2017) confirmed K. pneumoniae to be part 
of the normal gut microbiota of humans, and in agreement with Martin et al. (2016) 
showed GI carriage of the organism by the patient rather than throat carriage on 
admission to intensive care was associated with subsequent infection, confirming 
gut-colonising and infection isolates were the same in 80% of isolate pairs. 
Approximately 50% of K. pneumoniae infections resulted from the patients’ own 
microbiota, and Gorrie et al. (2017) supported Martin et al. (2016) with respect to 
screening patients for colonisation on admission to reduce the risk of infection in 
colonised and other patients. 
The healthcare environment, contamination of invasive devices (e.g. 
respirators, catheters) and excessive use of antibiotics also contribute to likelihood 
of nosocomial infections (Woldu, 2015; Holt et al., 2015). In the hospital setting, K. 
pneumoniae accounts for approximately 8% of all HAIs. The organism causes 
HAIs of the urinary tract, lower respiratory tract, and burn and surgical wound sites 
of immunocompromised patients, particularly those in intensive care units. It is 
also associated with late-onset sepsis and necrotising enterocolitis in preterm 
infants (Chen et al., 2019). Patients with KPC infections (typically caused by 
ST258 isolates) or PLA (caused by hypervirulent ST23 isolates) have been shown 
to carry their infecting strain in their GI tract for between 30 days (≤74%) and 6 
months (<30%) following discharge from hospital (Feldman et al., 2013). Recent 
use of antimicrobials is not associated with persistent carriage of carbapenemase-
producing K. pneumoniae (Feldman et al., 2013). 
 
4.1.2 Phenotypic and genomic characterisation of K. pneumoniae 
Traditionally, clinical laboratories have used phenotypic (API 20E, antibiotic 
susceptibility testing, MALDI-TOF) or PCR-based assays (antibiotic resistance and 
virulence genes) to characterise K. pneumoniae strains, while reference 
laboratories have used PFGE, PCR-based assays (VNTR profiling, limited capsule 
typing; Turton et al., 2010) and, more recently, some WGS analyses (for species 
	 
	
123	
identification and MLST). MLST has been used to identify ST258 strains, which 
carry the KPC gene and other AMR gene(s) and have been responsible for 
hospital infection outbreaks around the world (Grundmann et al., 2010; Livermore, 
2012a). More recently, WGS has demonstrated ST258 is a recombinant strain that 
has undergone capsular exchange since its emergence (Holt et al., 2015). 
The availability of cheap WGS has seen huge changes in the ways K. 
pneumoniae can be characterised and it is being used more frequently to 
understand AMR and infection outbreaks. The first major study to make use of 
high-throughput WGS was by Holt et al. (2015). They analysed the genomes of 
328 human and animal isolates of K. pneumoniae collected around the world, and 
confirmed K. pneumoniae was genomically complex, representing three species 
(K. pneumoniae (Kp1), Klebsiella quasipneumoniae (Kp2) and Klebsiella variicola 
(Kp3)) and phylogroup Kp2-B (Kp4), all capable of causing disease in humans. K. 
pneumoniae (Kp1) comprised more than 150 lineages with numerous multidrug-
resistant or hypervirulent clones, and was more frequently associated with human 
carriage. The K. pneumoniae strain population studied had a large accessory 
genome (i.e. genes found in <95% of strains) of 29,886 protein-coding genes, 
including virulence genes associated with invasive community-acquired diseases. 
Hospital-acquired strains encoded more AMR genes and fewer virulence 
genes (siderophores – aerobactin, yersiniabactin, salmochelin; toxin – colibactin) 
than community-acquired strains (Holt et al., 2015). SHV, OKP-2 and LEN β-
lactamases were core chromosomal genes of Kp1, Kp2 and Kp3, respectively, 
while genes conferring low-level resistance to fosfomycin and quinolones were 
core to all three species. (OKP-B has subsequently been found to be a core 
chromosomal gene of Kp4 (Rodrigues et al., 2019)). Other AMR genes were 
distributed unevenly throughout the species, and were referred to as “acquired 
AMR genes” to differentiate them from the core AMR genes. These acquired AMR 
genes were commonly found in human-associated strains of Kp1 and Kp2, with 
ESBL alleles of SHV found in 40% of human isolates. 
As more WGS data have become available for K. pneumoniae strains, it 
has become clear that the complex is genetically far more diverse than recognised 
by Holt et al. (2015). There are now seven phylogroups recognised within the K. 
pneumoniae complex, each corresponding to a different species: Kp1, K. 
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pneumoniae; Kp2, K. quasipneumoniae subsp. quasipneumoniae; Kp3, K. 
variicola subsp. variicola; Kp4, K. quasipneumoniae subsp. similipneumoniae; 
Kp5, K. variicola subsp. tropica; Kp6, ‘Klebsiella quasiivariicola’; Kp7, Klebsiella 
africana (Rodrigues et al., 2019). Their clinical significance is unclear as Kp1 to 
Kp7 strains are often misidentified as K. pneumoniae or K. variicola in clinical 
laboratories using standard laboratory methods (Rodrigues et al., 2018; 2019). 
Recently, protein markers that allow MALDI-TOF to differentiate the species have 
been described for Kp1 to Kp6, but they have yet to be adopted widely in clinical 
laboratories and reference MALDI-TOF spectra databases (Rodrigues et al., 
2018). 
 
4.1.3 Virulence factors of K. pneumoniae 
K. pneumoniae expresses two types of antigens on its cell surface that 
contribute to its mucosal colonisation and development of infections: the 
lipopolysaccharide O antigen and the capsular polysaccharide K antigen (Evrard 
et al., 2010). The structures of these components vary among strains, and both 
are essential to the virulence of K. pneumoniae. The capsular material forms thick 
bundles of fibrillous structures that cover the bacterium’s surface, protecting the 
bacterium from phagocytosis by polymorphonuclear granulocytes and preventing 
its killing by bactericidal serum factors via the complement-mediated cascade 
(Evrard et al., 2010). The O antigen, along with lipid A and the core 
oligosaccharide, makes up lipopolysaccharide, and is involved in inactivating 
dendritic cells (Evrard et al., 2010). Fimbriae and adhesins, together with K. 
pneumoniae’s ability to scavenge iron (using siderophores) from its surrounding 
environment, also serve as virulence factors (Broberg et al., 2014). 
Variation in the capsular K antigen allows the species to be classified into 
various serotypes. Seventy-eight K antigens and 12 distinct O antigens have been 
described based on serological data and are essential to the virulence of K. 
pneumoniae, but many clinical strains remain non-typeable (Shon et al., 2013; 
Fang et al., 2016). The capsular genes are encoded on a 10- to 30-kbp region of 
the genome known as the K locus (Wick et al., 2018). The key O antigen genes 
are encoded on the O (rfb) locus, but some genes (wbbY, wbbZ) that contribute to 
O antigen variation are found outside the O locus (Wick et al., 2018). For many 
years, capsule typing was restricted to five K types (K1, K2, K5, K54 and K57) 
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identified using PCR (Turton et al., 2010). PCR-based O-genotyping has also 
become possible, but is not used by PHE (Fang et al., 2016). By analysing protein-
encoding genes in WGS data, Wyres and Holt (2016) found there to be 134 
distinct capsular loci in K. pneumoniae, suggesting there are at least 134 distinct 
capsule types. It is now possible to use WGS data to K and O type K. pneumoniae 
genomes via Kaptive Web (http://kaptive.holtlab.net/) (Wick et al., 2018). 
The rmpA and rmpA2 (“regulator of mucoid phenotype”) genes are 
uncommon in strains characterised to date, but they are important virulence 
factors associated with hypermucoidy, as they upregulate capsule production 
(Broberg et al., 2014). rmpA and rmpA2 are associated with invasive human 
infections caused by ST23 isolates, which also typically carry three siderophore 
systems (aerobactin, salmochelin and yersinibactin) and/or a toxin (colibactin) 
(Holt et al., 2015). These invasive infections, particularly pyogenic liver abscess 
(PLA), affect healthy and immunocompromised individuals (Lee et al., 2017). rmpA 
has also been found in ST43 (along with yersiniabactin, salmochelin and 
aerobactin) and ST36 (along with yersiniabactin, colibactin and aerobactin), both 
linked to bacteraemia (Holt et al., 2015). rmpA2 upregulates K2 cps gene 
expression (Lai et al., 2003). There has been an increase in the number of cases 
of community-acquired PLA due to the hypervirulent K. pneumoniae ST23 K1 
serotype. Two small studies reported that K. pneumoniae was the responsible 
pathogen in 36% and 41% of cases; 70% of affected patients were Asian, but no 
information was available on travel histories or close contact with recent travellers 
to the Asian Pacific (Rahimian et al., 2004; Pastagia and Arumugam, 2008). Other 
infections caused by hypervirulent K. pneumoniae are endophthalmitis, infections 
of the central nervous system (including meningitis and brain abscess), 
osteomyelitis, septic arthritis and urinary tract infection (Fang et al., 2000; Chang 
et al., 2001; Shon et al., 2013). Endemic spread of hypervirulent strains is 
currently confined to Asian countries (Lee et al., 2017). While still rare, clinical 
isolates of hypervirulent, carbapenem-resistant K. pneumoniae have been 
reported, suggesting severe, untreatable infections could come to pose a 
significant threat to healthy individuals in the future (Lee et al., 2017). 
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4.1.4 Treatment of K. pneumoniae infections 
K. pneumoniae infections are mainly treated with cephalosporins, 
carbapenems and aminoglycosides. However, there is now emerging resistance to 
these antibiotics due to the bacterium producing ESBLs or carbapenemases that 
confer resistance to cephalosporins and carbapenems (Pitout et al., 2015; 
Sekyere et al., 2016). By acquiring a combination of resistance mechanisms, K. 
pneumoniae can become MDR as the carbapenem group of antibiotics is the last 
line of defence against Gram-negative infections that are resistant to other 
antibiotics. As a result, MDR K. pneumoniae infections are treated with 
combination therapy comprising β-lactams and aminoglycosides, or colistin and 
tigecycline as monotherapy (Woldu, 2015; Sekyere et al, 2016). 
The emergence of MDR strains of K. pneumoniae has become an urgent 
threat to human health due to their association with outbreaks of HAIs and 
community-acquired infections globally (Holt et al., 2015). Since carbapenemases 
are transferred from species via plasmids, GI-associated CPE and non-CPE 
organisms can serve as reservoirs and vectors (Viau et al., 2016). It is established 
that GI carriage contributes to K. pneumoniae infections (Martin et al., 2016; 
Gorrie et al., 2017), thereby contributing to carbapenem resistance and promoting 
cross-transmission of CPE in healthcare settings (Viau et al., 2016). In the UK, K. 
pneumoniae is a real challenge to infection control in both hospital and community 
settings: 1) because of its ability to spread and cause outbreaks; and 2) because 
decolonisation therapy only reduces levels of the bacterium without elimination 
(Curran and Otter, 2014). Most people are colonised with these organisms with no 
further complications but, in immunocompromised patients, colonisation can lead 
to endogenous infection, which can be a cause of cross-infection (Patel et al., 
2007; Curran and Otter, 2014). Bacteriophage (phage) therapy has been 
suggested as an alternative or adjunct treatment option in CPO-associated 
infections (Hoyles et al., 2014), and – as discussed in Chapter 3 – has been 
proposed as a means of decolonising patients upon admission to hospital. 
 
4.1.5 Aims of this Chapter 
In Chapter 2, I showed that the improved screening method I helped 
implement in the clinical laboratory increased the detection of K. pneumoniae from 
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clinical samples. In Chapter 3, I gained experience in analysing WGS data to 
characterise a small number of strains. I wished to extend my studies in this area 
by analysing a larger set of clinical isolates and focussing on K. pneumoniae, 
which is far more complex and has greater clinical impact than K. oxytoca and 
related species. 
Therefore, the first aims of this Chapter were to fully characterise a 
selection of K. pneumoniae isolates I collected during my time at Charing Cross at 
the genomic level and compare their antimicrobial susceptibility profiles with their 
genomic profiles, and to understand how genomic data could be used to identify 
several virulence genes in genomic data. 
Phages active against K. pneumoniae have been isolated from sewage, 
environmental and GI samples, and shown good therapeutic potential when tested 
in mice (reviewed in Herridge et al. (2019), Appendix 1). However, few lytic 
phages active against carbapenem-resistant K. pneumoniae have been isolated 
and characterised to date. In addition, many of the published studies do not 
characterise the bacterial strains infected by phages, making it impossible to know 
which phages could be used to treat K. pneumoniae infections in a clinical setting, 
or they do not adequately characterise the phage genomes, limiting the clinical 
application of phage gene products. As covered in Chapter 3, I believe phages 
may be used to decontaminate patients colonised with antibiotic resistant 
Klebsiella spp. and could contribute to infection control programmes. Therefore, 
the final aim of this Chapter was to isolate and begin to characterise lytic phages 
that infected carbapenem-resistant strains of K. pneumoniae. 
 
4.2 MATERIALS AND METHODS 
Refer to Chapter 3, section 3.2. 
 
4.3 RESULTS 
4.3.1 Initial characterisation of isolates included in my study 
Between March and April 2015 during the evaluation of new CPO screening 
methods (Chapter 2) in the microbiology laboratory of Charing Cross Hospital, a 
total of 49 different isolates were identified and sent to the PHE reference 
laboratory for further characterization. Of these, 36 isolates identified as K. 
pneumoniae by API 20E (n = 26 - profile number 5205773, 81.8 % K. pneumoniae; 
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n = 10 - 5215773, 97.3% K. pneumoniae) and MALDI-TOF (score of 2.3, highly 
probable species identification) were confirmed by PCR to carry a range of 
carbapenemases (Table 4.1). Twenty-two were NDM-positive, 10 were OXA-48-
positive, two were KPC-positive, and two were both NDM- and OXA-48-positive. 
Eight isolates were resistant (MIC 32 mg/L) to colistin, the last-resort antibiotic for 
treatment. Thirty-four of the isolates were resistant to the carbapenem indicator 
antibiotics ertapenem and temocillin, with an MIC greater than 32 mg/L for 
ertapenem. No data were available for two isolates (PS_Kpn4 and PS_Kpn16) as I 
was unable to test these in the clinical laboratory after moving jobs. Strains had 
variable resistance to meropenem: 28 were resistant (MIC greater than 32 mg/L), 
three had intermediate results, while two were sensitive (no data available for 
three isolates: PS_Kpn4, PS_Kpn16 and PS_Kpn27). 
 
4.3.2 Identification of isolates using WGS analyses 
As in Chapter 3, the WGSs of the 36 isolates identified by phenotypic 
methods as K. pneumoniae were generated. ANI values were determined for the 
isolates using reference strains for the seven phylogroups (species) of K. 
pneumoniae (Rodrigues et al., 2019). ANI values generated represent a 
measurement of how similar two genome sequences are to one another. If the 
genomes of two strains share >95 % ANI, they are considered to belong to the 
same species (Chun et al., 2018). PS_misc5 shared 98.97% ANI with Klebsiella 
variicola subsp. variicola Kp342 (Figure 4.1). All other strains were K. 
pneumoniae, sharing between 98.42% and 99.04% ANI with K. pneumoniae 
ATCC 13883T (Figure 4.1). Though it should be noted strains that shared >98.5 % 
ANI with K. pneumoniae shared >95 % ANI with K. africana (Figure 4.1). Chun et 
al. (2018) suggested strains belonging to different subspecies, and by extension 
closely related species, should be genomically coherent and form distinguishable 
clades by phylogenomic treeing. Phylogenetic analysis of the isolates with 
representative strains of the seven species of the K. pneumoniae complex 
(Rodrigues et al., 2019) confirmed the species affiliations identified using ANI 
(Figure 4.2). 
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Table 4.1: Phenotypic information for K. pneumoniae isolates included in this study. 
Strain API 20E* Source Ward† Resistance 
gene 
Antibiotic‡ 
    GEN CIP CFX TAZ AMO TEM CFT ERT TRI CEF CFN AUG COL TIG AZT TOB MER AMI 
PS_Kpn1 1 Perineum HJW NDM R R R R R R R R R R R R S S R R R R 
PS_Kpn2 1 Rectum ZCO NDM R R R R R R R R R R R R R S R R R R 
PS_Kpn3 1 Rectum ORDU OXA-48 S R R S R R S R R S R R S R R S R R 
PS_Kpn4 1 Cross-infectionƒ CWOP OXA-48/NDM ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
PS_Kpn7 1 Rectum ZCO NDM R R R R R R R R R R R R R S S R R R 
PS_Kpn9 2 Rectum HJW NDM R R R R R R R R R R R R S I R R R R 
PS_Kpn10 1 Rectum ZCO NDM  R R R R R R R R R R R R S S R R R R 
PS_Kpn11 1 Urine NU NDM R R R R R R R R R R R R S I R R R R 
PS_Kpn12 1 Rectum ZCO NDM R R R R R R R R R R R R S S R R R R 
PS_Kpn13 1 Rectum ZCO NDM R R R R R R R R R R R R S S R R R R 
PS_Kpn14 1 Rectum ZCO NDM R R R R R R R R R R R R S S R R R R 
PS_Kpn15 1 Rectum HDU OXA-48 S I R R R R R R R R R R ND R R S I S 
PS_Kpn16 1 Rectum AU OXA-48 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
PS_Kpn24 1 Rectum ZCO NDM R R R R R R R R R R R R R S S R R R 
PS_Kpn25 1 Rectum ZCO NDM R R R R R R R R R R R R R S R R R R 
PS_Kpn26 1 Rectum ICU NDM R R R R R R R R R R R R S S R R R R 
PS_Kpn27 2 Urine CWOP KPC S R ND R ND R R R R R ND R S ND ND ND ND ND 
PS_Kpn28 1 Urine RENAL OXA-48 R R ND R ND R R R R R ND R S R ND ND R S 
PS_Kpn29 1 Urine KERW NDM R R R R R R R R R R R R R S R R R R 
PS_Kpn30 2 Mouth  HA7 NDM R R R R R R R R R R R R R S S R R R 
PS_Kpn31 1 Perineum ICU NDM R R R R R R R R R R R R R S R R R R 
PS_Kpn32 1 Drain fluid DWU OXA-48 R R R R R R R R R R R R S I R R S R 
PS_Kpn33 1 Urine ZCO NDM R R R R R R R R R R R R S S R R R R 
PS_Kpn35 1 Urine ZCO NDM R R R R R R R R R R R R S S R R R R 
PS_Kpn36 1 Urine HEU OXA-48 S R R R R R R R R R R R R S R R S S 
PS_Kpn37 2 Wound HEU NDM R R R R R R R R R R R R S R R R R R 
PS_Kpn38 1 High vaginal swab CWOP NDM R R R R R R R R R R R R S R R R R R 
PS_Kpn39 1 Wound AE NDM R R R R R R R R R R R R S I R R R R 
PS_Kpn40 1 Wound OPD KPC S R R R R R R R R R R R S S S S R I 
PS_Kpn41 1 Leg GICU NDM R R R R R R R R R R R R S S R R R R 
PS_misc2 2 Groin ZCO OXA-48/NDM S R R R R R R R R R R R S S S S R I 
PS_misc3 2 Rectum DWU OXA-48 R R R R R R R R R R R R S S R R R R 
PS_misc5 2 Rectum ZCO OXA-48 I R R ND R R R R R R R R ND R R R R R 
PS_misc6 2 Rectum ZCO NDM S I R ND R R ND R R S S R ND S R R I ND 
PS_misc7 2 Rectum DWU OXA-48 S I R R R R R R R R R R ND I R S I S 
PS_misc8 2 Perineum ZCO OXA-48 S R R R R R R R R R R R ND I R S R S 
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*1, profile number 5205773, 81.8 % K. pneumoniae; 2, profile number 5215773, 97% K. pneumoniae. 
†HJW, John Humphrey Ward; ZCO, Zachary Cope Ward; ORDU, Outpatients Renal Dialysis Unit; CWOP, Chelsea and 
Westminster Outpatients; NU, Neptune Unit; HDU, High Dependency Unit; AU, Acute Unit; ICU, Intensive Care Unit; RENAL, Renal 
Unit; KERW, Kerr Ward; HA7, Hematology Ward; DWU, De Wardener Ward; HEU, Hemodialysis Unit; AE, Accident and 
Emergency; OPD, Outpatients Department; GICU , Geriatric Intensive Care Unit. 
‡GEN, gentamicin; CIP, ciprofloxacin; CFX, cefuroxime; TAZ, tazocin; AMO, amoxycillin; TEM, temocillin; CFT, cefotaxime; ERT, 
ertapenem; TRI, trimethoprim; CEF, ceftazidime; CFN, ceftoxitin; AUG, augmentin; COL, colistin; TIG, tigecycline; AZT, azteonam; 
TOB, tobramycin; MER, meropenem; AMI, amikacin. R, resistant; S, sensitive; I, intermediate; ND, no data. 
ƒNose, axilla and groin swabs. 
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Figure 4.1. ANI values for the 36 clinical isolates when compared against K. 
pneumoniae complex reference strains (Rodrigues et al., 2019). ANI data were 
generated using FastANI. The heatmap was generated from FastANI outputs by 
Dr L. Hoyles. 
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Figure 4.2. Unrooted phylogenetic tree showing the relationships of the clinical 
isolates with representatives of the seven species of the K. pneumoniae complex. 
Genomes included in the study of Rodrigues et al. (2019) were included in the 
analysis. The phylogenetic analysis was conducted by Dr L. Hoyles using 
PhyloPhlAn 0.99, which used 379 proteins common to each genome in its 
analysis. FastTree, which generates approximately maximum-likelihood trees for 
large alignments, was used by PhyloPhlAn. The tree was visualised using iTOL 
(https://itol.embl.de) and coloured using Adobe Illustrator. Scale bar, normalised 
fraction of total branch length. 
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4.3.3 Capsular (K), O antigen and multilocus sequencing typing of isolates 
using WGS data 
I uploaded the WGSs of the 36 isolates to the Institut Pasteur MLST 
database (https://bigsdb.pasteur.fr/klebsiella/klebsiella.html) to determine their MSLT 
sequence types (Table 4.2). K and O antigen types for the isolates were 
determined using Kaptive Web (Table 4.2). All but four of the strains could be 
assigned a ST. ST14 had greatest representation (n = 15), followed by ST15 (n = 
3), ST45 (n = 3), ST11 (n = 2) and ST258 (n = 2); all other STs (ST16, ST35, 
ST101, ST147, ST294, ST512 and ST716) were represented once. Twelve of the 
ST14 isolates were K2:O1v1, while three were K64:O1v1. All the ST45 isolates 
were K52:OL101, and both ST258 isolates were K107:O2v2. The remaining STs 
were represented by a range of K and O types (Table 4.2). 
PHE provided some MLST, K type, PFGE and VNTR data for 15 NDM-
positive K. pneumoniae strains that had been linked to an outbreak that occurred 
between July 2014 and March 2015 in two hospitals with spread occurring due to 
frequent contact between the two hospitals, but WGS data were not available from 
PHE (Table 4.3). In March 2015, two clinical cultures of a carbapenem-resistant K. 
pneumoniae were identified in Hospital B mainly from vascular inpatient wards 
prompting screening of all patients on the ward (Otter et al., 2017). In April 2015, 
screening in Hospital A mainly from renal inpatient wards identified one case that 
was epidemiologically linked to cases from July and December 2014. The spread 
occurred due to frequent contact between the hospitals, with 11 of the patients 
involved in the outbreak having contact with both Hospitals A and B in the three 
months before or after their date of first acquisition of CPE (Otter et al., 2017). 
Clusters of the outbreak strains shared the same, characteristic VNTR 
profiles, i.e. 9 isolates had the VNTR profile 634011211 (profile A (Hospital A) of 
Otter et al., 2017), and three had VNTR profile 634011311 (profile B (Hospital B) 
of Otter et al., 2017), while three strains had unique VNTR profiles (Table 4.3). 
Profiles A and B differed from each other by one repeat unit at one locus 
(underlined in the profile codes). 
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Table 4.2: K type, O antigen and MLST data for the strains included in this 
study. 
Strain K type O antigen MLST 
PS_Kpn11 K107 O2v2 ST258 
PS_Kpn27 K107 O2v2 ST258 
PS_Kpn40 K107 O2v2 ST512 
PS_misc6 K110 O2v1 ST716 
PS_Kpn30 K112 O1v1 ST15 
PS_Kpn41 K112 O1v1 ST15 
PS_Kpn12 K15 O4 ST11 
PS_Kpn16 K17 O1v1 ST101 
PS_Kpn9 K18 O2v1 * 
PS_Kpn1 K2 O4 * 
PS_Kpn10 K2 O1v1 ST14 
PS_Kpn13 K2 O1v1 ST14 
PS_Kpn14 K2 O1v1 ST14 
PS_Kpn24 K2 O1v1 ST14 
PS_Kpn25 K2 O1v1 ST14 
PS_Kpn28 K2 O1v1 ST14 
PS_Kpn29 K2 O1v1 ST14 
PS_Kpn31 K2 O1v1 ST14 
PS_Kpn33 K2 O1v1 ST14 
PS_Kpn35 K2 O1v1 ST14 
PS_Kpn38 K2 O1v1 ST14 
PS_Kpn7 K2 O1v1 ST14 
PS_Kpn32 K22 O1v1 ST35 
PS_Kpn36 K24 O2v1 ST11 
PS_misc7 K30 O1v1 ST294 
PS_Kpn37 K51 O3b ST16 
PS_Kpn15 K52 OL101 ST45 
PS_misc3 K52 OL101 ST45 
PS_misc8 K52 OL101 ST45 
PS_Kpn3 K64 O1v1 * 
PS_Kpn2 K64 O1v1 ST14 
PS_Kpn39 K64 O1v1 ST14 
PS_misc2 K64 O1v1 ST14 
PS_Kpn26 K64 O1v1 ST147 
PS_Kpn4 K64 O1v2 ST15 
PS_misc5 K81 OL101 * 
*, Unknown (no match in database). 
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Table 4.3: Genotypic data provided by PHE for outbreak strains compared 
with results determined in this study. 
Strain MLST K 
type 
VNTR 
profile 
PFGE 
profile 
This study 
      K type O antigen MLST 
PS_Kpn1 ND K2 634011311 ND K2 O4 * 
PS_Kpn29 ST14 K2 634011311 SMAR45 K2 O1v1 ST14 
PS_Kpn31 ND ND 634011311 SMAR45 K2 O1v1 ST14 
PS_Kpn30 ND ND 333011411 ND K112 O1v1 ST15 
PS_Kpn9 ND ND 3-2521331 ND K18 O2v1 * 
PS_Kpn11 ND ND 321321331 ND K107 O2v2 ST258 
PS_Kpn10 ND K2 634011211 ND K2 O1v1 ST14 
PS_Kpn13 ND ND 634011211 ND K2 O1v1 ST14 
PS_Kpn14 ND ND 634011211 ND K2 O1v1 ST14 
PS_Kpn2 ND K2 634011211 ND K64 O1v1 ST14 
PS_Kpn24 ND K2 634011211 ND K2 O1v1 ST14 
PS_Kpn25 ST14 K2 634011211 SMAR45 K2 O1v1 ST14 
PS_Kpn33 ST14 K2 634011211 SMAR45 K2 O1v1 ST14 
PS_Kpn35 ND ND 634011211 ND K2 O1v1 ST14 
PS_Kpn7 ST14 K2 634011211 ND K2 O1v1 ST14 
ND, No data provided by PHE. 
*, Unknown type. 
 
 
4.3.4 Genomic characterisation of AMR genes 
The protein sequences of the genes encoded by the isolates were 
compared against the latest release of CARD (Jia et al., 2017). No protein 
sequences were found to have a perfect CARD match for all 36 isolates (Figure 
4.3). However, KpnE and KpnF had perfect/strict CARD match for all 36 isolates. 
In addition, a strict CARD match was seen for all 36 isolates for five other genes 
(acrD, emrR, CRP, KpnG and KpnH). Strict CARD match was also seen for 35/36 
isolates for acrB (all but PS_Kpn1), baeR (all but PS_Kpn25), marA (all but 
PS_Kpn1), msbA (all but PS_Kpn3), mtfA (all but PS_Kpn1) and pmrF (all but   
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Figure 4.3. Comparison of genome data for the 36 (35 K. pneumoniae, one K. 
variicola) isolates with sequences in The Comprehensive Antibiotic Resistance 
Database (CARD) (Jia et al., 2017). Strict CARD match, not identical but the bit-
score of the matched sequence is greater than the curated BLASTP bit-score cut-
off; perfect CARD match, 100% identical to the reference sequence along its entire 
length. Loose matches are not shown to avoid presenting false positives based on 
sequences with low homology and bit-scores below CARD BLASTP cut-off 
recommendations. BLASTP analyses carried out by me and image produced by 
Dr L. Hoyles. 
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PS_Kpn4); whilst strict CARD match was shown for 34/36 isolates (exceptions 
PS_Kpn1 and PS_Kpn3) for mdtC, for 33/36 isolates (exceptions PS_Kpn1, 
PS_Kpn3 and PS_Kpn4) for ampH β-lactamase, and for all isolates except 
PS_Kpn1, PS_Kpn2, PS_Kpn3 and PS_Kpn4 for mdtB. 
Presence of OXA-1, SAT-1, oqxA, KpnE and KpnF was predicted for all 
ST14 strains (perfect CARD match) (Figure 4.3). In addition, all ST14 strains 
encoded (strict CARD match) oqxB and msbA; as well as the five genes listed 
above which were encoded by all 36 isolates, and seven of the nine genes 
encoded by most (≥ 32) of the isolates (baeR and mdtB being the exceptions). 
Interestingly, AAC(6’)-lb-cr was predicted (perfect CARD match) for all ST14 
K2:O1v1 isolates but not encoded by the three ST14 K64:O1v1 strains (PS_Kpn2, 
PS_Kpn39 and PS_misc2). The presence of a number of other AMR genes was 
predicted (perfect CARD match) for the majority of ST14 strains: APH(3’)-V1, 
armA, BRP(MBL), dtrA-12, msrE and mPHE (not PS_Kpn25 and PS_Kpn28); 
CTX-M-15 (not PS_Kpn7 and PS_Kpn24); and acd2 (not PS_Kpn25, PS_Kpn28 
and PS_Kpn38). Furthermore, sul1 (perfect/strict CARD match for all but 
PS_Kpn28), FosA6 and OmpK37 (strict CARD match for all but PS_Kpn2) were 
also encoded by most ST14 strains. 
Presence of BRP(MBL), CTX-M-15, CMY-6, KpnE and KpnF genes was 
predicted (perfect CARD match) for all three ST15 strains, which also encoded 
(strict CARD match) oqxB and the previously listed genes encoded by all/majority 
of 36 isolates. 
ST45 strains (n = 3) were predicted to encode CTX-M-15, KpnF, OXA-232, 
QnrB1, SHV-1, sul-2 and TEM-1 genes (perfect CARD match), as well as 
encoding (strict CARD match) APH(3’)-lb, APH(3’)-ld, oqxA, oqxB, OmpK37 and 
remaining 15 genes listed above (encoded by all/majority of 36 isolates). 
ST11 strains were both predicted to encode CTX-M-15, KpnF, oqxA, OXA-
1, QnrB1 and SHV-11 genes (perfect CARD match), as well as encoding (strict 
CARD match) FosA6, oqxB, OmpK37 and remaining 15 genes listed above 
(encoded by all/majority of 36 isolates). 
ST258 strains were both predicted to encode aadA2, KPC-3, KpnF, mphA, 
oqxA, oqxB, sul1 and TEM-1 genes (perfect CARD match), as well as encoding 
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(strict CARD match) AAC(6’)-lb10, APH(3’)-la, FosA6, OmpK37 and remaining 15 
genes listed above (encoded by all/majority of 36 isolates). 
All 36 isolates were confirmed to encode at least one NDM-, OXA- or KPC- 
gene (perfect CARD match), with numerous isolates predicted to encode more 
than one such gene (Table 4.4). No strict CARD matches were seen for these 
genes (Figure 4.3). Only four isolates (PS_Kpn16, PS_Kpn32, PS_misc5 and 
PS_misc7) were predicted to encode OXA-48, despite eight other isolates also 
having positive OXA-48 PCR data from the PHE reference laboratory. The 
presence of KPC-3 was confirmed for the two isolates (PS_Kpn27 and PS_Kpn40) 
identified by PCR to carry the KPC resistance gene, along with four other isolates 
(all of which also had NDM-/OXA- genes) – three NDM strains and one OXA-
48/NDM strain (PCR data). Three (PS_Kpn11, PS_Kpn25 and PS_Kpn38) of the 
22 isolates characterised as carrying the NDM resistance gene by the PHE 
reference laboratory PCR were negative for CARD matches for NDM- genes (i.e. 
below CARD BLASTP cut-off recommendations for strict and perfect matches). 
Although they were each confirmed to encode OXA-1 and/or OXA-9 (Table 4.4). 
The presence of NDM-1, OXA-1 and OXA-232 was confirmed for both PS_Kpn4 
and PS_misc2, characterized as OXA-48/NDM resistant by the reference 
laboratory. 
Protein sequences associated with colistin resistance genes were also of 
particular interest in this study as eight clinical isolates (including 7 outbreak 
strains) displayed colistin resistance phenotypically. Colistin resistance is 
inherently seen in some Gram-negative bacteria such as Serratia, Brucella and 
Burkholderia species (Ah et al., 2014). Acquired colistin resistance mainly occurs: 
1) due to mutational changes in many endogenous genes involved in 
lipopolysaccharide synthesis involving the mgrB gene and upregulation of 
PhoP/PhoQ, these are the two sensor-regulator system which influence the 
synthesis of lipopolysaccharides (Poirel et al., 2014); and 2) through horizontal 
acquisition of genes as shown by the recent discovery of plasmid-encoding mcr 
genes (Liu et al., 2016). However, no CARD matches were seen for known colistin 
resistance genes (i.e. below CARD BLASTP cut-off recommendations for strict 
and perfect matches). 
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Table 4.4: Comparison of PCR and WGS resistance gene data. 
Strain Resistance 
gene 
NDM-1 NDM-5 NDM-7 OXA-1 OXA-9 OXA-48 OXA-181 OXA-232 KPC-3 
PS_Kpn1 NDM +   + +    + 
PS_Kpn2 NDM  +   +   +  + 
PS_Kpn3 OXA-48 +   + +     
PS_Kpn4 OXA-48/ 
NDM 
+   +    + + 
PS_Kpn7 NDM  +   +      
PS_Kpn9 NDM +   +      
PS_Kpn10 NDM  +   +      
PS_Kpn11 NDM     +    + 
PS_Kpn12 NDM +   +      
PS_Kpn13 NDM  +   +      
PS_Kpn14 NDM +   +      
PS_Kpn15 OXA-48        +  
PS_Kpn16 OXA-48    +  +    
PS_Kpn24 NDM +   +      
PS_Kpn25 NDM     +      
PS_Kpn26 NDM +   +      
PS_Kpn27 KPC         + 
PS_Kpn28 OXA-48    +   +   
PS_Kpn29 NDM +   +      
PS_Kpn30 NDM +   +      
PS_Kpn31 NDM +   +      
PS_Kpn32 OXA-48    +  +    
PS_Kpn33 NDM +   +      
PS_Kpn35 NDM +   +      
PS_Kpn36 OXA-48    +   +   
PS_Kpn37 NDM   + +      
PS_Kpn38 NDM    + +     
PS_Kpn39 NDM +   +    +  
PS_Kpn40 KPC         + 
PS_Kpn41 NDM +       +  
PS_misc2 OXA-48 
/NDM 
+   +    +  
PS_misc3 OXA-48        +  
PS_misc5 OXA-48      +    
PS_misc6 NDM  +        
PS_misc7 OXA-48    +  +    
PS_misc8 OXA-48        +  
+, Positive by CARD (BLASTP) analysis. 
 
 
4.3.5 Genomic characterisation of virulence genes 
BLASTP searches were conducted against protein sequences included in 
VFDB (Liu et al., 2019), with results confirmed by comparison with searches made 
through the VFDB VFanalyzer web portal (http://www.mgc.ac.cn/cgi-
bin/VFs/v5/main.cgi). 
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All strains were predicted to encode enterobactin (siderophore, linked to 
iron acquisition), AcrAB, RcsAB, type 1 fimbriae and Escherichia coli common 
pilus, and a range of capsule genes (as expected from results presented in Table 
4.2). All strains except PS_Kpn41 were predicted to encode type 3 fimbriae 
(associated with biofilm formation). Twenty-nine of the strains (PS_Kpn1, 
PS_Kpn2, PS_Kpn3, PS_Kpn4, PS_Kpn7, PS_Kpn10, PS_Kpn11, PS_Kpn12, 
PS_Kpn13, PS_Kpn14, PS_Kpn15, PS_Kpn16, PS_Kpn24, PS_Kpn25, 
PS_Kpn28, PS_Kpn29, PS_Kpn30, PS_Kpn31, PS_Kpn32, PS_Kpn33, 
PS_Kpn35, PS_Kpn36, PS_Kpn38, PS_Kpn39, PS_Kpn41, PS_misc2, PS_misc3, 
PS_misc7 and PS_misc8) were predicted to encode the siderophore 
yersiniabactin. None of the strains encoded the siderophore salmochelin. Two 
strains (PS_Kpn4 and PS_Kpn41) were predicted to encode the siderophore 
aerobactin, and rmpA. PS_Kpn9 was the only strain to encode the allantoin 
utilisation operon. PS_misc7 encoded the complete colibactin gene cluster, while 
two strains (PS_Kpn1 and PS_Kpn11) encoded 14/16 genes of the cluster. 
	
4.3.6 Isolation of phages that infect the clinical isolates, and their host 
ranges 
Lytic phages were isolated for nine of the 36 clinical isolates (Tables 4.5 
and 4.6), seven K. pneumoniae OXA-48 and two K. pneumoniae NDM. In total, 25 
phages were isolated from Mogden wastewater samples (tanks A–E); none were 
isolated from Ascot wastewater samples tested. One phage each was isolated 
from all five tanks (A–E) for both PS_Kpn32 and PS_misc5. Four morphologically 
distinct phages (in terms of plaque morphologies) were isolated for PS_Kpn3 from 
tank C, as well as one PS_Kpn3 phage from tank D. One PS_misc6 phage each 
from tanks B–E, one PS_misc3 phage each from tanks B and E, one PS_Kpn15 
phage and one PS_Kpn36 phage from tank A, and one PS_Kpn37 phage and one 
PS_misc7 phage from tank E. 
The ability of the 25 purified phages to infect a panel of clinical Klebsiella 
isolates (Table 4.5, Table 4.6) was determined using the spot assay. Variation was 
seen across the isolated lytic phages, in relation to both depolymerase activity 
(haloes observed around plaques) and host range. However, depolymerase 
activity needs further investigation for some phages due to faint/possible haloes 
(unclear) being recorded. Bacteriophage PS_Kpn32_D displays the broadest host 
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range, showing activity against all three K. michiganensis strains, 21 K. 
pneumoniae isolates (including 14 of the 15 outbreak strains; PS_Kpn30 was not 
tested due to resuscitation issues) and the single K. variicola isolate tested (Table 
4.5). Although all PS_Kpn phages displayed host ranges including more than one 
Klebsiella type (e.g. included strains from multiple Klebsiella species and/or 
multiple K. pneumoniae ST). In addition, PS_Kpn phages were successfully 
isolated for K. pneumoniae stains harbouring each of the three major resistance 
genes of NDM, OXA-48 and KPC. PS_misc phages displayed narrower host 
ranges (only one or two Klebsiella isolates) than PS_Kpn phages, with the 
exception of bacteriophage PS_misc7_E (two K. michiganensis strains and 20 K. 
pneumoniae isolates) and PS_misc6_C (two K. michiganensis strains, one K. 
pneumoniae isolate (PS_misc6) and the K. variicola isolate) (Table 4.6). 
Ongoing phage work includes further phenotypic characterisation of the 
phages, and WGS analysis. Once completed, a report will be given to IBMS and a 
paper published in an IBMS journal for me to satisfy the conditions of the funding 
provided for this work. 
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Table 4.5: Host ranges of the lytic PS_Kpn phages against clinically relevant Klebsiella isolates. 
Results are only shown for those phages that showed activity against one or more of the test strains. 
Species Strain MLST K, O types 3Ci 3Ciia 3Ciib 3Ciic 3D 15A 32A 32B 32C 32D 32E 36A 37E 
K. michiganensis PS_Koxy1 * *, * + + + +   + + + + +  + 
K. michiganensis PS_Koxy2 * *, *  + +    + + + + +  + 
K. michiganensis PS_Koxy4 * *, *       + ?d + + + +   
K. pneumoniae PS_Kpn1 * K2, O4          +    
K. pneumoniae PS_Kpn2 ST14 K64, O1v1   +    + +  + d   + 
K. pneumoniae PS_Kpn3 * K64, O1v1 + + + + + d       + + 
K. pneumoniae PS_Kpn4 ST15 K64, O1v2 + + + +          
K. pneumoniae PS_Kpn7 ST14 K2, O1v1       + +  + d   + 
K. pneumoniae PS_Kpn10 ST14 K2, O1v1  + +       + d   + 
K. pneumoniae PS_Kpn11 ST258 K107, O2v2       + d + d + d + d + d   
K. pneumoniae PS_Kpn12 ST11 K15, O4       + + + + +  + 
K. pneumoniae PS_Kpn13 ST14 K2, O1v1 + + + +      + d   + 
K. pneumoniae PS_Kpn14 ST14 K2, O1v1       +   + d    
K. pneumoniae PS_Kpn15 ST45 K52, OL101      +        
K. pneumoniae PS_Kpn16 ST101 K17, O1v1 +  +           
K. pneumoniae PS_Kpn24 ST14 K2, O1v1          + d    
K. pneumoniae PS_Kpn25 ST14 K2, O1v1  + +       + d   + 
K. pneumoniae PS_Kpn27 ST258 K107, O2v2       + d + d + d + d + d + d  
K. pneumoniae PS_Kpn28 ST14 K2, O1v1       + d + d + d + d + d   
K. pneumoniae PS_Kpn29 ST14 K2, O1v1          + d    
K. pneumoniae PS_Kpn31 ST14 K2, O1v1          + d    
K. pneumoniae PS_Kpn32 ST35 K22, O1v1     + d  + d + d + d + d + d + d  
K. pneumoniae PS_Kpn33 ST14 K2, O1v1          + d    
K. pneumoniae PS_Kpn35 ST14 K2, O1v1          + d    
K. pneumoniae PS_Kpn36 ST11 K24, O2v1            +  
K. pneumoniae PS_Kpn37 ST16 K51, O3b       + + + + +  + 
K. pneumoniae PS_Kpn38 ST14 K2, O1v1       + + + + d +  + d 
K. pneumoniae PS_Kpn39 ST14 K64, O1v1            + + d 
	 
	
143	
                 
                 
Species Strain MLST K, O types 3Ci 3Ciia 3Ciib 3Ciic 3D 15A 32A 32B 32C 32D 32E 36A 37E 
K. pneumoniae PS_Kpn40 ST512 K107, O2v2       + d + d + d + d + d +  
K. pneumoniae PS_Kpn41 ST15 K112, O1v1             + d 
K. pneumoniae PS_misc2 ST14 K64, O1v1            +  
K. pneumoniae PS_misc3 ST45 K52, OL101 + d + d + d + d + d         
K. variicola PS_misc5 * K81, OL101      + d    +  +  
K. pneumoniae PS_misc6 ST716 K110, O2v1        + d + d     
K. pneumoniae PS_misc7 ST294 K30, O1v1       + + + + +   
K. pneumoniae PS_misc8 ST45 K52, OL101      ++        
K. pneumoniae P010F ST253 *, O1v2            + d  
K. pneumoniae P057K W * K11, O3/O3a            + d + d 
K. grimontii P038I * *, *            + d  
+, Lytic; d, depolymerase activity (haloes formed round plaques); ?d, may be depolymerase activity (requires further study); –, no 
activity. 
*, Unknown type. 
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Table 4.6: Host ranges of the lytic PS_misc phages against clinically relevant Klebsiella isolates. 
Results are only shown for those phages that showed activity against one or more of the test strains. 
Species Strain MLST K, O types 3B 3E 5A 5B 5C 5D 5E 6B 6C 6D 6E 7E 
K. michiganensis PS_Koxy1 * *, *         +   + 
K. michiganensis PS_Koxy2 * *, *         +   + 
K. michiganensis PS_Koxy4 * *, *    + d + d  + d      
K. pneumoniae PS_Kpn1 * K2, O4            + 
K. pneumoniae PS_Kpn2 ST14 K64, O1v1            + 
K. pneumoniae PS_Kpn3 * K64, O1v1 + + d           
K. pneumoniae PS_Kpn7 ST14 K2, O1v1            + 
K. pneumoniae PS_Kpn10 ST14 K2, O1v1            + 
K. pneumoniae PS_Kpn12 ST11 K15, O4            + 
K. pneumoniae PS_Kpn13 ST14 K2, O1v1            + 
K. pneumoniae PS_Kpn14 ST14 K2, O1v1            + 
K. pneumoniae PS_Kpn15 ST45 K52, OL101            + 
K. pneumoniae PS_Kpn24 ST14 K2, O1v1            + d 
K. pneumoniae PS_Kpn25 ST14 K2, O1v1            + d 
K. pneumoniae PS_Kpn28 ST14 K2, O1v1            + d 
K. pneumoniae PS_Kpn29 ST14 K2, O1v1            + d 
K. pneumoniae PS_Kpn31 ST14 K2, O1v1            + d 
K. pneumoniae PS_Kpn33 ST14 K2, O1v1            + d 
K. pneumoniae PS_Kpn35 ST14 K2, O1v1            + d 
K. pneumoniae PS_Kpn38 ST14 K2, O1v1            + 
K. pneumoniae PS_misc3 ST45 K52, OL101 + d + d           
K. variicola PS_misc5 * K81, OL101   + ?d + ?d + ?d + ?d + ?d  + d    
K. pneumoniae PS_misc6 ST716 K110, O2v1        + d + d + d + d + d 
K. pneumoniae PS_misc7 ST294 K30, O1v1  +   +       + 
+, Lytic; d, depolymerase activity (haloes formed round plaques); ?d, may be depolymerase activity (requires further study); –, no 
activity. 
*, Unknown type. 
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4.4 DISCUSSION 
4.4.1 WGS identified a clinical strain of K. variicola subsp. variicola 
As with the K. michiganensis isolates characterised in Chapter 3, WGS 
analyses were more accurate than phenotypic tests (API 20E, MALDI-TOF) for 
characterisation of K. pneumoniae complex isolates, with one strain (PS_misc5) 
found to represent K. variicola subsp. variicola and not K. pneumoniae (Figure 4.1, 
Figure 4.2). Detection of the β-lactamase LEN-2 in its genome (Figure 4.3) 
confirmed PS_misc5’s affiliation to K. variicola, as this is a core gene unique to the 
species (Holt et al., 2015). Long et al. (2017) highlighted the inability of MALDI-
TOF to differentiate Kp1, Kp2 and Kp3 strains from one another in a study of 
ESBL-producing K. pneumoniae isolated from clinical infections. They used WGS 
to allow species differentiation, and also characterised the first K. variicola strains 
to carry KPC or NDM genes. It is recommended that reference MALDI-TOF 
spectra databases in clinical and reference laboratories are updated to include 
data from Rodrigues et al. (2018), who have identified protein biomarkers that 
allow differentiation of six of the seven species of the K. pneumoniae complex. 
This will allow greater recognition of the role of non-K. pneumoniae (Kp1) isolates 
in infection. 
The strain I characterised here (PS_misc5 (unknown ST, K81:OL101), 
isolated from a rectal swab) was resistant to 15 of the 18 tested antibiotics (Table 
4.1). PCR testing had shown it to encode the β-lactamase OXA-48, which was 
confirmed by comparison of WGS data with CARD (Figure 4.3; Table 4.4). There 
are only two other reports of OXA-48-encoding K. variicola in the literature, one 
strain in each (Haldorson et al., 2018; Potter et al., 2018). PS_misc5 also encoded 
a range of AMR factors (crAB, MdtBC, CRP, BaeR, MsbA, MdfA, OqxAB, KpnEF, 
KpnGH) associated with multidrug efflux pumps, and resistance to polymyxin 
(PmrF), cefotaxime and cefoxitin (OmpK37), and β-lactams (E. coli ampH β-
lactamase), and virulence genes (AcrAB, enterobactin, RcsAB, type 1 and 3 
fimbriae, E. coli common pilus) linked to immune evasion, iron uptake, 
upregulation of capsule synthesis, adherence and biofilm formation, and 
colonisation of epithelial cells, respectively. Potter et al. (2018) demonstrated 
pilus-encoding K. variicola established higher titres than K. pneumoniae in murine 
models of bladder infection, leading them to suggest K. variicola should be 
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characterised to species level to improve patient outcomes during infection. 
Maatallah et al. (2014) described K. variicola as a frequent cause of bloodstream 
infections in Sweden, associated with higher mortality than K. pneumoniae. 
However, there are few other data available with respect to the role of this 
bacterium in infections. A colistin-resistant hypermucoid strain of K. variicola 
encoding rmpA, rmpA2, aerobactin, salmochelin and yersiniabactin has been 
isolated from the blood of patient in China (Lu et al., 2018). The colistin resistance 
was associated with the presence of a D150G substitution in PhoP, part of the 
PhoP-Q two-component system, which is known to mediate colistin resistance. An 
outbreak in a Bangladeshi neonatal unit was recently reported, associated with 
hypervirulent MDR K. variicola ST771 (Farzana et al., 2019). 
Results from this Chapter and Chapter 3 have shown Klebsiella spp. can 
only be reliably identified based on WGS. But WGS or the bioinformatics expertise 
necessary to process and interpret sequence data are not available within clinical 
laboratories. Therefore, clinical laboratories often rely on PCR-based methods to 
differentiate species that cannot be split using phenotypic methods. Garza-Ramos 
et al. (2015) designed a multiplex-PCR probe system able to differentiate K. 
variicola from K. pneumoniae with high accuracy using the unique genes in the 
species’ genomes. M-PCR-1 was used to assay a collection of MDR (n = 503) and 
antimicrobial-sensitive (n = 557) K. pneumoniae clinical isolates. K. variicola was 
detected with a prevalence of 2.1% (23/1,060), with13/23 isolates MDR, and 10/23 
isolates antimicrobial sensitive. rpoB gene sequence analysis of the K. variicola-
positive isolates confirmed the multiplex-PCR results. Implementation of this PCR 
in the clinical laboratory may allow better recording of K. variicola in clinical 
laboratories and facilitate epidemiological studies. 
 
4.4.2 Antibtiotic resistance of K. pnuemoniae 
For the OXA-48 strains, two isolates (PS_Kpn32 and PS_Kpn36) were 
sensitive to meropenem with a zone size <25mm and E-test MIC < 0.12mg/L. As 
OXA strains may not show resistance to all carbapenemase indicator antibiotics, 
i.e. can give very low level carbapenem resistance without cross-resistance to 
cephalosporins, they often remain susceptible to meropenem. However, 
resistance can be picked by ertapenem, in addition to showing high levels of 
resistance to temocillin and tazobactam. Ertapenem is a more sensitive indicator 
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for detecting carbapenem resistance than meropenem, but it is also the analogue 
most affected by porin-mediated mechanisms and so is the least specific (PHE, 
2016b). KPC enzymes and MBLs tend to confer broader effects on the β-lactam 
resistance profile of the host strain. 
Note: Since 2015 the screening cut-off point recommended by EUCAST 
(European Committee on Antimicrobial Susceptibility Testing) for zone size for 
meropenem has changed to <28mm (MIC remains the same >0.125 mg/L). 
Temocillin zone size and MIC were also under consideration by EUCAST, as 
temocillin was also used as an indicator antibiotic for the detection of CPE 
especially OXA-48 (Woodford et al., 2013) and used as an alternative treatment to 
urinary tract infection with bacteria producing ESBLs in a clinical setting. I had to 
do a verification for temocillin that zone sizes of ≥ 20mm and ≥ 12mm correspond 
to MIC of ≤ 8mg/L and 32 ≤mg/L, respectively (as recommended by Vanstone et 
al., 2018). Once the verification was approved, the recommendation of Vanstone 
et al. (2018) was used to interpret susceptibility to temocillin. Another change to 
consider was that at the time of my study disc diffusion testing using colistin 10 mg 
disc was done to detect colistin susceptibility, but no zone size interpretation was 
available in EUCAST guidelines. Thus, any isolates with reduced zone size to 
colistin were tested with colistin e-test to determine the MIC (MIC colistin 
susceptibility was interpreted against EUCAST criteria; R >2 mg/L). When these 
isolates were referred to PHE’s Antimicrobial Resistance and Healthcare 
Associated Infections (AMRHAI) Reference Unit for characterisation and 
susceptibility testing (PHE used agar dilution method), the reports came back with 
differences in colistin susceptibility compared to my data. This made me aware 
that disc diffusion for colistin can give rise to false susceptibility results and 
currently EUCAST (EUCAST, Version 9.0, 2019) or NCCLS (National Committee 
for Clinical Laboratory Standards) documents do not provide interpretive criteria 
for the testing of colistin. EUCAST now recommends that colistin MIC 
determination should be performed using broth microdilution (Gales et al., 2001; 
Tan and Ng, 2007). To this end I am currently evaluating the broth microdilution 
method at Wexham Park Hospital. 
This discrepancy between the clinical laboratory and PHE results was also 
highlighted in the study carried out at the time of the outbreak at West London 
ICHNT (Otter et al., 2017). In this study colistin resistance was detected in isolates 
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from 25/38 (65.8%) patients for which colistin susceptibility was determined by 
PHE; the median colistin MIC was 8 mg/L. Only 8/25 (32.0%) isolates identified as 
colistin-resistant by PHE were reported as colistin resistant by our hospital clinical 
laboratory, meaning that colistin resistance was not detected until late in the 
outbreak in July 2015. This did not affect patient management at the time as 
colistin was not used for therapeutic purposes. 
Two clusters of colistin-resistant isolates, one on the renal wards in Hospital 
A within VNTR sub-clone A, and one on the vascular wards at Hospital B within 
VNTR sub-clone B were found in the study of Otter et al. (2017). PHE WGS 
analysis identified three separate mechanisms of colistin resistance: two due to 
different mutations that each caused an early stop codon in the mgrB gene, and 
one due to a L/Q substitution at amino acid position 396 in phoQ. These are 
consistent with Olaitan et al. (2014) who reported evidence of widespread colistin-
resistant K. pneumoniae due to inactivation of mgrB, a PhoP/PhoQ regulator. 
Giani et al. (2015) reported a large hospital outbreak of 93 bloodstream infections 
caused by colistin-resistant KPC-producing K. pneumoniae which was mostly 
explained by clonal expansion of a single mgrB deletion mutant. Taken together, 
this suggests that the clonal spread of K. pneumoniae with mutational colistin 
resistance may be a more important clinical threat than resistance through 
plasmid-mediated genes, and underlines the need for robust infection control 
interventions to prevent the clonal spread of resistance determinants (Otter et al., 
2017). Although colistin resistance is seen more in clinical settings, understanding 
of the clinical and epidemiological implications of the various types of colistin 
resistance is limited, with very few data on the frequency of emergence, fitness 
impact and strain variation (Ah et al., 2014), and advice on how to limit the 
emergence of colistin resistance through better antibiotic stewardship is also 
lacking (Otter et al., 2017). 
 
4.4.3 Carbapenemase gene analyses of K. pneumoniae 
The PHE reference laboratory used a multiplex-PCR-based technique for 
detection of genes encoding carbapenemases belonging to different classes. 
Primers were designed to amplify the following genes: class A (KPC, IMI, NMC, 
GES AND SME), class B (IMP, VIM, GIM, NDM, KHM, TMB, DIM, SIM AND SPM) 
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and class D (OXA-48-like) carbapenemases. Three different multiplex reaction 
mixtures were defined and evaluated for the detection of all these genes. 
K. pneumoniae is an important nosocomial pathogen, known to cause 
pneumonia, urinary tract, wound and blood infections (Brisse et al., 2009). It is 
often encapsulated, with over 100 known capsule types now recognised (Wyres 
and Holt, 2016). The capsule is an important virulence factor, and some capsular 
types, particularly K1 and K2 but also K54 and K57 (Fang et al., 2007), are 
associated with a community-acquired invasive PLA syndrome. In particular, the 
virulent clone ST23, referred to as CC23 (K1) or the K1 cluster, identified by MLST 
and PFGE (Turton et al., 2007) carries additional factors that increase its 
virulence: i.e. plasmid-borne rmpA (regulator of mucoid phenotype A) and wcaG 
(encoding capsular fucose synthesis), which together enhance the ability of the 
bacterium to evade phagocytosis by macrophages (Fang et al., 2007). The 
capsular type together with the putative virulence factors (rmpA and wcaG) were 
also included in the multiplex-PCR, with serotype-specific targets for capsular 
types K1, K2, K5 and K57. The remaining targets sought to detect the 16S-23S 
internal transcribed spacer region in K. pneumoniae as both K. pneumoniae and 
K. pneumoniae subsp. ozaenae give a band and can be distinguished on the basis 
of their malonate and Vogues-Proskauer reactions. 
The reference laboratory confirmed that 22/36 clinical isolates were NDM-
positive, 10 were OXA-48-positive, two were KPC-positive, and two were positive 
for both NDM and OXA-48 resistance genes. Eight of the 22 K. pneumoniae NDM 
clinical isolates were positive for the K2 capsular type common in the UK, and all 
22 K. pneumoniae NDM were negative for rmpA/wcaG virulence factors. 
Since the population of K. pneumoniae isolates belonged to an outbreak 
situation in a nosocomial setting, it was important to identify possible cases of 
transmission. This was performed by comparison of DNA fingerprints using PFGE, 
which provides an excellent method for this purpose together with VNTR analysis. 
Identification of these loci is useful for epidemiological investigations, since they 
have a relatively high mutation rate, the addition or deletion of sequence units 
usually occurring as a result of slipped strand mispairing during replication 
(Yazdankhah and Lindstedt, 2007). Using these methods, the isolates were 
described by a series of numbers and the profiles compared. Here we describe 
eight VNTR loci for K. pneumoniae, which provide discrimination at the same level 
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as using multiplex-PCR coupled with VNTR analysis, providing a rapid means of 
characterisation and typing isolates. 
The K. pneumoniae NDM outbreak strains, ST14 with K2 capsular type, 
isolated in this study were related to the ones isolated in previous studies and 
belonged to the clone of outbreak strain dissimilated from the Indian subcontinent 
(Giske et al., 2012). The first-reported NDM-positive isolates (Yong et al., 2009) 
were two isolates from Oman (Poirel et al., 2010) and seven from Nairobi, Kenya 
(Poirel et al., 2011b). All belonged to ST14, a member of the large CC292 complex 
and are clonal, suggesting that some strains could potentially cause outbreaks, 
which our data has corroborated. Woodford et al. (2011) described K. pneumoniae 
ST14 as a host lineage for the NDM-1 enzyme and a frequent host of CTX-M 
enzymes. In addition, ST14 is a single locus variant of ST15, which frequently 
carries CTX-M ESBLs. The ST14 isolates with NDM-1 carbapenemase are 
extremely MDR, as seen with this study: they are known to also harbour ESBLs 
and acquired AmpC enzymes besides the NDM MBL, thus conferring resistance to 
all β-lactams; they tend to also produce 16S methylases, often ArmA or RmtC, 
which confer resistance to all clinically useful aminoglycosides. Most remain 
susceptible to polymyxins, although resistance has been observed in some 
isolates (Kumarasamy et al., 2010) as was the case in this study with 8 NDM 
strains (some belonging to the ST14 cluster) resistant to colistin. Worryingly, some 
of the ST14 isolates in this study carried genes determining serotype K2, which is 
one of the K. pneumoniae serotypes associated with invasive disease similar to 
those isolated from a study by Giske et al. (2012). 
 
4.4.4 MLST of strains 
MSLT analysis of the 36 isolates identified 15 ST14 isolates, 12 capsular 
type K2 and three K64, all O1v1. Eleven of the ST14 isolates were part of the 
outbreak, isolated from patients from the same ward and sharing the same 
antibiotic resistance genes (blaCTX-M-15, blaNDM-1, blaSHV-28), with a few having an 
additional resistance gene (either blaOXA-181, blaOXA-1, blaOXA-232, blaOXA-48 or blaKPC-
3). The ST14 isolates also shared similar genes encoding for aminoglycoside with 
quinolone resistance gene. Common genes for efflux pump activation, which also 
contributes to various antibiotic resistances, were also identified (all 36 clinical 
isolates). Two ST258 isolates were identified, both harboured blaKPC-3 together 
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with blaSHV and blaTEM β-lactamases. Both also shared the same capsular antigen 
(K107) and O antigen (O2v2) together with various genes for quinolone and 
aminoglycoside resistance. Three isolates belonged to ST45, harbouring blaOXA-232 
together with blaSHV and blaTEM β-lactamases, and shared the same capsular 
antigen (K52) and O antigen (OL101) together with various genes for quinolone 
and aminoglycoside resistance. The remaining isolates belonged to either ST11, 
ST15, ST16, ST35, ST101, ST147, ST294, ST512 or ST716 (each with distinct K 
types) with some having a common O antigen (O1v1 being most common). Of the 
36 isolates, for 22 carbapenem resistance was due to the presence of blaNDM-1, for 
four it was due to the presence of blaOXA-48, for five it was due to blaOXA-48 
derivatives blaOXA-232 and blaOXA-181, and for three it was due to blaKPC-3. 
K. pneumoniae strains are intrinsically resistant to ampicillin due to the 
presence of the SHV β-lactamase (Class A). A derivative of blaSHV is blaLEN 
(Tärnberg et al., 2009), with the two not easily differentiated using PCR. Both class 
A β-lactamases were present in some of the K. pneumoniae isolates in this study. 
Most of the 36 clinical isolates carried several AMR genes, the majority of which 
are acquired via horizontal plasmid transfer (Holt et al., 2015). 
 
4.4.5 K. pneumoniae OXA-48 
In general, the results of my WGS AMR analyses were consistent with the 
reference laboratory PCR findings for the 36 clinical isolates, with a few disparities. 
Of particular interest was the identification of the OXA-48 carbapenamse genes. 
The reference laboratory identified 12 OXA-48-producers, whereas WGS detected 
only four (the other eight being OXA-48 variants that are not differentiated by the 
generic PCR, namely OXA-181 and OXA-232). Potron et al. (2013b) characterised 
OXA-232, differing from OXA-181 by one amino acid substitution, leading to a 
weaker capacity to hydrolyse imipenem than OXA-181 and OXA-48. K. 
pneumoniae OXA-232 strains are able to hydrolyse all penicillins except temocillin, 
which has been reported to be a poor substrate of OXA-232. This has led to using 
temocillin as a valuable phenotypic tool for the presumptive detection of OXA-48 in 
clinical laboratories. However, results from this study showed that temocillin 
should be used carefully to detect OXA-48-like-producers, since some OXA-48 
variants, such as OXA-232, possess a weak capacity to hydrolyse this β-lactam. 
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The blaOXA-232 gene was identified in three enterobacterial isolates recovered from 
patients who had a link with India, further confirming the spread in the Indian 
subcontinent of OXA48-like carbapenemases in hospital settings.	
CARD results (Figure 4.3) showed PS_Kpn25 harboured a CTX-M-15 
ESBL β-lactamase, blaOXA-1 and blaSHV-28, whereas the reference laboratory 
identified it as carrying an NDM carbapenemase, with colistin resistance. 
 
4.4.6 Genomic identification of virulence factors of K. pneumoniae using 
VFDB 
Hypervirulent K. pneumoniae have been found to have more active 
siderophores, encoded by multigene operons that are included in the VFDB (Liu et 
al., 2019). These siderophores facilitate iron transport across bacterial cell 
membranes, with iron essential for almost all life processes. Enterobactin along 
with one or both of aerobactin and yersiniabactin are associated with hypervirulent 
strains, with salmochelin rarely detected (Holt et al., 2015). Yersiniabactin is the 
most common virulence factor associated with human K. pneumoniae infections 
(Liu et al., 2019). Enterobactin was predicted to be encoded by all 35 K. 
pneumoniae strains, while yersiniabactin was predicted to be encoded by 29/35 
strains (i.e. they encoded the full complement of genes for the operons of both 
siderophores). Strains producing enterobactin (with or without yersiniabactin 
production) essentially belong to hypervirulent K. pneumoniae, which are 
undergoing a global dissemination from the Asian Pacific region (Shon et al., 
2013) and are known to cause life-threatening infections both in young and healthy 
individuals from the community. 
Two ST15 strains (PS_Kpn4 and PS_Kpn41) were predicted to encode 
the siderophore aerobactin (the most common siderophore secreted by 
hypervirulent K. pneumoniae; Liu et al., 2019) and the “regulator of mucoid 
phenotype” rmpA. ST23 isolates with this phenotype are considered hypervirulent 
(Broberg et al., 2014), suggesting PS_Kpn4 and PS_Kpn41 are hypervirulent 
strains. PCR done by PHE for rmpA did not pick up this gene, suggesting the 
primers they use lack specificity. So far hypervirulent K. pneumoniae are relatively 
sensitive to most antibiotics, but as my study clearly shows MDR hypervirulent K. 
pneumoniae are now a concern in the West London Hospitals. 
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Additional virulence factors included in VFDB cover efflux pumps (AcrAB), 
antiphagocytosis (capsule), toxins (colibactin), capsule regulation (RcsAB), 
nutrition (allantoin utilisation), adherence and biofilm formation (type 1 and 3 
fimbriae, E. coli common pilus), and immune evasion (capsule). 
All 35 K. pneumoniae strains encoded AcrAB, a multidrug efflux pump that 
may also represent a novel virulence factor required for K. pneumoniae to resist 
innate immune defense mechanisms of the lung, thus facilitating the onset of 
pneumonia (Padilla et al., 2010). They also all encoded RcsAB, responsible for 
upregulation of capsule (cps) expression (Liu et al., 2019), and type 1 fimbriae and 
Escherichia coli common pilus (both associated with adherence and biofilm 
formation; Liu et al., 2019). All strains except PS_Kpn41 were predicted to encode 
type 3 fimbriae (associated with biofilm formation). 
One strain (PS_Kpn9) encoded the allantoin utilisation operon, a 
nutritional factor known to increase nitrogen availability during infection, and 
associated with hypervirulent K. pneumoniae strains that cause PLA (Chou et al., 
2004; Liu et al., 2019). 
PS_misc7 encoded the genotoxic microbial metabolite colibactin, which 
causes breaks in double-stranded DNA and is associated with development of 
chronic inflammation and bacterially induced colorectal cancer (CRC) (Lai and Lin, 
2010; Wilson et al., 2019). PS_Kpn1 and PS_Kpn11 encoded 14/16 genes 
required to produce colibactin. Whether the toxin is produced by these strains 
would need to be confirmed in vitro. Lai and Lin (2010) showed that PLA caused 
by K. pneumoniae significantly increased the risk of CRC. The carriage of the 
colibactin gene cluster may thus serve as a molecular basis underlying the 
epidemiological link between K. pneumoniae and CRC. More than 25% of K. 
pneumoniae strains isolated from Taiwan carried colibactin genes, and 66% 
belonged to the K1 type which is responsible for the development of invasive 
diseases such as PLA (Lai et al., 2014). The detection of the colibactin gene 
cluster in my isolates is of concern as different types of virulent K. pneumoniae are 
circling in the hospital environment and in the community of the West London area 
and if not checked may cause an outbreak.  
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4.4.7 K. pneumoniae phages and their therapeutic potential 
The phage results in this study demonstrated the ability to isolate lytic 
phages for AMR Klebsiella clinical isolates harbouring carbapenemase resistance 
genes KPC, NDM and OXA-48, including colistin-resistant strains (a rare 
occurrence). PS_Kpn phages showed broad host ranges, against different 
Klebsiella types, with depolymerase activity often shown. Previous studies have 
shown that the phage-encoded enzymes (depolymerase) can counteract the 
resistance of encapsulated K. pneumoniae to key mechanisms of the innate host 
defense such as complement-mediated lysis and phagocytosis by macrophages 
(Lin et al., 2014; Pan et al., 2015; Majkowska-Skrobek et al., 2018; Chanishvili and 
Aminov, 2019). In addition, depolymerases are reportedly highly specific for a 
particular capsule serotype, as demonstrated by Lin et al. (2014) who used 
bacteriophage NTUH-K2044-K1-1 (that infects K. pneumoniae NTUH-K2044, 
capsular type K1) for diagnosis and treatment of K1 K. pneumoniae infections in 
mice. However, my data showed a number of Klebsiella bacteriophages with 
depolymerase activity against multiple K types (Table 4.5, Table 4.6). 
The broad-spectrum activities of the phages in this study suggest they could 
be used to produce an effective cocktail consisting of several different phages, 
which would reduce the likelihood of phage-resistant bacteria developing during 
therapy (Oh et al., 2019). This study also shows the scope for using phages to 
control the dissemination of K. pneumoniae. In addition, bacteriophages could also 
be used for decolonisation purposes, leading to the reduction of the load of K. 
pneumoniae clones and thus reducing the chances of their transmission. Due to 
their relatively high specificity, phages could be used in a targeted manner, having 
little to no impact on the human gut microbiota compared to when conventional 
antibiotics are used. These features make bacteriophages potential alternatives to 
antibiotic therapies for clinical applications in infections caused by K. pneumoniae.  
 
4.5 SUMMARY 
In this Chapter the initial phenotypic and genotypic results obtained for the 
36 MDR K. pneumoniae clinical isolates from the microbiology laboratory of 
Charing Cross Hospital were further investigated by WGS analyses, using a 
number of different genomic databases. While the majority of the strains were 
confirmed to be K. pneumoniae by WGS data, one was K. variicola, highlighting 
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the need for more refined characterisation methods in clinical laboratories. Some 
differences were seen in the number of carbapenemases detected for each strain 
and in relation to potential mechanism for colistin resistance. The genomic 
database CARD provided a wider range of protein sequences (for genes and 
regulators) to identify the different genes involved in carbapenem resistance. It 
aided my understanding of the various genes the bacteria harboured and that may 
be activated by external forces, thereby potentially guiding clinical application of 
antibiotics (i.e. identifying ones that should not be administered in order to reduce 
potential for increased resistance; as was the case regarding colistin resistance). It 
also highlighted that reference laboratories need to look closely at bacterial WGS 
data before setting targets for clinically relevant markers. From a clinical viewpoint, 
the in-depth knowledge obtained by WGS may not be necessary as all clinicians 
are interested in is whether a bacterium carries a resistance gene (or not) and 
speed of detection is paramount. 
Similar to Chapter 3, this Chapter highlighted MALDI-TOF identification of 
bacteria used by the clinical laboratories is unable to differentiate closely related 
species. The identification of strains encoding both aerobactin and rmpA, and 
strains encoding colibactin along with their MDR phenotypes highlights 
hypervirulent, MDR K. pneumoniae strains are in circulation in West London 
Hospitals and are a cause of concern with respect to potential outbreaks. 
Lytic phages, which may provide an alternative therapeutic option (including 
bacteriophage cocktails) to antibiotics, were successfully isolated for clinically 
relevant MDR Klebsiella strains. These require additional characterisation and 
warrant further investigation of their potential applications in clinical settings. 
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CHAPTER 5: GENERAL DISCUSSION 
 
Antibiotics are becoming a limited resource due to the rise in 
Enterobacteriaceae presenting with resistance to quinolones, aminoglycosides 
(due to change in target site or enzymatic breakdown) and cephalosporins 
because these bacteria have acquired ESBLs and AmpC-type β-lactamases 
combined with porin loss. This has resulted in the increased use of carbapenems 
in hospitals, either as regimen escalation or as first-line empirical agents in 
settings where multidrug resistance is endemic (Livermore, 2012b). More 
worryingly, the increased use of carbapenems has resulted in the emergence of 
Enterobacteriaceae with carbapenem-hydrolysing β-lactamases 
(carbapenemases), rendering them resistant to antibiotics such as meropenem 
and ertapenem. Carbapenemases include MBLs of the NDM, IMP and VIM 
families, as well as non-MBLs such as KPC and OXA-48 (Livermore and 
Woodford, 2000). 
The emergence of carbapenemases is of great concern as these enzymes 
provide a far more efficient and stable mechanism of resistance to carbapenems 
than combinations of ESBLs and impermeability. Moreover, acquired 
carbapenemases have the potential for horizontal spread between different 
species of clinically relevant Enterobacteriacae (i.e. Escherichia/Shigella, 
Klebsiella, Enterobacter, Citrobacter and Raoultella spp.), Pseudomonas spp. and 
Acinetobacter spp. Carbapenems are one of the most important last-resort 
antibiotics. In response to a small number of CPO outbreaks in hospitals in 
England in 2013, PHE developed a toolkit of guidance to promote the early 
detection, management and control of CPO colonisation and infections in acute 
hospitals (PHE, 2015). An NHS England Patient Safety Alert was issued with the 
CPO toolkit in March 2014, requesting all acute trusts to have a CPE plan by June 
2014 (NHS, 2014). 
In every hospital it is the diagnostic microbiology laboratory that plays an 
important role in the detection of CPOs, to aid in therapy and to improve infection 
control. GI carriage of CPOs is an important source of transmission. Isolation of 
carriers is one strategy that can be used to limit the spread of these bacteria. 
At the request of PHE to promote early detection of CPOs, as a senior 
Biomedical Scientist and antibiotic lead in the microbiology laboratory at Charing 
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Cross Hospital, my part in a team response was to develop, implement and test a 
screening programme (Chapter 2) that was cost-effective, with a quick turnaround 
time and showing maximum sensitivity with reasonable specificity, ease of use and 
able to detect multiple types of carbapenemases. Other factors that I needed to 
consider when selecting and implementing the most suitable screening 
programme for our Trust were the prevalence of resistant bacteria with resistance 
determinants within the geographical region the Trust was covering together with 
the patient population. As detailed in Chapter 2, the chromogenic agar Colorex™ 
mSuperCARBA™ 1 (E&O) was found to be the best medium to screening isolates 
due its high limit of detection and CPO colonies grew much better on this medium 
so it was easy for staff to read results. Culture-based methods may not be optimal 
for infection control practices because of their long turnaround time and the fact 
presumptive identification of CPOs by cultivation still has to be confirmed by other 
methods. In addition to the reasons given previously, the rationale behind 
selecting a culture-based chromogenic agar for the initial screening was due to the 
fact culture-based testing was easier to implement, as the necessary equipment 
and knowledge are already present in the routine microbiology laboratory. These 
tests also have the potential to detect reduced susceptibility to carbapenems 
caused by newly emerging mechanisms even when the turnaround time is still 
more than 24 h. Chromogenic medium was selected over routine medium because 
chromogenic agars incorporate enzyme substrates that release a pigment when 
hydrolysed by bacterial enzymes (Bedernjak, 2010). Adding antibiotics to the 
medium makes it selective for a particular resistance trait. The pigmentation of the 
colonies makes it easier for laboratory staff to spot the CPOs and the presence of 
antibiotics cuts off the growth of the commensal microbiota within the sample. This 
is especially important when screening for CPOs from stool or rectal samples, as 
these sample types inherently have a high bacterial load, with CPOs representing 
a small proportion of the total bacteria in the majority of samples. Therefore, this 
cultivation-based approach provides specificity and convenience at a relatively low 
cost and with minimal to no staff training required. 
In the clinical laboratory, suspected CPOs were subsequently identified to 
species level using MALDI-TOF MS (Bruker), with selection of resistant organisms 
assisted by CAT ID (Mast) with a panel of selected antibiotics. Resistant 
organisms were then referred to the PHE reference laboratory for identification of 
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resistance mechanisms and typed to the strain level using PCR- or WGS-based 
approaches. Xpert® Carba-R PCR (Cephid) was only used to confirm positive 
carriers, their contacts and those patients who have returned from travels from 
CPO-prevalent countries. Active CPO surveillance using this assay, supplemented 
with immediate patient isolation, proved to be an effective measure to limit the 
spread of CPO in our Trust. 
Numerous studies have proved WGS testing to be a promising approach for 
screening for carriage of CPOs, as analyses of WGS data offer faster availability 
of results and increased sensitivity compared with traditional testing methods. In 
our screening programme, nucleic acid amplification testing (NAAT) or WGS are 
not used for screening rectal samples due to various anticipated limitations. These 
included the cost of the test and the fact that most of these tests have been 
designed to cover only the most common carbapenemases together with the 
inability to detect new or unanticipated carbapenemases. The concern about 
detecting new resistant carbapenemases together with newly emergent variants of 
previously characterised genes will need to be addressed by constant vigilance in 
updating targets in a chosen assay. Another challenge for nucleic-acid-based 
testing direct from samples (rather than isolating pure cultures of bacteria) DNA is 
extracted from stool, as faeces often contains PCR-inhibiting substances, and 
poor results may be obtained due to excessive shearing of DNA (Claassen et al., 
2013). 
A major limitation of the work outlined in Chapter 2 is the lack of variety of 
individual carbapenemase classes tested in real time. At the time of the evaluation 
study, NDM was the most prevalent type of carbapenem resistance in K. 
pneumoniae across the five hospital sites covered by the Charing Cross 
microbiology laboratory. Consequently, many of the isolates used to evaluate the 
performance of the culture plates were NDM strains. One of the things I would do 
differentently in a new evaluation study would be to include clinical isolates of K. 
pneumoniae with a greater range of resistance mechanisms to validate and verify 
the different phenotypic and genotypic methods. 
A strength of this work was its real-world environment. The evaluation was 
carried out using bacterial isolates that were representative of the population and 
showed a distribution of resistance mechanisms within the bacterial populations 
within the five hospitals. This was highlighted by the data generated by PHE, and 
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also through the genomic studies I carried out in Chapters 3 and 4. Another 
strength of the study was that the screening method was trialled on 19,644 CPO 
screens from 9,514 patients. The data were collected over a 6-month period from 
a diverse patient group across three hospital sites from central and north-west 
London, the inclusion of patients spanning the CPO risk spectrum, including 
patients from high-risk specialties including ICU and renal units, and robust 
statistical analysis accounting for repeated measures. This allowed the infection 
control team of the Trust to test an important national recommendation related to 
performing three sequential admission screens for CPOs, with the conclusion that 
the potential benefit did not outweigh the operational cost. The findings of this 
follow-on study have been published recently (Mookerjee et al., 2018). 
In addition, the screening study (Chapter 2) was the first to evaluate the 
Colorex™ mSuperCARBA™ 1 (E&O) in a London hospital to identify the K. 
pneumoniae NDM outbreak, with some isolates showing colistin resistance (Otter 
et al., 2017). It was also the first study to discover a novel blaGES-5 carbapenemase 
gene in K. oxytoca, which through WGS analyses was confirmed to be K. 
michiganensis (Chapter 3). 
With the introduction of improved screening programmes for CPOs, I 
believe as resistance to carbapenems is increasingly reported, the diagnostic 
microbiology laboratory has an important role to play in the rapid detection of 
CPOs in order to aid in therapy selection and improve infection control. Although 
techniques used to detect CPOs are diverse and abundant their sensitivities and 
specificities remain inconclusive. Genotypic techniques are used to confirm 
presence of carbapenemase genes, and are mostly used in reference laboratories 
such as those of PHE. Vanstone et al. (2018) evaluated the EntericBio CPE real-
time PCR assay (Serosep Ltd) for the detection of the common carbapenemase 
resistance genes NDM, KPC, OXA-48-like, VIM, IMP and GES along with a variety 
of the less common genes with 100 % sensitivity and specificity, improving 
turnaround time but still with the limitation of not being able to detect unknown 
resistance. However, this could offer an improvement and upgrading of the Xpert® 
Carba-R PCR (Cephid) for our workflow. But beyond that, I strongly believe 
culture-based methods are still essential and crucial for the initial detection of 
CPOs known and unknown. Chromogenic media are a new generation of media 
which can be considered as a truly rapid culture-based method for 
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carbapenemase detection and offer a sensitive, convenient, and relatively low-cost 
method for identifying CPOs. I also believe that evaluation and improvement of the 
screening methods does not stop with this study or that of Mookerjee et al. (2018), 
but with increased knowledge on carbapenemases, screening methods should be 
updated regularly due to ongoing technical developments and the emergence of 
new carbapenemase variants (Hammoudi et al., 2014). 
During the outbreak screening period in 2015 using the new algorithm 
described in Chapter 2, while collecting isolates for my research I came across a 
few isolates that showed resistance to ertapenem and a low MIC to meropenem 
that grew on the new selective medium. MALDI-TOF identified the isolates as K. 
oxytoca. In-house PCR was negative for the five common carbapenemase genes. 
As part of an outbreak study by Eades et al. (2016), the isolates were identified by 
PHE as K. oxytoca, carrying a novel blaGES-5 gene. MLST analysis with WGS data 
(not available to me) showed the isolates to be ST138. WGS analyses conducted 
in Chapter 3 showed these isolates to be K. michiganensis. This highlights our 
current reference MALDI-TOF databases lack discriminative power, which results 
in misidentification of pathogens. This to me raises concerns as to the accuracy of 
our reports regarding K. oxytoca-associated infection samples and the true 
prevalence of K. michiganensis from an epidemiological perspective. 
Detailed WGS analysis of the K. michiganensis isolates (Chapter 3) 
confirmed they carried blaGES-5 and were ST138, but also showed they encoded 
blaSHV-66, blaTEM-1 and ESBL blaCTX-M-5. Because these strains were isolated from 
the gut of hospitalised patients who were immunocompromised and on various 
antibiotics, and because I wanted to learn more about basic bioinformatics, using 
the information provided by Tse et al. (2017), I looked at whether the strains 
encoded the kleboxymycin biosynthetic gene cluster associated with production of 
enterotoxins (tilimycin, tilivalline) known to be causative agents of non-C. difficile 
AAHC. All three strains encoded the complete 12-gene operon for the cluster. 
Further analyses showed the cluster to also be encoded by K. grimontii and ‘K. 
pasteurii’ isolates (Chapter 3). Previously, the cluster was thought to be unique to 
K. oxytoca. Faecal carriage of K. michiganensis may be more clinically important 
than K. oxytoca (Chen et al., 2019). Therefore, it is possible that K. oxytoca is not 
the only Klebsiella causative agent of AAHC, and laboratories may need to screen 
for presence of toxigenic Klebsiella isolates. Otherwise this could be a silent killer 
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if undetected from a clinical perspective. Further study is needed to investigate 
possible linkage between cytotoxin production and adverse clinical outcomes in K. 
michiganensis and K. oxytoca infections. From a clinical laboratory perspective, 
the only screening we do related to AAHC is for C. difficle toxin. Out of ~100 
samples screened each day, on average four to five will be confirmed C. difficle 
toxin-positive. It is plausible that some of the C. difficile-negative samples may 
harbour toxigenic K. oxytoca, K. michiganensis or related bacteria. I am hopeful 
that from the information generated in this study, clinical microbiologists and the 
infection control team review their policies to increase the range of organisms to 
screen in AAHC (and antibiotic-associated diarrhoea) samples. If so, a rapid 
method for screening samples, such as PCR kits or enzyme-linked 
immunoassays, would need to be developed for detection of the enterotoxins. 
Chapter 4 was dedicated to K. pneumoniae, as during the 2015 screening 
period, the majority of the Enterobacteriaceae isolated were shown by MALDI-TOF 
to be K. pneumoniae. Thirty-six of the isolates were characterised genomically. 
Thirty-five of the strains were found to be K. pneumoniae, while one was K. 
variicola subsp. variicola. This reinforces my comments in relation to the findings 
from Chapter 3: reference MALDI-TOF databases used in clinical laboratories 
need to be updated to provide accurate species identification and epidemiological 
data. 
Many studies have shown K. pneumoniae to be among the most frequent 
organisms causing HAIs worldwide. It is represented by the ‘K’ in the ESKAPE 
pathogens, the six most significant and dangerous causes of drug-resistant 
hospital infections identified by the Infectious Diseases Society of America 
(Pendleton et al., 2013). It has also been recognised by the World Health 
Organization, Centers for Disease Control and Prevention, European Union, and 
other organisations as a significant threat to global public health as many strains 
are MDR (WHO, 2014), causing hospital outbreaks that are especially associated 
with the carbapenem-resistant clones. K. pneumoniae is also the organism in 
which the most new MDR genes are being discovered, before becoming 
widespread in other Gram-negative bacterial pathogens. These include ESBL, with 
its derivatives SHV and CTX-M, the carbapenemases KPC and NDM, and most 
recently mcr-1, the first plasmid-borne gene to be associated with colistin 
resistance. 
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In this study, I characterised the K. pneumoniae population circulating in our 
Trust (clinically important phylogenetic lineage) using MLST, and analyses of AMR 
and virulence genes. ST14 was the most common strain type, which is 
unsurprising as a number of the strains in my collection came from an outbreak 
(Otter et al., 2017). The majority of ST14 (the cluster of outbreak strain at the West 
London Hospital Trust) belonged to the CG ST14/15 group capsular type K2, O 
antigen O1v1 with common resistance gene blaNDM-1, co-harbouring ESBL 
blaCTX-M-15 type, other β-lactamases blaSHV28, blaTEM-1 with quinolone and 
aminoglycoside resistance. Most of the outbreak cluster isolates also carried the 
virulence factor enterobactin or enterobactin with yersiniabactin, associated with 
PLA, belonging to the hypervirulent K. pneumoniae which are undergoing a global 
dissemination from the Asian Pacific. In fact, all 36 clinical isolates including the K. 
variicolla possessed all the virulence factors described by De Jesus et al., (2015) 
putting them under the hypervirulent strain category. Two isolates carrying 
blaKPC-3 gene belonging to the popular global outbreak CG ST258 and its 
derivative ST512 common in the United States were also amongst the collection 
together with ST43 (common in Europe) and ST147 (common in the middle east). 
This variation of strain types highlights the population diversity within the London 
area together with worldwide mobility (travel) bringing about carriage and spread 
of resistance. Other common carbapenemase resistance genes in this collection of 
clinical isolates were the blaOXA-48 with its variants blaOXA-232 and blaOXA-
181, the tests we employed at our laboratory were unable to detect the variants. 
Using the genomic database CARD, I was able to identify the presence of the 
pmrF operon and the KpnEF efflux (in all 36 isolates) which has been linked to 
colistin resistance and/or the potential to acquire colistin resistance, as well as 
identification of the genotoxin colibactin gene cluster in three of the K. pneumoniae 
isolates and its potential link to chronic inflammation and colorectal cancer in 
humans. 
This study using various genomic databases has allowed me to collect a 
wealth of information on Klebsiella spp. that are present in the West London area 
of UK. With this information a clinician can provide the best patient care and 
management which in turn can help infection control. 
This study has clearly shown WGS is able to yield unambiguous data that 
enables a complete analysis of the whole genome, including MDR and virulence 
	 
	
163	
genes as well as enabling more accurate characterisation. I expect WGS may 
ultimately become a highly powerful tool for both outbreak investigations and 
molecular characterisation of antibiotic resistance genes in routine clinical settings. 
However, WGS is still relatively expensive and requires an automated data 
interpretation system and a publicly available database. As such, routine 
implementation of WGS in clinical laboratories may not occur for several years but 
if this is the future then genomics and bioinformatics must be included as part of a 
Biomedical Scientists training.  
A part of my research was to isolate bacteriophages against these very 
MDR Klebsiella spp. from sewage water. To this end I isolated seven K. 
michiganensis phages with lytic activity against the three toxigenic GES-5-positive 
K. michiganensis isolates which showed wide host range with both lytic and 
depolymerase activities against a collection of clinically relevant Klebsiella 
isolates. Twenty four K. pneumoniae phages and one K. variicolla phage were 
also isolated and demonstrated broad host range against different MDR Klesiella 
clinical isolates (K. pneumoniae, K. grimontii, K.variicolla and K. michiganensis). 
Initial attempts were also made to isolate DNA of sufficient quantity and quality for 
restriction enzyme profiling and WGS to characterise the phages, with mixed 
results. Accordingly, said genetic characterisation of the phages from this study is 
ongoing, together with further phenotypic characterisation, as they may have 
therapeutic uses in AAHC treatment regimens and can potentially be used in a 
cocktail format to eradicate gut colonisation of MDR Klebsiella spp. 
Currently faecal microbiota transplantation (FMT) is used to restore normal gut 
microbiota in patients with C. difficile infection. Further studies are looking into 
whether FMT can be used to decolonise MDR organisms and prevent recurrent 
MDR infections (Saha et al., 2019). This study has shown the potential for phages 
to be used therapeutically for gut decolonisation. However, further research is 
required to investigate such applications, including in vivo (animal and human) 
trials of phage or phage cocktails. With the current antibiotics crisis there is an 
increased interest in phage research and discussion of its usage and introduction 
of rules are being talked about at the Committee for Medicinal Products for Human 
Use at the European Medicines Agency (EMA). This may lead to EMA introducing 
a new regulatory framework for phage therapy. At these discussions there is also 
a possibility of introducing policies regarding adaptive licensing to allow limited 
	 
	
164	
clinical use of phage therapy (Nilsson, 2014). Due to the lack of effective 
strategies to address the current unmet medical need for treatment of antibiotic-
resistant infections, and in the absence of approved alternatives, some clinicians 
are turning to empirical ones, such as phage therapy, for compassionate treatment 
which is approved by the Food and Drug Administration (McCallin et al., 2019). 
 
	CHAPTER 6: PERSONAL REFLECTION 
 
As I reflect on my journey while studying on the Professional Doctorate 
Programme (PDP), I also need to include the journey commencing before the 
course. The journey takes me back to 2005, when I attended a conference about 
bacteriophage (phage) and learned how one day these viruses would be useful to 
humankind. This subject really fascinated me, and I kept all the related documents 
in a secure place and thought to myself "I will come to this one day". At work I 
always expressed my interest in phage therapy to colleagues explaining that one 
day these bacteria-killing viruses may be our long-awaited solution to antibiotic 
resistance. 
Then one day in October 2013, the departmental training officer at Charing 
Cross Hospital asked me if I wanted to study further, and without hesitation I 
expressed my interest to enrol in the PDP. She agreed that I should enrol for the 
course which would allow me to carry out research on phage. That seemed 
appropriate at the time with so much antibiotic resistance in bacteria, phages could 
be the long-awaited solution to treating antibiotic-resistant infections. I did not 
waste any time and enrolled on to the PDP at the University of Westminster, 
knowing deep within my very being this was a divine intervention.  
I knew this was a big project I was taking on with being in full time 
employment at a senior level of great responsibility and with a family to take care 
of; I embarked on this great adventure with an inquisitive mind.  
 
6.1 Remaining persistent amid challenging situations/and how these 
challenges were overcome 
First, for any individual their main reason to embark on a PDP journey 
should be based on their true passion for research (in an area of interest) and 
academia and not based on any other interest. As when the rubber hits the road 
and when facing challenges, it is the passion for the research subject which will 
provide the fundamental driving force for you to carry on and not give up. This was 
true for me many times, as situations at work and changes in personal 
circumstances have been major challenge for me over the past 4 years. It has 
been incredibly difficult for me to get time off to complete my research. As I work 
for a very busy department with staff shotages it was difficult for my employers to 
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give me study time: both at the West London NHS Healthcare Trust (Imperial 
College London) and from my current employers (Frimley Health Trust).  
In addition to my work-place challenges, I have had a very difficult time over 
the past 18 months due to the ill health of my husband. In October 2017 he 
underwent a triple bypass heart operation and is still recovering from it. I have had 
to juggle my research with caring for him and working full time (in a new 
environment). All this has taken its toll on me and it was the passion for the 
research subject that kept me going. Another thing that helped me to overcome 
my challenges was building good relationships with my supervisors; which become 
an important factor that shaped the rest of my academic and personal life during 
PDP research. Dr McCartney allowing me to have space in her laboratory at the 
University of Reading (from September 2016) to do my work has been a great help 
to me. Without this I would not have been able to do my practical work nearer to 
home; so also saving time travelling. My work place does not have the necessary 
expertise or equipment that are necessary for the phage work. 
Another thing that caused concerns in the early years of the PDP was, 
although I knew clearly what my research aims and objectives were, I did not have 
all the necessary practical skills to carry out my work; i.e. methods of isolation of 
phages or the different kind of molecular methods, DNA extraction, genome 
sequencing and bioinformatics were all very new to me. But I was able to 
overcome these challenges by finding my supervisors, Dr Hoyles and Dr 
McCartney, were experts in these areas and we shared research interests. They 
provided me with the training and resources I needed to successfully carry out my 
research. In this way I was very fortunate to find a team of supervisors that 
matched and complimented my strengths and weaknesses as an individual. 
Especially as PDP taught modules were catered more towards the social sciences 
rather than clinical sciences, and the second year of the programme concentrated 
on research and various research methodologies aimed for social sciences. This 
period allowed me to begin to recognise and understand the various research 
methods but none of these methodologies were useful for my research. During this 
period, I relied heavily on my supervisors for support and guidance. 
Another challenge I had to overcome was how would I find the funding to 
cover my tuition fees and funding for the research expenses. I reflected on this 
and how I had felt at the time using the Gibbs Reflective Cycle (1988), my feelings 
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at this time were quite hopeless. On evaluation of the situation, I was already 
working full time and there were no funds to put aside for the studies. I presented 
my research ideas to colleagues and connections outside of work with no results. 
My breakthrough came when my employers (West London Imperial College 
Healthcare NHS Trust) approval of my Professional Doctorate; one of the 
conditions was that my project had to meet a need for the Trust. To this end, and 
as part of the Microbiology team at Charing Cross Hospital, I was asked to 
organise and run a large screening programme to identify a streamlined way of 
quickly identifying carbapenemase-resistant Enterobacteriaceae (CRE) present in 
patients admitted to acute wards (renal, paediatric intensive care) and all 
immunocompromised hospitalised patients treated within the five hospitals of the 
Trust. This involved screening patient samples on different growth media. The 
reason for needing a rapid, cost-effective, streamlined isolation procedure was 
because the Trust was experiencing an increase in antibiotic-resistant organisms 
(especially those resistant to carbapenems) and the Trust needed to satisfy 
surveillance requirements of Public Health England (PHE) for multidrug-resistant 
organisms. The successful completion of this task allowed the infection control 
team of the Trust to fund half of my tuition fee for the first two years of the PDP.  
In addition, before I could start the second part of my research to isolate 
phage that killed the collection of confirmed carbapenem isolates from the initial 
study, I had to find funding to cover research expenses. I started applying to 
different charities. When application forms were rejected there was a feeling of 
despair but success came when I was awarded funding by the Institute of 
Biomedical Science (IBMS) for my phage work (Appendix 3), and a summary of 
my work was published in the October 2016 edition of The Biomedical Scientist 
which bought about recognition of my work to a wider audience.  
As I embarked on the phage side of my research, changes had to be made 
to the original aims due to time restraints.  
Another milestone to overcome was in late 2017. I found a job nearer to 
home and moved to the Frimley Health Trust, so needed to get ethics approved to 
continue using my bacterial isolates after I had left West London Imperial College 
Healthcare NHS Trust. To my surprise approval was granted by the Tissue Bank 
at Imperial College without any opposition but one clause was that I must 
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acknowledge Imperial Trust Microbiology for the isolates in my thesis and any 
publications resulting from it.  
As I reflect on my PDP journey and how it has shaped me as a researcher, 
I can say at the end of it all I have produced a coherent 40,000+-word thesis with 
likely publication of my work in scientific journals. The research has produced 
results which are very promising and further work could bring about a therapy for 
carbapenem-producing organisms (CPOs) and will have succeeded in answering 
the initial research question; could phage therapy be used to eradicate the 
carriage of CPOs in the gut of healthy humans? 
On a personal level, the PDP has stretched me intellectually. During the 
past four years I have not just learned about my research topic but have also 
learned many core skills that I can apply to my job. It takes practice to become a 
good writer and communicator. My PDP student years have included much 
practice in writing funding applications (Appendix 3), poster presentation at 
conference (Appendix 2), reports and journal manuscripts, and also writing up the 
dissertation. The feedback I have received from my supervisors and peer 
reviewers has helped to improve my communication skills. And I am still learning 
and improving in this area. Research skills are valuable even in my field of work. 
As a trained researcher, I am now able to determine the best approach to a 
question, find relevant data, design a way to analyse it and make sense of my 
findings. My job also requires a great degree of project management. Finishing my 
dissertation requires me to design a project, make a realistic timeline, overcome 
setbacks, and manage stakeholders, which requires strong organisational and 
leadership skills. The PDP also helped me to improve my critical thinking skills as 
it trained me to approach problems systematically, see the links between ideas, 
evaluate arguments, and analyse information to come up with my own 
conclusions. PDP also allowed me to improve my skills in working with other 
people as doing tasks successfully requires knowing how to divide up a task and 
delegate, get along with others, communicate effectively (both in teams and also 
public speaking in the form of presentation), and resolve conflict.  
The emotional stretching came with the various demands on my life and the 
separate roles that I must fulfil (as a Senior Biomedical Scientist, a part time PDP 
student and as a family woman). With all this I still sustained my enthusiasm and 
stimulus by selecting a highly interesting and timely topic. My balanced 
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relationship with my supervisors and the clearly defined expectations and focus on 
the target, self-motivation, discipline, a good work ethic and time management 
helped me to achieve what I thought the impossible. 
One thing I have discovered within these four years about myself is that I 
am a researcher, I enjoyed the research aspects of the PDP. When looking in to 
the future, my deepest desire would be to continue with this research and succeed 
in completing to find a final answer for the research question. This may involve a 
change of career and looking for opportunities such as a postdoctoral research 
position in this area or similar. 
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APPENDIX 1 
Preprint version follows, which is available from PeerJ Preprints. 
 
Herridge, W.P., Shibu, P., O’Shea, J., Brook, T.C., Hoyles, L. (2019). 
Bacteriophages of Klebsiella spp., their diversity and potential therapeutic uses. 
PeerJ Preprints. 7, e27890v1 https://doi.org/10.7287/peerj.preprints.27890v1. 
 
The peer-reviewed version of the article was published after this thesis was 
examined. 
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Klebsiella spp. are commensals of the human microbiota, and a leading cause of 
opportunistic nosocomial infections. The incidence of multi-drug resistant (MDR) 
strains of Klebsiella pneumoniae causing serious infections is increasing, and K. 
oxytoca is an emerging pathogen. Alternative strategies to tackle infections caused 
by these bacteria are required as strains become resistant to last-resort antibiotics 
such as colistin. Bacteriophages (phages) are viruses that can infect and kill 
bacteria. They and their gene products are now being considered as alternatives or 
adjuncts to antimicrobial therapies. Several in vitro and in vivo studies have shown 
the potential for lytic phages to combat MDR K. pneumoniae infections. Ready 
access to cheap sequencing technologies has led to a large increase in the number 
of genomes available for Klebsiella-infecting phages, with these phages 
heterogeneous at the whole-genome level. This review summarises our current 
knowledge on phages of Klebsiella spp. and highlights technological and biological 
issues relevant to the development of phage-based therapies targeting these 
bacteria.  
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INTRODUCTION 
Klebsiella spp. belong to the family Enterobacteriaceae and are non-motile, capsulate, 
Gram-negative bacilli. Klebsiella pneumoniae is a commensal bacterium found in the 
gastrointestinal and respiratory tracts, and on the skin of healthy individuals. It is also 
ubiquitous in the environment. It is an opportunistic pathogen capable of causing a wide 
range of community-acquired and nosocomial infections such as urinary tract infections 
(UTIs), respiratory tract infections, and infections of wounds and soft tissue [1]. It has, in 
recent years, become one of the world’s leading causes of nosocomial infections with an 
increasing mortality rate, particularly in immunocompromised individuals, neonates and 
the elderly. It is also increasingly implicated in severe community-acquired infections such 
as pneumonia and meningitis [2]. Due to its widespread distribution and genetic make-up, 
K. pneumoniae has rapidly become a global threat to public health [3]. Similar to K. 
pneumoniae, Klebsiella oxytoca is an opportunistic pathogenic in humans, and is 
becoming increasingly associated with nosocomial infections, particularly in 
immunocompromised patients [4]. It is also acquiring antimicrobial resistance genes and 
is detected throughout the UK [5, 6]. Consequently, it is now considered the second most 
clinically important pathogen of the genus Klebsiella [4]. 
 
Given the reduction in the effectiveness of antimicrobial therapeutics to treat Klebsiella-
associated infections, alternative strategies must be developed in response. This literature 
review will focus on bacteriophages (phages) of Klebsiella spp. and their potential for use 
as alternative antimicrobial agents. 
 
Antibiotic resistance and Klebsiella spp. 
Antibiotic resistance is defined as the ability of a bacterium, such as K. pneumoniae, to 
resist the effects of antimicrobial drugs that it was previously sensitive to. The 
development of antibiotic resistance is a result of the evolutionary process of natural 
selection, by which pathogenic bacteria are able to overcome the selection pressure 
applied to them during antimicrobial treatment, rendering the drug less effective [7]. The 
first antibacterial agents were discovered between 1910 and 1935 [8–10] with the most 
famous being the discovery of penicillin by Alexander Fleming in 1929. Hailed as ‘magic 
bullets’ in the fight against infection, these first antibacterial agents paved the way for the 
discovery of almost all classes of antibiotics in use today [11]. 
 
Despite early evidence of the possibility for future antibiotic resistance [12] and warnings 
that unrestricted use could reduce their effectiveness [13], antimicrobials have been taken 
for granted. The continued overuse of antibiotics in both healthcare and agricultural 
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settings over the course of the last century has contributed to the evolution and 
emergence of antibiotic-resistant strains of Klebsiella spp. and other Gram-negative 
bacteria. 
 
K. pneumoniae strains are frequently resistant to extended-spectrum β-lactams such as 
penicillins and cephalosporins. Extended-spectrum β-lactamase (ESBL)-producing K. 
pneumoniae are able to target the β-lactam ring structure within antibiotic compounds, 
neutralising their antimicrobial activity [14]. Pathogenic ESBL-producing K. pneumoniae 
derive their antibiotic resistance enzymes most commonly from acquired genes such as 
SHV-5 and CTX-M-15 [14, 15]. Ever since ESBL-producing K. pneumoniae were first 
described by Knothe et al. [16] in Germany, K. pneumoniae carrying CTX-M-15 have 
spread throughout the world and are associated with a steadily increasing incidence of 
both nosocomial infections and, more recently, community-acquired infections with an 
increasing mortality rate [17–20]. 
 
ESBL-producing K. pneumoniae strains remain susceptible to the carbapenem class of 
antibiotics, which includes imipenem and meropenem. However, there is increasing 
incidence of K. pneumoniae infections caused by strains that have become resistant to 
even carbapenems. These multi-drug resistant (MDR) organisms are thought to have 
evolved in response to the increased use of carbapenems against ESBL-producing K. 
pneumoniae, with several independently evolved genetic elements conferring 
carbapenem resistance. Klebsiella pneumoniae carbapenemase (KPC) was first 
discovered in the United States [21] and has since spread to all other parts of the world 
[22]. 
 
In Europe, KPC was found to be the most common carbapenemase resistance gene in K. 
pneumoniae hospital-acquired infections (45%), followed by oxacillinase-48 (OXA-48-like) 
(37%), New Delhi metallo-β-lactamase (NDM) (11%), and Verona integron-encoded 
metallography-β-lactamase (VIM) (8%) [23]. In the UK, confirmed cases of KPC, OXA-48-
like, NDM, and VIM rose from 0 to 1 cases in 2007 to 661, 621, 439 and 86 cases, 
respectively, in 2015 [24]. The spread of OXA-48-like K. pneumoniae strains has occurred 
mostly in the Mediterranean and Northern Africa and is primarily spread via ST101 strains 
as a result of travel in the regions, whereas ST395 is associated with clonal outbreaks 
throughout Europe [25]. 
 
NDM carbapenemase-producers originated in India, primarily in strains of Escherichia coli 
and K. pneumoniae, and have spread throughout the world as a direct result of travel to 
		 174	
and from the Indian subcontinent [26, 27]. Nordmann et al. [27] showed that more than 
half of NDM isolates from the UK were from patients with a history of travel to India or 
Pakistan. The UK appears to have the highest concentration of NDM isolates in Europe 
currently [28].  
 
While MDR K. pneumoniae is itself a problem, its ubiquitous presence in both animal and 
human hosts, as well as in the environment, combined with its ability to acquire and 
maintain antimicrobial resistance plasmids and to pass those plasmids on to other Gram-
negative bacteria, puts it into a relatively unique position to be able to amplify the spread 
of antimicrobial resistance genes throughout the world [29]. The contribution of K. 
pneumoniae to the antimicrobial resistance crisis is difficult to quantify. However, a recent 
population genomics study has shown that within- and between-hospital spread of 
carbapenem-resistant K. pneumoniae is the major driver of expansion of these bacteria 
within Europe, with carbapenemase-resistant isolates concentrated in clonal lineages 
ST11, ST15, ST11 and ST258/ST512 and their derivatives [30]. K. pneumoniae (and 
likely K. oxytoca) will continue to play a key role in the development of antimicrobial 
resistance and is, therefore, a prime target for novel antibacterial therapeutics [29]. 
 
Risk factors for Klebsiella infections 
Primarily an opportunistic pathogen prevalent in the hospital setting, K. pneumoniae has 
become a common cause of hospital-acquired infections, such as UTIs and bloodstream 
infections (BSIs), in which antibiotic-resistant strains are becoming more difficult to treat 
and are associated with an increased mortality rate. Perhaps the most ubiquitous risk 
factors for all forms of hospital-acquired K. pneumoniae colonisation and infection are 
patient exposure to antibacterial agents and the length of hospital stay. Indeed, there 
consistently appears to be a positive correlation between the length of time a patient is 
required to stay in hospital and the chance of acquiring a K. pneumoniae infection simply 
due to the increased exposure to healthcare-associated pathogens with time [31–33]. 
Moreover, a considerable number of studies aimed at identifying risk factors associated 
with such infections recognise previous antibiotic treatment as an important factor, 
particularly the widespread use of cephalosporins in the case of ESBL-producing K. 
pneumoniae infection [34], and carbapenems, fluoroquinolones, glycopeptides and 
aminoglycosides for infections caused by carbapenemase-producing K. pneumoniae [31]. 
 
Not surprisingly, invasive procedures, such as surgical intervention and catheterisation, 
are also strongly associated with the acquisition of K. pneumoniae infection. Patients who 
are subject to invasive procedures such as the installation of a central venous catheter, for 
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example, are likely to be immunocompromised individuals who have been hospitalised for 
a severe underlying health condition. These patients are, therefore, particularly 
susceptible to opportunistic infections which could lead to a BSI, in the aforementioned 
example, soft tissue and wound infections in patients subject to surgical procedures, or 
even severe cases of pneumonia or meningitis in neonates [35, 36]. 
 
Clinical features of disease may also be an important risk factor in the development of K. 
pneumoniae infection. Meatherall et al. [37] identified chronic liver disease and cancer as 
being the most significant factors involved in the development of K. pneumoniae 
bacteraemia; several studies have evidenced a link between diabetes mellitus and 
invasive K. pneumoniae infection as a result of poor glycaemic control and subsequent 
bacterial resistance to phagocytosis [34, 38, 39]. Nouvenne et al. [32] suggested an 
association between cardiovascular, respiratory, renal and neurological diseases, and 
colonisation and infection by carbapenem-resistant K. pneumoniae. 
 
K. oxytoca is the causative agent of paediatric antibiotic-associated haemorrhagic colitis, 
caused by overgrowth of the bacterium with the release of cytotoxin when the intestinal 
microbiota is disturbed by antibiotic treatment [40, 41]. Likely due to a combination of 
improved detection methods [6], increased international travel [5], contaminated hospital 
equipment [5], increasing numbers of immunocompromised patients and more complex 
treatment regimens, K. oxytoca is being isolated more frequently from neonatal intensive 
care units than in the past, and is now also being found in a range of clinical samples from 
adult patients admitted to critical care centres. K. oxytoca is showing multidrug resistance 
and appears to have higher drug resistance compared with K. pneumoniae, though this 
requires further study [42]. 
 
Virulence factors of Klebsiella spp. 
K. pneumoniae, despite being considered an opportunistic pathogen, possesses an 
arsenal of virulence factors that enable the bacterium to both infect its host and resist the 
host immune response allowing it to cause severe disease. The most studied virulence 
factors associated with K. pneumoniae are the capsule, lipopolysaccharide (LPS), 
fimbriae and siderophores. 
 
The capsule is an extracellular matrix made up of strain-specific polysaccharides that 
surrounds the bacterium forming a thick fibrous structure. The capsular polysaccharides 
produced by K. pneumoniae are called K antigens and, given that the polysaccharide 
produced depends on the strain of K. pneumoniae, they have been traditionally used to 
		 176	
identify the strain using serological techniques [43]. The role of the capsule in human 
disease has been studied extensively and it is thought to have a defensive role by 
providing protection against phagocytic immune cells, blocking complement-mediated 
lysis and reducing levels of proinflammatory cytokines [44, 45]. Indeed, the virulence of K. 
pneumoniae is greatly reduced in the absence of a capsule, as shown by infection of mice 
with acapsular mutants [46], and greatly increased in so-called hypervirulent strains which 
produce more capsular material resulting in a hypermucoviscous phenotype [2]. 
 
The LPS is composed of an O antigen, an oligosaccharide core and lipid A, and protrudes 
from the bacterial membrane [47]. The primary role of LPS in K. pneumoniae infection is 
protection from the complement-mediated lysis of bacterial cells by binding of the 
complement component C3b away from the bacterial membrane, preventing the formation 
of the membrane attack complex C5b-9. This is carried out by the O antigen of the LPS 
which, when absent, makes K. pneumoniae more susceptible to complement-mediated 
bacterial lysis [48]. 
 
K. pneumoniae expresses fimbriae which are membrane-adhesive protrusions involved in 
the adhesion of the bacterium to host surfaces facilitating its invasion. Two main types of 
fimbriae are exhibited by K. pneumoniae: type 1 fimbriae which are filamentous, and type 
3 fimbriae which are helix-like in shape [49]. Moreover, the expression level of each type 
varies depending on the surface to which the bacteria attach. Type 1 fimbriae are 
expressed in the urinary tract and the bladder, but not in the gastrointestinal tract or the 
lungs [50]. Struve et al. [50, 51] speculate that the downregulation of type 1 fimbriae may 
be because it reduces the ability of K. pneumoniae to penetrate the intestinal mucus layer 
in the gastrointestinal tract, as is seen with E. coli; whereas in the lungs, selection against 
fimbriated cells occurs due to rapid elimination by phagocytes. Type 3 fimbriae bind to 
extracellular matrices and medical devices, and are important for the development of 
biofilms [51]. 
 
Finally, K. pneumoniae must acquire iron from the environment to grow and multiply. 
There is very little free iron to be found in mammalian hosts, so the bacterium must 
express siderophores. These are molecules that have a higher affinity for iron than 
mammalian iron transport molecules, such as transferrin, enabling the bacteria to obtain 
iron for rapid growth and subsequent invasion. The primary siderophore expressed by K. 
pneumoniae is enterobactin, expressed in the majority of pathogenic strains; however, 
salmochelin, yersiniabactin, colibactin and aerobactin can also be expressed. Indeed, 
hypervirulent strains of K. pneumoniae are able to express multiple siderophores and are 
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particularly associated with the expression of salmochelin, yersiniabactin, colibactin and/or 
aerobactin [52]. 
 
Genetic diversity of clinically relevant Klebsiella spp. 
In keeping with the diversity of its virulence factors, antibiotic resistance mechanisms and 
clinical presentations, strains of K. pneumoniae also possess highly diverse and flexible 
genomes capable of producing considerable phenotypic variation. Indeed, the diversity of 
K. pneumoniae is such that the species is widely accepted to exist as four distinct 
phylogroups: KpI, KpII-A, KpII-B and KpIII, which have been suggested to have diverged 
into three distinct species: K. pneumoniae (KpI), K. quasipneumoniae (KpII) and K. 
variicola (KpIII) [52]. 
 
In their whole-genome sequencing and pangenome-wide association study, Holt et al. [52] 
found that severe community-acquired infections were more often caused by phylogroup 
KpI that expressed siderophores and ‘regulators of mucoid phenotype genes’ rmpA and 
rmpA2, which regulate capsule production. Moreover, their study also confirmed the 
presence of SHV, OKP and LEN β-lactamases as core chromosomal genes of all 
phylogroups, whereas acquired antibiotic-resistance genes were more commonly found in 
KpI and KpII commensal isolates compared to either hospital-acquired or community-
acquired infection isolates, suggesting antibiotic resistance plays more of a role in 
opportunistic hospital-acquired infections caused by commensal K. pneumoniae, whereas 
more severe community-acquired infections are caused by strains enriched with virulence 
factors such as siderophores and increased capsular production. 
 
Hypermucoviscous strains of K. pneumoniae – i.e. those that exhibit virulence genes such 
as yersiniabactin and rmpA – were first described in Southeast Asia and are commonly 
associated with community-acquired pyogenic liver abscess [53]. These hypervirulent 
strains very rarely exhibit the antibiotic resistance gene profiles commonly associated with 
opportunistic hospital-acquired infections, and until recently have remained treatable with 
antibiotics [54]. However, K. pneumoniae isolates with combined hypervirulence and 
antibiotic resistance are emerging. Given the highly diverse genome of the species, and 
the increasing selective pressures being applied to them in the form of antibiotics, 
hypervirulent antibiotic-resistant K. pneumoniae is threatening to become untreatable [52, 
54]. 
 
A pangenome study of K. oxytoca strains isolated from bloodstream infections the UK and 
Ireland showed that K. oxytoca has a highly diverse population, composed of several 
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distinct phylogroups (KoI, KoII, KoV, KoVI) [5]. It shares numerous antimicrobial genes 
and mechanisms with K. pneumoniae. K. oxytoca has been far less studied than K. 
pneumoniae, and extensive studies of its global epidemiology are required [5]. 
 
PHAGES OF KLEBSIELLA SPP. 
A phage is a virus that infects bacteria and, as such, is found in all environments where 
bacteria would normally thrive. Viruses were initially suggested as a possible cause of 
clear zones on bacterial culture plates by William Twort in 1915, and in 1917 Felix 
d'Herelle confirmed this discovery, coining the term ‘bacteriophage’ [55, 56]. Prior to the 
discovery of the first antimicrobial agents, phages were considered the cure for bacterial 
infections and d’Herelle performed the first experimental phage therapy using an oral 
phage solution to treat dysentery [57]. However, after the discovery of antimicrobial 
compounds such as penicillin, the therapeutic uses of phages were largely left alone due 
to the subsequent success of the antibiotic era. Phages remained useful, however, for 
scientific research as tools to improve our understanding of molecular biology, horizontal 
gene transfer and bacterial evolution, and as diagnostic tools [58]. More recently though, 
given the rise in the number of MDR infections caused by bacteria such as K. 
pneumoniae, the use of phages has again come to the forefront as a potential alternative 
to current antimicrobial chemotherapies. 
 
Life cycles 
Phages primarily have two distinct life cycles they are able to adopt in order to reproduce: 
the lytic cycle and the lysogenic cycle. Both life cycles begin with the attachment of a 
phage to the surface of the bacterial host, followed by the subsequent injection of the 
phage’s genetic material into the cell. In the lytic life cycle, the viral genome produces 
proteins that initiate the degradation of the bacterial genome, allowing the viral genetic 
material to take control of the host cellular machinery for the sole purpose of replicating 
the viral genome, synthesising viral proteins and assembling those proteins into viable 
phage particles that are released from the bacterial cell in large numbers, destroying the 
host. The phages that are released are then able to continue infecting bacteria nearby. In 
the lysogenic life cycle, the viral genetic material is incorporated into the bacterial DNA, 
forming a prophage, and is replicated passively upon replication of the bacterial genome 
without destroying the host. Prophages in the lysogenic cycle are able to enter the lytic 
cycle under certain conditions (e.g. in the presence of environmental stressors), and begin 
actively replicating and producing viable phages at the expense of the host [59]. 
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Although the lytic/lysogenic phage life cycle is a well-established concept in phage 
biology, we now know there are multiple phage life cycles. Pseudolysogeny is the process 
by which the phage genome enters a bacterial host but neither stably establishes itself as 
a prophage nor initiates a destructive replicative response, remaining inactive and 
possibly awaiting more desirable environmental conditions for viral replication [60]. 
Chronic infection, resulting in the shedding of phage particles over long periods of time 
without destruction of the host cell, can occur with infection of filamentous phages in 
Mycoplasma [47]. Finally, the carrier state life cycle occurs when a heterogeneous 
population of bacteria, containing individuals both sensitive and resistant to a given lytic 
phage, leads to the destruction of sensitive bacteria and the survival of resistant bacteria 
creating a stable equilibrium between viral and bacterial propagation [60]. 
 
In the context of using phages as a therapeutic alternative to antimicrobial chemotherapy, 
those that reliably employ the lytic life cycle to reproduce are most suitable given that the 
end result is the destruction of bacterial host cells. Additionally, phages that are able to 
switch between multiple life cycles may not make reliable treatment options due to the 
possibility of dormancy and subsequent re-establishment of bacterial infection. This is just 
one aspect of comprehensive phage characterisation that is an important consideration 
when choosing appropriate phage treatments. 
 
Phage characterisation 
Phages of K. pneumoniae have been isolated from a variety of sources worldwide 
including wastewater, sewage, seawater and human intestinal samples, and belong to 
one of three families of the order Caudovirales (Table 1). These families make up the 
entirety of the order and are described as non-enveloped, tailed phages, with icosahedral 
heads containing double-stranded DNA: Myoviridae are characterised by long, straight, 
contractile tails; Siphoviridae by long, flexible, non-contractile tails; and Podoviridae by 
short, non-contractile tails [61]. 
 
Genomic comparisons of lytic K. pneumoniae phages of the order Caudovirales highlight 
a variety of useful similarities and differences. The expression of polysaccharide 
depolymerases, for example, has been observed in several recently discovered phages of 
K. pneumoniae [62–64] and these enzymes have a role in the degradation of the capsule 
surrounding the exterior of the bacterium. The breakdown of the capsule by phage 
depolymerases has been purported to combat K. pneumoniae biofilms [65] and increase 
the susceptibility of the bacterium to antibiotics, phage infection and the immune system 
[64]. Additionally, phage depolymerase action can be observed in the laboratory with the 
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production of ‘haloes’ around clear zones of lysis on bacterial culture plates after infection 
of K. pneumoniae with phage particles. This has become the basis for important 
laboratory methods used in the characterisation of novel phages, revealing phage 
specificity and host range [66]. 
 
Moreover, differences observed among Myoviridae, Podoviridae and Siphoviridae can be 
useful for preliminary identification. For example, sequence analysis reveals that 
Myoviridae tend to have a much larger genome size and a smaller GC content compared 
to Podoviridae and Siphoviridae (Table 1). Restriction analysis, which uses bacterial 
restriction enzymes to digest phage DNA, can also help to estimate the size of the phage 
genome in addition to identifying those that are already known to science prior to 
extensive characterisation, and analysis by transmission electron microscope is able to 
reveal morphological characteristics such as phage tail structures [64]. Phylogenetic 
analyses show several Klebsiella phages belong to accepted genera within the 
Siphoviridae, Podoviridae and Myoviridae, while others belong to new lineages with – as 
yet – no standing in viral taxonomy (Figure 1, Supplementary Material). 
 
Specificity and host range 
To infect its host, a lytic phage must first attach itself to a susceptible bacterial cell. It 
achieves this by recognising and binding a specific receptor on the surface of the host 
cell. This interaction between the phage tail structure and host receptor allows the phage 
to both identify susceptible bacteria and position itself for injecting its genetic material into 
the cell. Adsorption to the host can occur via any external structure depending on the 
phage and host, but in Gram-negative bacteria, such as K. pneumoniae, these can 
include the capsule, pili, outer membrane proteins, sugar moieties or LPS [67]. This 
process, therefore, determines host range, i.e. the breadth of hosts that any given phage 
can infect. 
 
D'Andrea et al. [68] showed that their newly discovered lytic phage φBO1E was able to 
specifically target KPC-producing K. pneumoniae of the pandemic clonal group 258 
(CG258) clade II lineage, but not those of the closely related clade I lineage, due to the 
recognition and targeting of specific capsular polysaccharides present on strains 
belonging to clade II. In contrast, Verma et al. [69] found that the lytic phage KPO1K2, 
specific for K. pneumoniae B5055, could infect multiple strains of K. pneumoniae as well 
as some strains of E. coli and, therefore, has a relatively broad host range compared to 
the clade-specific phage φBO1E. 
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It is generally considered, in the context of their therapeutic use, that lytic phages with a 
broad host range (e.g. at genus or species level) are more beneficial in combatting 
bacterial infection than those with a narrow host range (e.g. at strain level). Phages with a 
narrow host range are inappropriate for presumptive or prophylactic treatment, for 
example, and would rely on identification of an infective agent prior to treatment. 
Additionally, even phages considered to have a broad host range would generally have a 
narrower spectrum of activity compared to antibiotics [70]. Therefore, efforts to increase 
the spectrum of activity of phage treatment has led to the development of phage cocktails, 
to increase the host range by using multiple phages in a single treatment [71], and even 
the hybridisation of phage tail structures to increase the host range artificially [72]. 
 
THERAPEUTIC POTENTIAL OF KLEBSIELLA PNEUMONIAE PHAGES 
There are a number of considerations to be made when selecting phages suitable for use 
as therapeutic antimicrobial agents. Firstly, phages must be effective in killing K. 
pneumoniae. During phage characterisation, in vitro assessments of phage lysis and burst 
size are carried out on cultures of K. pneumoniae. Phages that produce rapid lysis of a 
bacterium and release large numbers of phage particles will produce large clear plaques. 
Moreover, phages with a broad host range are generally considered more useful than 
those with narrow host range so that multiple strains may be targeted at once [73]. 
Secondly, lytic phages, due to the nature of their life cycle, clear bacteria quickly and 
efficiently compared to lysogenic phages, which integrate their genetic information into the 
host genome and remain dormant for an unspecified amount of time. In addition, 
lysogenic phages may transfer genes into the host that can confer toxin production and 
antibiotic resistance traits to the bacterium, thus making the infection more virulent and 
difficult to treat [73]. 
 
In vivo experimentation 
Following in vitro investigations, the safety and effectiveness of any new therapeutic 
candidate must be measured in a suitable animal or insect model prior to human trials. In 
the case of K. pneumoniae phage research, mouse models have been used to investigate 
the effect of phage treatment against wound and soft tissue infections [74], pneumonia 
[66], liver abscesses [76] and bacteraemia [77], closely mirroring the spectrum of disease 
caused by the bacterium in humans. More recently, Galleria mellonella larvae have been 
used to test the efficacy of lytic phages and phage-encoded products to clear K. 
pneumoniae infections [78–80]. 
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Kumari and colleagues have carried out a series of murine-based experiments aimed at 
identifying the therapeutic potential of the K. pneumoniae phage Kpn5. Isolated as one of 
five phage candidates (Kpn5, Kpn12, Kpn13, Kpn17, and Kpn22) from samples of sewage 
[81], Kpn5 was found to be the most effective, compared to the other four, when used to 
treat burn wound infections caused by K. pneumoniae B5055 in BALB/c mouse models 
[82]. When administered by intraperitoneal injection, Kpn5 produced an average 96.66% 
survival rate compared to the negative controls which had a survival rate of 0% [83]. 
Additionally, when compared to topical treatments with both natural products (honey and 
aloe vera gel) [84] and antimicrobial agents (silver nitrate and gentamicin) [85], Kpn5 was 
found to be superior in both cases, providing a higher level of protection and reduced 
mortality rates. However, despite the promising results that this research group has 
produced, the authors note the possibility of K. pneumoniae forming resistance to Kpn5, 
as highlighted in their in vitro experiments, and provide no data on phage host range, 
having used only a single strain of K. pneumoniae throughout their studies. 
 
The delivery method of phage treatment is also an important consideration. For example, 
intraperitoneal injection is rarely used in human treatment given the relative ease of 
intravenous injection in most cases. In experiments carried out to treat murine lobar 
pneumonia, Cao et al. [75] determined that intranasal delivery of phage 1513 was able to 
produce a survival rate of 80% in the Swiss-Webster mouse model, compared to 0% of 
negative controls, 2 h after nasal inoculation of MDR K. pneumoniae 1513 as well as 
visibly reduced lung injury, in comparison to negative controls. Chhibber et al. [83] 
demonstrated that intraperitoneal injection of phage SS administered immediately after 
intranasal inoculation of K. pneumoniae B5055 into BALB/c mice resulted in complete 
clearance of bacteria in 5 days, compared to 10 days in untreated mice, although the 
authors state that even a short delay of 6 h post inoculation rendered treatment 
ineffective. However, Singla et al. [86] found that phage KPO1K2, encased in a liposome, 
was effective in treating lobar pneumonia induced in BALB/c mice by intranasal 
inoculation of K. pneumoniae B5055, even when phage treatment was delayed by up to 3 
days. 
 
Although there is a difference in the choice of phage in these published reports, and so 
studies cannot be compared directly, it does highlight the importance of investigating 
differing delivery methods of phage treatment, not only in a logistical sense but also in 
elucidating the most efficient method of delivery according to the type of infection and the 
length of incubation prior to treatment. Moreover, these studies have each measured the 
in vivo effect of phage treatment against only one strain of K. pneumoniae, providing no 
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information regarding phage host range. Further experiments should, therefore, seek to 
determine whether the host range(s) of their respective phages are broad enough to be 
considered useful for therapeutic purposes. 
 
While several studies have reported successful use of K. pneumoniae phages to clear 
infections in murine and Galleria models, the effects of phage infection on the microbiome 
(i.e. microbiota, metabolome) must now be considered when assessing phages 
(individually or as phage cocktails) as a viable treatment or patient decontamination 
measure. Hsu et al. [87] showed that infection with lytic phages caused an increase in 
phage resistance (28% to 68%) in a known bacterial population common to the human gut 
microbiota. Quantitative shifts in sensitive and non-sensitive strains were seen, 
highlighting the system-level effect of phage infection. Phage infection did not necessarily 
clear the target species but instead modulated the ecosystem towards a more stable gut 
environment. Phages inducing simultaneous knockdown of Enterococcus faecalis and 
Bacteroides fragilis populations had little effect on the microbiota compared with 
Escherichia coli and Clostridium sporogenes phages, which caused significant decreases 
(106 per gram stool) in Bacteroides vulgatus, Proteus mirabilis and Parabacteroides 
distasonis populations, and 108 per gram stool decreases in Akkermansia muciniphila and 
Bacteroides fragilis populations. Perturbation of the microbiota by phages also affected 
the metabolome. Abundance of 17% of examined compounds was altered significantly in 
the presence of phages. During initial phage infection, Hsu et al. observed a 10-, 17-, and 
2-fold reduction in tryptamine, a microbiome-associated metabolite known to play a role in 
accelerating gastrointestinal transit in mice [88]. This led them to suggest phage infection 
could be used to modulate the microbiome in a targeted manner to influence systemic 
health. 
 
Combination therapy 
A number of in vitro experiments have identified the possibility of bacterial resistance 
arising as a result of phage therapy [71, 75, 81, 89, 90]. To reduce the emergence of 
phage-resistant strains of K. pneumoniae during treatment, research has begun to explore 
combination therapy either by using phage cocktails or combining phage treatment with 
antibacterial drugs. 
 
Gu et al. [71] generated a phage cocktail (i.e. a combination of phages that have different 
but overlapping host specificities) made up of three lytic phages (GH-K1, GH-K2 and GH-
K3) specific to K. pneumoniae strain K7. The authors found that co-culture of K7 with the 
phage cocktail produced fewer phage-resistant variants of K7 and a more efficient 
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reduction in bacterial load compared to cultures treated with a single phage. Moreover, 
when treating bacteraemic mice, produced by intraperitoneal injection of K7, the phage 
cocktail produced a significantly lower blood bacterial count and enhanced mouse survival 
rates compared to mice treated with individual phages. A similar phenomenon was seen 
by Chadha et al. [89], who aimed to resolve K. pneumoniae B5055 burn-wound infections 
in BALB/c mice and found that their phage cocktail (made up of Kpn1, Kpn2, Kpn3, Kpn4 
and Kpn5) induced a greater decrease in bacterial load compared to treatment with 
individual phages and a complete bacterial clearance in a shorter time. 
 
Finally, in combining a lytic phage with ciprofloxacin against K. pneumoniae biofilms, 
Verma et al. [91] demonstrated a reduction in the development of both phage-resistant 
and ciprofloxacin-resistant K. pneumoniae strains, as well as having an enhanced effect 
against bacterial biofilms compared to individual treatments. 
 
Human trials 
The progression of phage research from in vivo experimentation to clinical trials involving 
humans has generated some friction among regulatory bodies in Western countries. 
However, countries in Eastern Europe and the former Soviet Union have routinely used 
phages in their healthcare systems for many years [92]. For example, the Eliava Institute 
of Bacteriophages, Microbiology and Virology in Georgia, and the Hirszfeld Institute of 
Immunology and Experimental Therapy in Poland both produce and supply phage 
therapeutic products specifically for routine human use [93]. 
 
In the West, regulatory issues surrounding the use of phages as therapeutic agents has 
hindered progress somewhat. It is not that there are specific regulations that prevent the 
use of phages in this way, but rather a lack of regulation that has placed limitations on 
progress. The unique nature of phages compared to traditional therapeutic agents, as 
evolving and self-replicating biological entities, requires them to have new rules and 
regulations regarding their safety, production and use. It is this lack of regulation in the EU 
and the UK, combined with a lack of interest from pharmaceutical companies, and the 
concept of personalised medicine often associated with phage therapeutics, which in itself 
is a new method of infection control, that makes approval for human trials a lengthy and 
difficult process [94]. However, it should be noted that the Belgian government has 
introduced a pragmatic framework that facilitates tailored phage therapy (magistral phage 
regulatory framework) allowing non-authorized phage products to be prepared by a 
pharmacist, for a given patient in line with a prescription from a physician and complying 
with relevant standards [95]. Phages are very occasionally and only under exceptional 
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circumstances used therapeutically in the wider EU under the umbrella of Article 37 
(Unproven Interventions in Clinical Practice) of the Declaration of Helsinki [95]. 
 
Despite these regulatory hurdles, a limited number of human trials have been carried out 
in relation to phage therapy, although none have specifically targeted K. pneumoniae. 
Rhoads et al. [96], based in the USA, carried out a phase I clinical trial on 42 patients with 
chronic venous leg ulcers to investigate the safety of a phage preparation specific to 
Pseudomonas aeruginosa, Staphylococcus aureus and E. coli. The authors reported no 
adverse effects of phage treatment. In the same year, Wright et al. [97], based in the UK, 
carried out a phase I/II clinical trial to determine the safety and efficacy of their phage 
product targeting P. aeruginosa in chronic otitis. Their study involved 24 patients with 
chronic otitis and showed a reduction in P. aeruginosa counts and, again, no adverse 
effects of phage treatment. Although consisting of a small sample size, the apparent 
success of these first human trials did little to prompt changes to the regulatory obstacles 
currently associated with phage therapy. 
 
Future directions 
Phage therapy shows promise as a potential response to the continued development and 
spread of MDR K. pneumoniae. In vitro and in vivo studies have confirmed the potential 
for phages to be used individually, as phage cocktails and in combination with current 
antimicrobial chemotherapeutic drugs. Moreover, the routine use of phage therapy in 
Eastern Europe, and the results from the small number of human trials that have been 
carried out in the West, suggest that phages are generally considered safe for use in 
humans. However, the lack of progress toward amending EU and UK regulations to 
account for phage therapy has hampered progress. The focus of future direction in the 
area of phage research must be to overcome this obstacle. 
 
USING PHAGE-DERIVED GENE PRODUCTS 
Another avenue of phage research aimed at finding therapeutic solutions to MDR K. 
pneumoniae is the potential to use specific phage gene products rather than phages 
themselves to combat infection. This kind of treatment could be advantageous in that it 
would be easier and quicker to gain clinical approval of a recombinant protein product 
over the direct use of phages. Indeed, phage-derived recombinant proteins may be used 
to directly combat infections caused by bacteria such as K. pneumoniae, or as part of a 
combinatory approach to complement or enhance current antimicrobial regimes. 
 
Phage proteins 
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In the lytic life cycle of an infecting phage particle, there are a number of proteins that the 
phage can use to ensure successful adsorption, infection, replication and release of 
progeny. In terms of potential antimicrobial agents against K. pneumoniae, there are a 
number of biologically interesting proteins to consider. Peptidoglycan hydrolases and 
polysaccharide depolymerases are normally present on the tail spikes of a phage particle 
and are involved in successfully infecting a bacterium after adsorption. Polysaccharide 
depolymerases degrade the macromolecular carbohydrates that make up the capsule 
surrounding the bacterial cell wall, whereas peptidoglycan hydrolases break down the 
peptidoglycan layer to penetrate the cell wall and access the cytoplasm to allow the phage 
to deposit its genetic material [98]. 
 
Holins, endolysins and spanins are proteins that are produced after the infection of a 
bacterium, and are involved in the process of cell lysis whereby assembled phage 
particles ‘burst’ from the cell in order to spread and continue the infection cycle. Holins are 
hydrophobic transmembrane proteins that mediate the permeabilisation of the inner cell 
membrane. This cannot independently cause cell lysis; however, it allows endolysins and 
spanins to translocate from the cytoplasm, where endolysins degrade the peptidoglycan 
layer in between the inner and outer cell membranes, and spanins disrupt the outer cell 
membrane present on Gram-negative bacteria. This is followed by bacterial cell lysis via 
osmolysis [98]. 
 
Polysaccharide depolymerases 
The capsule of K. pneumoniae is an important virulence factor and allows the bacterium to 
avoid phagocytosis and complement-mediated lysis. It is, therefore, a prime target for 
recombinant phage-derived proteins and has been studied extensively. For example, tail 
tubular protein A (TTPA), a structural tail protein of phage KP32, was shown to have 
additional polysaccharide depolymerase activity. Pyra et al. [99] cloned and expressed 
TTPA in E. coli and determined its enzymatic activity by agar spot tests on lawns of K. 
pneumoniae PCM2713, which produced translucent zones of reduced growth. 
Subsequent microscopic analysis of treated and untreated K. pneumoniae revealed cells 
treated with TTPA were stripped of their capsules. In a similar process of cloning, 
expression and agar spot-testing, Pan et al. [100] discovered nine polysaccharide 
depolymerases expressed by phage ΦK64-1, each of which demonstrated activity against 
a specific capsular type of K. pneumoniae which corresponded to the broad host range of 
the phage itself. This is interesting because not only does it confirm the role of enzymes 
such as polysaccharide depolymerases in the determination of phage-host specificity, but 
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it also lends the idea of artificially generated cocktails of recombinant enzymes that can 
target a wide range of K. pneumoniae strains. 
 
A number of in vivo experiments have also been carried out investigating the effect of 
polysaccharide depolymerases on K. pneumoniae infection. Majkowska-Skrobek et al. 
[80] identified, cloned and expressed a KP36-derived capsule depolymerase, depoKP36, 
which produced haloes on lawns of K. pneumoniae in agar spot-tests. The authors tested 
the ability of depoKP36 to treat infection caused by K. pneumoniae in Galleria mellonella 
and found that 100% of the larvae died without treatment, up to 40% survived when 
treated with depoKP36 post infection, and depoKP36 treatment of bacteria prior to 
infection resulted in only a 23% death rate. These results suggest that the decapsulating 
action of depoKP36 on K. pneumoniae produced a decreased ability of the bacterium to 
resist the host immune response. This was confirmed in subsequent research [101]. 
 
Endolysins 
Endolysins have been studied extensively for use against Gram-positive bacteria, due to 
the absence of an outer cell membrane found in Gram-negative bacteria such as K. 
pneumoniae which would normally hinder the action of the enzyme in the absence of 
spanins. However, recent research has produced some promising results regarding the 
use of endolysins against Gram-negative bacteria also. Maciejewska et al. [102] produced 
a recombinant endolysin from the K. pneumoniae phage KP27 and analysed its 
peptidoglycan-degrading activity on a range of Gram-negative bacteria, including strains 
of K. pneumoniae, P. aeruginosa, Salmonella enterica and E. coli, by co-incubation of 
bacteria and endolysin. The recombinant enzyme successfully lysed all strains of bacteria 
that were tested. However, the outer membrane of bacteria was permeabilised prior to 
endolysin treatment. This suggests that any potential endolysin-based infection control 
agents require mixing with outer-membrane-permeabilising agents to be effective against 
K. pneumoniae [102]. 
 
To overcome the need for additional outer-membrane-permeabilising agents during 
treatment of Gram-negative bacterial infections, artificial lysins (Artilysins) have been 
developed by the fusion of a phage endolysin with an outer-membrane-destabilising 
peptide [103]. Artilysins specific for K. pneumoniae have yet to be developed, but they 
have been successfully created for use against P. aeruginosa [104] and Acinetobacter 
baumannii [105]. This technology opens up the possibility of developing artificial 
endolysins for use in human therapy against not only MDR K. pneumoniae but also MDR 
Gram-negative infections. 
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Further research 
Recombinant polysaccharide depolymerases and artificial endolysins have the potential to 
be used as therapeutic agents in the fight against MDR K. pneumoniae. Polysaccharide 
depolymerases are able to degrade the capsule, an essential virulence factor of K. 
pneumoniae, which could find uses such as boosting the host immune response against 
the bacterium, and breaking down biofilms to allow current antibiotic regimes to more 
easily access bacterial cells. Artificial endolysins have the potential to work against 
infection as an independent antimicrobial agent. Further research is required in this area 
to fully realise the potential of such phage-derived recombinant proteins, and in doing so 
the mechanisms by which they are able to inhibit bacterial growth and/or eliminate 
infection may lead to new breakthroughs. Importantly, an obvious advantage over phage 
therapy is that recombinant protein products for use in humans have well-defined and 
established rules and regulations regarding their production, safety and use in the EU and 
UK, whereas phage therapy does not. 
 
CONCLUDING REMARKS 
The increasing incidence of hospital-acquired and community-acquired infections caused 
by MDR K. pneumoniae and hypervirulent K. pneumoniae, respectively, is rapidly 
becoming a global threat to public health. The emergence of strains that are both MDR 
and hypervirulent is even more of a concern. K. pneumoniae is becoming as much of a 
threat today as its non-resistant counterparts were over a century ago prior to the 
discovery of antimicrobial compounds such as penicillin. In response, research efforts 
have begun to look back in time at a once-abandoned approach to bacterial infection, 
namely phage therapy. It is becoming increasingly clear that there is potential for phages 
and their gene products to become novel sources of antimicrobial strategies against MDR 
bacteria for which current treatment regimens are simply becoming ineffective at 
countering. However, the field of phage therapy is still very much in its infancy and is 
fraught with difficulties, both novel and familiar. 
 
Safety 
One of the major obstacles facing phage therapy are the novel safety implications 
regarding the use of self-replicating biological entities in humans. For example, it is 
evident that phages are capable of carrying antibiotic resistance [106] and toxin-encoding 
[107] genes that could be transferred to the target bacterium via the process of 
transduction. Proper characterisation is, therefore, important when considering phages for 
therapeutic uses, and the presence of potentially harmful genes is commonly screened for 
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during this process. However, the absence of harmful genes does not guarantee phage 
safety. 
 
For example, the nature of a lytic phage is to increase its number at the expense of 
bacterial hosts. While this is the primary aim of phage therapy, little research has been 
conducted regarding the potential side-effects of this phenomenon. This is an important 
consideration because phages with a broad host range, or those within a phage cocktail, 
are often considered more appropriate for phage therapy. It is evident from the recent 
work of Hsu et al. [87] that introduction of even a single phage into the mouse microbiota 
can have effects on the microbiome. What effect might therapeutic use of phages have on 
the normal microbiota of a human? Might it be safer to use individual phages, with a 
narrow host range, to minimise disruption of the commensal microbiota? If so, phage 
therapy will rely on very specific identification of infecting bacteria, and having the correct 
phage available for treatment. Or perhaps this particular side effect may be deemed 
acceptable, as is the case with current antibiotic regimens. Additionally, the number of 
clinical trials that have assessed the safety of phage therapy in humans is limited, and 
those that have occurred have consisted of small sample sizes and often rely on patient-
generated data [93]. 
 
Practicality 
The second barrier that must be overcome are the practical issues associated with phage 
therapy in the EU and UK. As discussed earlier, the regulations required to govern the 
safety, production and use of virus-based infection control mechanisms do not currently 
exist. The last attempt at tackling these regulatory hurdles came in the form of a phase II 
clinical trial funded by the European Commission. “Launched in 2013 and achieved in 
2017, PhagoBurn was the world first prospective multicentric, randomised, single blind 
and controlled clinical trial of phage therapy ever performed according to both Good 
Manufacturing (GMP) and Good Clinical Practices (GCP)” [108]. Although the project 
attempted to define appropriate practices for phage therapy during its assessment of 
efficacy and tolerability of phage-treated burn-wound infections [109], only temporary 
allowances were made. While recommendations for subsequent clinical trials were given, 
no further regulatory improvements have been attempted. 
 
Moreover, if regulations are updated to account for phage therapy, where would 
producers of phage products stand in relation to intellectual property? Can naturally 
occurring biological entities be patented and sold, or would this be reserved for phage 
cocktails and phage–drug combinations that exhibit ‘unnatural’ antimicrobial properties? 
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Indeed, in terms of personalised medicine, phage cocktails may require production within 
the healthcare setting to suit a specific patient’s needs. In this case, would the ingredients 
of a phage cocktail need to be individually patented and sold, or could cocktails be 
developed with the pliability for patient-specific modifications later? In the absence of 
profitable, patented technology, pharmaceutical companies may be reluctant to fund the 
research and development of such treatments. 
 
Phage resistance 
Finally, it could be argued that the issues surrounding phage therapy may be abrogated 
by using phage gene products instead. Being more akin to conventional antimicrobial 
therapeutics, they would be subjected to the well-established drug development 
processes and standards of production and safety that are currently in place. However, 
the use of both phages and their gene products against bacterial infection may still be 
subject to the age-old problem of bacterial resistance. Indeed, some of the studies 
outlined in this literature review suggest, or provide evidence of, the possibility of 
resistance against phage therapy, although this phenomenon has yet to be observed in 
vivo. 
 
The first warnings regarding the development of antibiotic resistance [12, 13] went 
unheeded, resulting in the spread of MDR bacteria such as K. pneumoniae, and are the 
grounds upon which phage therapy has become a renewed topic of research. The 
development of novel antimicrobial agents is, therefore, not enough to combat infection 
and bacterial resistance in the long term. Strategies regarding the use of any novel 
antimicrobial treatments must be developed to minimise the risk of the development of 
resistance. In terms of phage therapy, such strategies might involve using combination 
treatments: for example, phage–drug combinations or complex phage cocktails designed 
to minimise the selection pressures applied against bacteria during treatment. 
 
Prevention should be the primary focus of healthcare-associated infection control 
procedures. The implementation or improvement of policies aimed at reducing the risk of 
patients developing bacterial infections must be concurrent with the development of novel 
antibacterial therapeutics to minimise the spread of resistance to treatment. Such 
procedures may include hand and environmental decontamination, safe installation and 
maintenance of medical devices, prompt removal of medical devices that are no longer 
needed, screening and decolonisation programmes, and cautious use of antimicrobial 
agents. 
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Future research 
The future of phage research is a promising one. Phages are perhaps the most numerous 
of all biological entities on the planet and as such could be the most valuable source of 
therapeutic solutions. As we further elucidate the interactions between phage and 
bacterium, as predator and prey, advances in our understanding of the molecular 
mechanisms defining such interactions may afford us new information and ideas that can 
be applied to infection control. Indeed, phage research has already led to the 
development of artificial phage-derived antibacterial proteins – Artilysins [103] – and the 
artificial alteration of phage host range to infect a greater range of bacteria than is 
naturally possible is just beginning to come to fruition [72]. 
 
Furthermore, recent technological advances have seen next-generation sequencing 
(NGS) become increasingly used in phage research, providing a more robust platform 
from which to launch detailed phage characterisation, screening of harmful genes and 
evaluating potentially useful gene products [110]. Further technological advancements, 
and categorisation of information attained from methods such as NGS can only lead us 
onwards, providing new solutions to old problems. 
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Table 1. Known phages with that infect one or more strains of Klebsiella 
Phage Family RefSeq/GenBank 
accession no. 
Genome 
size (bp) 
Source Reference 
vB_KpnM_KpV477 Myoviridae NC_031087 168272 Clinical sample [112] 
ZCKP1 Myoviridae MH252123 150925 Freshwater [65] 
KP15 Myoviridae NC_014036 174436 Irrigated fields [64] 
JD001 Myoviridae NC_020204 48814 Seawater [113] 
0507-KN2-1 Myoviridae NC_022343 159991 Sewage [114] 
Matisse Myoviridae NC_028750 176081 Sewage [115] 
Miro Myoviridae KT001919 176055 Sewage [116] 
PKO111 Myoviridae NC_031095 168758 Sewage [117] 
PMBT1 Myoviridae LT607758 175206 Sewage [118] 
vB_KpnM_KB57 Myoviridae NC_028659 142987 Sewage Volozhantsev et al.* 
vB_Kpn_F48 Myoviridae MG746602 170764 Sewage [119] 
GH-K2 Myoviridae Not Available Unknown Sewage [71] 
Kpn1 Myoviridae Not Available Unknown Sewage [89] 
Kpn2 Myoviridae Not Available Unknown Sewage [89] 
Kpn3 Myoviridae Not Available Unknown Sewage [89] 
Kpn4 Myoviridae Not Available Unknown Sewage [89] 
vB_KpnM_BIS47 Myoviridae KY652726 147443 Sewage plant [120] 
JD18 Myoviridae NC_028686 166313 Unknown Fan et al.* 
vB_KleM-RaK2 Myoviridae NC_019526 345809 Unknown [121] 
Mineola Myoviridae MH333064 166130 Unknown Boeckman et al.* 
May Myoviridae MG428991 159631 Unknown Nguyen et al.* 
Menlow Myoviridae MG428990 157281 Unknown Newkirk et al.* 
vB_KpnM_KpV79 Myoviridae MF663761 47760 Unknown Komisarova et al.* 
vB_KpnM_KpV52 Myoviridae KX237516 47405 Unknown Komisarova et al.* 
1611E-K2-1 Myoviridae MG197810 47797 Unknown Lin et al.* 
KP179 Myoviridae MH729874 162630 Unknown Kozlova et al.* 
KP1 Myoviridae MG751100 167989 Unknown Kim* 
3 LV-2017 Myoviridae KY271397 35100 Unknown [122] 
4 LV-2017 Myoviridae KY271398 33540 Unknown [122] 
Kpn112 Myoviridae KJ021043 35560 Unknown Chandekar et al.* 
K64-1 Myoviridae NC_027399 346602 Untreated water [123] 
KPV15 Myoviridae KY000080 167034 Wastewater [124] 
KP27 Myoviridae NC_020080 174413 Wastewater plant [64] 
KP34 Podoviridae NC_013649 43809 Cesspool holding 
tank 
[125] 
vB_KpnP_KpV475 Podoviridae NC_031025 42201 Clinical sample [126] 
vB_KpnP_KpV74 Podoviridae KY385423 44094 Clinical sample [126] 
vB_KpnP_KpV48 Podoviridae KX237514 44623 Clinical sample [126] 
KP32 Podoviridae NC_013647 41119 Roadside ditch [64] 
P13 Podoviridae Not Available 45976 Sewage [127] 
vB_KpnP_KpV41 Podoviridae NC_028670 44203 Sewage [126] 
vB_KpnP_KpV71 Podoviridae NC_031246 43267 Sewage [126] 
vB_KpnP_KpV766 Podoviridae KX712071 41283 Sewage [126] 
vB_KpnP_KpV767 Podoviridae KX712070 40395 Sewage [126] 
vB_KpnP_KpV763 Podoviridae KX591654 40765 Sewage [126] 
K5-2 Podoviridae KY389315 41116 Sewage [128] 
K5-4 Podoviridae KY389316 40163 Sewage [128] 
KPO1K2 Podoviridae Not Available ~42000 Sewage [69] 
Kpn5 Podoviridae Not Available ~24000 Sewage [81] 
Kpn12 Podoviridae Not Available ~24000 Sewage [81] 
Kpn13 Podoviridae Not Available ~24000 Sewage [81] 
Kpn17 Podoviridae Not Available ~24000 Sewage [81] 
Kpn22 Podoviridae Not Available ~24000 Sewage [81] 
phiNK5 Podoviridae Not Available ~29000 Sewage [76] 
Phage SS Podoviridae Not Available Unknown Sewage [83] 
Henu1 Podoviridae MK203841.1 40352 Sewage [129] 
vB_KpnP_BIS33 Podoviridae KY652725 41697 Sewage plant [120] 
vB_KpnP_IL33 Podoviridae KY652724 41335 Sewage plant [120] 
vB_KpnP_PRA33 Podoviridae KY652723 40605 Sewage plant [120] 
F19 Podoviridae NC_023567 43766 Unknown Chen et al.* 
K11 Podoviridae NC_011043 41181 Unknown Savalia et al.* 
Pylas Podoviridae MH899585 70408 Unknown Powell et al.* 
vB_KpnP_IME321 Podoviridae MH587638 39906 Unknown [130] 
SH-Kp 152234 Podoviridae KY450753 40578 Unknown Zhi et al.* 
KP8 Podoviridae MG922974 73679 Unknown Bokovaya et al.* 
SH-Kp 152410 Podoviridae MG835568 40945 Unknown Xu et al.* 
KP-Rio/2015 Podoviridae KX856662 43557 Unknown Meira et al.* 
KN4-1 Podoviridae LC413195 41219 Unknown [131] 
KN3-1 Podoviridae LC413194 41059 Unknown [131] 
KN1-1 Podoviridae LC413193 40236 Unknown [131] 
kpssk3 Podoviridae MK134560 40539 Unknown Shi et al.* 
phiKpS2 Podoviridae KX587949 44024 Unknown [132] 
myPSH1235 Podoviridae MG972768 45135 Unknown [79] 
2044-307w Podoviridae MF285615 40048 Unknown Zhao* 
6 LV-2017 Podoviridae KY271400 19260 Unknown [122] 
vB_KpnP_IME205 Podoviridae KU183006 41310 Unknown Bai et al.* 
vB_Klp_5 Podoviridae Not Available Unknown Unknown [133] 
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Phage Family RefSeq/GenBank 
accession no. 
Genome 
size (bp) 
Source Reference 
vB_Klp_6 Podoviridae Not Available Unknown Unknown [133] 
vB_KpnP_KpV289 Podoviridae NC_028977 41054 Untreated sewage [134] 
NTUH-K2044 Podoviridae NC_025418 43871 Untreated water [135] 
K5 Podoviridae NC_028800 41698 Wastewater Schneider et al.* 
phiBO1E Podoviridae KM576124 43865 Wastewater [68] 
KPV811 Podoviridae KY000081 42641 Wastewater [124] 
vB_Kp1 Podoviridae NC_028688 40114 Wastewater plant Alvez et al.* 
vB_Kp2 Podoviridae NC_028664 43963 Wastewater plant Alvez et al.* 
vB_KpnP_SU503 Podoviridae NC_028816 43809 Wastewater plant [136] 
vB_KpnP_SU552A Podoviridae NC_028870 43595 Wastewater plant [136] 
AltoGao Podoviridae MF612071 43012 Wastewater plant [137] 
SopranoGao Podoviridae MF612073 61644 Wastewater plant [137] 
KLPN1 Siphoviridae NC_028760 49037 Human caecum [138] 
KPP5665-2 Siphoviridae MF695815 39241 Mastitis milk [139] 
1513 Siphoviridae NC_028786 49462 Sewage [75] 
PKP126 Siphoviridae NC_031053 50934 Sewage [117] 
Sushi Siphoviridae NC_028774 48754 Sewage [140] 
vB_KpnS_KpV522 Siphoviridae KX237515 51099 Sewage Komisarova et al.* 
TSK1 Siphoviridae MH688453 49861 Sewage [90] 
IME207 Siphoviridae NC_031924 47564 Sewage [141] 
vB_KpnS_GH-K3 Siphoviridae MH844531.1 49427 Sewage [71, 142]  
48ST307 Siphoviridae KY271402 52338 Unknown [122] 
KPN N98 Siphoviridae MG835858 59214 Unknown Jeon et al.* 
YMC16/01/N133_KPN_B
P 
Siphoviridae MF476925 58387 Unknown Jeon et al.* 
YMC15/11/N53_KPN_BP Siphoviridae MF476924 59100 Unknown Jeon et al.* 
KPN N54 Siphoviridae MF415413 59100 Unknown Jeon et al.* 
KPN N141 Siphoviridae MF415412 49090 Unknown Jeon et al.* 
KPN U2874 Siphoviridae MF415411 59087 Unknown Jeon et al.* 
KPN N137 Siphoviridae MF415410 59100 Unknown Jeon et al.* 
Seifer Siphoviridae MH817999 58197 Unknown Salazar et al.* 
SH-Kp 160016 Siphoviridae KY575286 49170 Unknown Zhi et al.* 
Sugarland Siphoviridae MG459987 111103 Unknown Erickson et al.* 
vB_Kpn_IME260 Siphoviridae KX845404 123490 Unknown Xing et al.* 
NJR15 Siphoviridae MH633487 49468 Unknown Hao et al.* 
NJS3 Siphoviridae MH633486 49387 Unknown Hao et al.* 
NJS2 Siphoviridae MH633485 50132 Unknown Hao et al.* 
TAH8 Siphoviridae MH633484 49344 Unknown Hao et al.* 
phiKO2 Siphoviridae NC_005857 51601 Unknown [143] 
NJS1 Siphoviridae MH445453 49292 Unknown Zhu et al.* 
JY917 Siphoviridae MG894052 37655 Unknown Hao et al.* 
vB_KpnS_IME279 Siphoviridae MF614100 42518 Unknown Zhao et al.* 
1 LV-2017 Siphoviridae KY271401 29880 Unknown [122] 
2 LV-2017 Siphoviridae KY271396 44400 Unknown [122] 
2b LV-2017 Siphoviridae KY271395 44279 Unknown [122] 
5 LV-2017 Siphoviridae KY271399 47014 Unknown [122] 
vB_Kp3 Siphoviridae KT367887 48493 Unknown Alvez et al.* 
phiKp-lyy15 Siphoviridae Not Available Unknown Unknown [144] 
vB_Klp_1 Siphoviridae Not Available Unknown Unknown [133] 
vB_Klp_3 Siphoviridae Not Available Unknown Unknown [133] 
vB_Klp_4 Siphoviridae Not Available Unknown Unknown [133] 
KOX1 Siphoviridae KY780482 50526 Wastewater [145] 
phage Z Siphoviridae Not Available Unknown Wastewater [63] 
KP36 Siphoviridae NC_029099 49818 Wastewater plant [64] 
MezzoGao Siphoviridae MF612072 49807 Wastewater plant [137] 
GH-K1 Unknown Not Available Unknown Sewage [71] 
PBKP05 Unknown Not Available 30240 Unknown [146] 
Kpp95 Unknown Not Available ~175000 Unknown [147] 
*No paper associated with the RefSeq/GenBank record(s). 
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Figure 1. Phylogenetic placement of dsDNA Klebsiella phages within the order 
Caudovirales. Placement of 109 genomes (Table 1) within ViPTree version 1.9 [148] was 
checked on 6 August 2019. Those sequences (n = 84) that clustered together in groups of 
three or more were analysed with their nearest phylogenetic relatives using ViPTreeGen 
v1.1.2 (--ncpus 8 --method ‘bioinj’) and a non-redundant set of genomes (fasta file of input 
sequences and newick-format file available in Supplementary Material) to generate the 
tree shown (annotated using https://itol.embl.de and Adobe Illustrator). Taxonomy of 
phages was checked via https://talk.ictvonline.org/taxonomy/ (release 2018b); accepted 
species names are written in italics. A phylogenetic tree showing the placement of the 
remaining 25 Klebsiella genomes within ViPTree version 1.9 is available in 
Supplementary Material. 
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APPENDIX 2 
Poster presented at European Congress of Clinical Microbiology and Infectious 
Diseases, Amsterdam (April 2016). 
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1. Isolation of lytic bacteriophages active against antibiotic-resistant Klebsiella 
pneumoniae 
 
2. Purpose and background of proposed study 
The global spread of carbapenemase-producing Enterobacteriaceae – especially 
Klebsiella pneumoniae – has reached a concerning level and is a critical medical and 
public health issue [1]. The number of confirmed carbapenemase-producing organism 
(CPO) isolates referred from UK laboratories has increased from 5 per year (2003–2007) 
to as many as 1,000 (2013) [2]. CPOs are extremely multidrug-resistant (carbapenems, 
penicillins and cephalosporins) and often carry genes that confer resistance to other 
antimicrobials (aminoglycosides and quinolones) leading to limited therapeutic options [3]. 
K. pneumoniae-associated infections (urinary tract, blood, pneumonia, burn-wound) occur 
mostly in adults in high-dependency units. Capsular type K1 carbapenem-resistant K. 
pneumoniae strains causing community-acquired pyogenic liver abscess are on the 
increase globally [4]. Information on capsular types associated with other infections is 
lacking; Public Health England’s screening programme can only identify five of the 78 
known capsular types of K. pneumoniae [5]. However, capsular type and other strain 
characteristics can be determined using whole-genome sequence data 
(http://bigsdb.web.pasteur.fr). 
Controlling the spread of K. pneumoniae is difficult because of the diversity of 
carbapenem-hydrolysing enzymes and because resistance genes spread among different 
bacteria [2]. K. pneumoniae inhabits the gastrointestinal tract and decolonisation therapy 
only reduces the number of bacteria without elimination [2]. Most people colonised with K. 
pneumoniae have no further complications but, in immunocompromised patients, 
colonisation can lead to endogenous infection, which can be a cause of cross-infection [2]. 
Patients with invasive CPO infections are twice as likely to die as those infected with 
antibiotic-sensitive strains [6]. 
Bacteriophage therapy has been suggested as an alternative or adjunct treatment 
option in CPO-associated infections [7]. Bacteriophages are ubiquitous viruses of 
bacteria, found in water sources, sewage and the intestines of animals [8]. Lytic 
bacteriophages are recommended for phage therapy because they kill bacteria, infecting 
only the target bacterium and not affecting the microbiota or human cells. In 
bacteriophage therapy, lytic bacteriophages multiply in their host bacterium at the site of 
the infection until the bacteria are killed, then the phages are excreted from the body in 
urine and faeces [9]. Lytic bacteriophages active against K. pneumoniae have shown 
good therapeutic potential in mice [10–13]. No lytic bacteriophages active against 
carbapenemase-resistant K. pneumoniae have been isolated and characterised. Strains 
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included in bacteriophage studies are not well characterized, making it impossible to know 
which bacteriophages should be used to treat K. pneumoniae infections in a clinical 
setting. In addition, the genomes of bacteriophages included in these studies are not well-
characterised, limiting the clinical applications of bacteriophage gene products (such as 
holins and lysins) as adjuncts or alternatives to antibiotic therapy. 
It is hypothesised that bacteriophages and their gene products can be used to treat K. 
pneumoniae-associated infections in vitro, and ultimately used in vivo and in 
decolonization therapy to reduce transmission of K. pneumoniae from the gut of patients 
upon admission to hospital and hands of hospital personnel. This project aims to (i) 
isolate, from sewage samples, lytic bacteriophages active against a collection of 13 well-
characterized antibiotic-resistant K. pneumoniae strains isolated in west London hospitals 
since 2010; fully characterise (genomically and phenotypically) the bacteriophages and 
their host bacteria; screen the bacteriophages against a panel of 200 randomly selected 
K. pneumoniae clinical isolates to determine their host ranges; and use the 
bacteriophages singly and in phage cocktails to determine their in vitro effectiveness at 
killing K. pneumoniae. 
 
3. Methods 
Permission has been granted to collect sewage samples from the Mogden and Ascot 
Sewage Treatment Works (Thames Water). These samples will be centrifuged and filter-
sterilized to remove debris and bacteria, leaving only bacteriophages [8]. The following 
applies to each of the 13 antibiotic-resistant isolates to be used in the study. To 1 ml of 
sterile 10x concentrated nutrient broth, 9 ml of filtered sewage will be added. The sample 
will be inoculated with 200 microlitres of an overnight culture of K. pneumoniae, and 
incubated overnight at 37 °C. Cultures will then be centrifuged and the supernatants used 
in spot assays using the double-agar method [8] to determine whether bacteriophages 
have been isolated. Bacteriophage-positive samples will be processed [10] so that 
bacteriophages can be propagated to purity; their DNA will then be extracted [10]. 
Molecular fingerprints will be generated for all bacteriophages to identify those that are 
unique [14]. Unique bacteriophages will be characterized phenotypically [14], and their 
whole-genome sequences (and those of their host bacteria) determined (microbesNG; 
http://microbesng.uk). Genomes will be annotated [10], and bacteriophage gene products 
with potential clinical applications will be identified for future work. Lytic activity of 
bacteriophages will be tested against all the antibiotic-resistant isolates and 200 clinical 
isolates. In vitro killing activity of bacteriophages will be tested against strains singly and in 
bacteriophages cocktails [15] to identify bacteriophages suitable for future in vivo studies. 
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4. Major benefits of a successful outcome to the project 
One of the major problems facing the Imperial College Healthcare Trust (ICHT) is the 
rapid emergence of antibiotic-resistant K. pneumoniae (CPO) in high-dependency units. 
Presence of antibiotic-resistant K. pneumoniae in patients is due to previous antibiotic 
therapy and transmission of organisms from the guts of patients and hands of hospital 
personnel. Currently no decolonisation therapy is available for gut carriage of CPOs: 
antibiotic therapy leads to eradication of the normal gut microbiota, which can result in the 
emergence of opportunistic pathogens and development of potentially life-threatening 
conditions such as Clostridium difficile-associated diarrhoea. Bacteriophages isolated in 
this study will ultimately be used in a topical form to suppress or eradicate gut carriage of 
CPOs once patients have screened positive, thereby preventing infection with these 
organisms which in turn will help to control CPO-associated infections in hospitals and 
provide better patient care and management. This study will result in at least one 
publication. Outputs of studies will be offered for oral/poster presentations at national and 
international conferences. The work will be presented internally to staff at Charing Cross 
Hospital, to disseminate the findings of the work to clinicians, technicians and researchers 
working in the field. 
 
5. Key references 
[1] WHO (2014). 
http://reliefweb.int/sites/reliefweb.int/files/resources/9789241564748_eng.pdf. 
[2] Curran & Otter (2014). J Infect Prevent 15, 193-198. 
[3] Livermore & Woodford (2006). Trends Microbiol 14, 413-420. 
[4] Lin et al. (2014). J Infect Dis 210, 1734-1744.  
[5] Turton et al. (2010). J Med Microbiol 59, 541-547. 
[6] Falagas et al. (2014). Emerg Infect Dis 20, 1170-1175. 
[7] Inal (2003). Arch Immunol Ther Exp 51, 237-244. 
[8] Hoyles et al. (2014). Res Microbiol 165, 803-812. 
[9] Sulakvelidze et al. (2001). Antimicrob Agents Chemother 45, 649-659. 
[10] Hoyles el al. (2015). PeerJ 3, e1061. doi:10.7717/peerj.1061.  
[11] Karumidze et al. (2013). Curr Microbiol 66, 251-258.  
[12] Cao et al. (2015). BioMed Res Int 2015, 752930. doi:10.1155/2015/75293. 
[13] Kumari et al. (2011). J Med Microbiol 60, 205-210. 
[14] Kęsik-Szeloch et al. (2013). Virol J 10,100. doi:10.1186/1743-422X-10-100. 
[15] Alves et al. (2016). Microb Biotechnol 9, 61-74. doi:10.1111/1751-7915.12316.
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